https://www.gilead.com/ 2026-02-11 daily 0.5 https://www.gilead.com/early-careers 2025-10-08 daily 0.5 https://www.gilead.com/interns 2025-10-16 daily 0.5 https://www.gilead.com/nevpp 2025-11-07 daily 0.5 https://www.gilead.com/discoverypath 2025-02-12 daily 0.5 https://www.gilead.com/search-result 2025-02-12 daily 0.5 https://www.gilead.com/science 2025-12-16 daily 0.5 https://www.gilead.com/news 2025-11-17 daily 0.5 https://www.gilead.com/media 2025-11-17 daily 0.5 https://www.gilead.com/medicines 2025-08-05 daily 0.5 https://www.gilead.com/responsibility 2026-01-09 daily 0.5 https://www.gilead.com/stories 2025-10-17 daily 0.5 https://www.gilead.com/company 2026-02-12 daily 0.5 https://www.gilead.com/tdf-litigation 2025-02-12 daily 0.5 https://www.gilead.com/contact-us 2025-02-12 daily 0.5 https://www.gilead.com/careers 2025-08-05 daily 0.5 https://www.gilead.com/cookie-statement 2025-02-12 daily 0.5 https://www.gilead.com/privacy-statements 2025-02-12 daily 0.5 https://www.gilead.com/social-media-guidelines 2025-02-12 daily 0.5 https://www.gilead.com/terms-of-use 2025-02-12 daily 0.5 https://www.gilead.com/global-operations 2025-02-12 daily 0.5 https://www.gilead.com/sitemap 2025-02-12 daily 0.5 https://www.gilead.com/404 2025-02-12 daily 0.5 https://www.gilead.com/privacy-statements 2025-02-12 daily 0.5 https://www.gilead.com/science/overview 2024-08-19 daily 0.5 https://www.gilead.com/science/therapeutic-areas 2026-01-09 daily 0.5 https://www.gilead.com/science/pipeline 2025-10-30 daily 0.5 https://www.gilead.com/science/research 2025-04-24 daily 0.5 https://www.gilead.com/science/clinical-trials 2024-10-23 daily 0.5 https://www.gilead.com/science/diversity-in-clinical-trials 2024-08-31 daily 0.5 https://www.gilead.com/news/news-details 2024-09-12 daily 0.5 https://www.gilead.com/medicines/overview 2025-06-19 daily 0.5 https://www.gilead.com/medicines/patient-safety 2024-09-05 daily 0.5 https://www.gilead.com/medicines/medication-access 2025-03-25 daily 0.5 https://www.gilead.com/medicines/authorized-distributors 2025-06-18 daily 0.5 https://www.gilead.com/responsibility/overview 2024-08-19 daily 0.5 https://www.gilead.com/responsibility/esg 2025-02-24 daily 0.5 https://www.gilead.com/responsibility/sustainability 2025-10-01 daily 0.5 https://www.gilead.com/responsibility/health-equity 2025-05-30 daily 0.5 https://www.gilead.com/responsibility/giving-at-gilead 2025-07-11 daily 0.5 https://www.gilead.com/responsibility/global-health-and-access 2025-03-11 daily 0.5 https://www.gilead.com/responsibility/inclusion-and-diversity 2025-03-11 daily 0.5 https://www.gilead.com/responsibility/medical-education 2024-09-05 daily 0.5 https://www.gilead.com/stories/overview 2024-09-05 daily 0.5 https://www.gilead.com/stories/scientific-innovation 2025-07-30 daily 0.5 https://www.gilead.com/stories/access-and-health-equity 2024-06-26 daily 0.5 https://www.gilead.com/stories/people-and-culture 2024-06-26 daily 0.5 https://www.gilead.com/stories/all-stories 2024-08-19 daily 0.5 https://www.gilead.com/stories/2020-year-in-review-rising-beyond 2024-09-13 always https://www.gilead.com/stories/4-questions-global-experts-convene-to-identify-key-measures-to-long-term-success-in-hiv 2024-08-19 always https://www.gilead.com/stories/4-questions-on-gilead-new-technical-development-center-with-stacey-ma-and-jamie-moore 2025-09-03 daily 0.5 https://www.gilead.com/stories/4-questions-with-dr-javier-cortes 2024-08-19 always https://www.gilead.com/stories/4-questions-with-flavius-martin 2024-08-19 always https://www.gilead.com/stories/4-questions-with-jared-baeten 2024-08-19 always https://www.gilead.com/stories/4-questions-with-professor-maria-buti-understanding-hepatitis-d 2024-08-19 always https://www.gilead.com/stories/4-questions-with-see-phan 2024-08-19 always https://www.gilead.com/stories/a-car-t-caregivers-journey-rickys-story 2025-09-10 daily 0.5 https://www.gilead.com/stories/a-career-rooted-in-championing-diversity-and-inclusion-jesse-story 2024-08-19 always https://www.gilead.com/stories/a-cut-above-the-rest-innovative-barbershop-program-educates-indigenous-men-about-hiv 2024-08-19 always https://www.gilead.com/stories/a-legacy-of-helping-to-address-viral-pandemics 2024-08-19 always https://www.gilead.com/stories/a-look-at-overall-survival-data-in-cancer-clinical-trials 2024-08-19 always https://www.gilead.com/stories/a-look-inside-gilead-inflammation-pipeline 2025-10-09 daily 0.5 https://www.gilead.com/stories/a-personal-journey-to-make-science-more-inclusive 2024-08-19 always https://www.gilead.com/stories/a-workplace-for-tomorrow 2024-08-19 always https://www.gilead.com/stories/adonis-timone-aims-to-create-change-with-advocates-for-youth 2024-08-19 always https://www.gilead.com/stories/advancing-global-health-equity-in-tropical-regions 2024-08-19 always https://www.gilead.com/stories/advancing-oncology-care-through-gileads-research-scholars-program 2025-03-05 daily 0.5 https://www.gilead.com/stories/advocating-for-black-women-with-triple-negative-breast-cancer-rickis-story 2024-08-19 always https://www.gilead.com/stories/aids-memorial-quilt-panels-on-display-at-gilead 2026-02-06 always https://www.gilead.com/stories/aidsvu-online-mapping-tool-helps-visualize-hivs-impact-in-the-united-states 2025-04-15 daily 0.5 https://www.gilead.com/stories/all-stars-project-empowers-youth-through-performance 2024-08-19 always https://www.gilead.com/stories/an-open-letter-from-daniel-oday-chairman-and-ceo 2025-07-29 daily 0.5 https://www.gilead.com/stories/an-open-letter-from-daniel-oday-june-22 2024-08-19 always https://www.gilead.com/stories/an-open-letter-from-daniel-oday-june-29 2025-09-08 always https://www.gilead.com/stories/an-open-letter-from-our-chairman-and-ceo 2024-08-19 always https://www.gilead.com/stories/an-open-letter-from-our-chairman-and-ceo-april-10 2025-09-08 always https://www.gilead.com/stories/an-open-letter-from-our-chairman-and-ceo-april-29 2024-08-19 always https://www.gilead.com/stories/an-open-letter-from-our-chairman-and-ceo-oct-8 2024-08-19 always https://www.gilead.com/stories/an-open-letter-on-ukraine-from-daniel-oday-chairman-and-ceo 2024-08-19 always https://www.gilead.com/stories/an-update-on-covid-19-from-our-chairman-and-ceo 2025-09-08 always https://www.gilead.com/stories/an-update-on-ukraine-from-daniel-oday-chairman-and-ceo 2024-08-19 always https://www.gilead.com/stories/art-captures-the-experiences-of-women-living-with-metastatic-breast-cancer 2024-08-19 always https://www.gilead.com/stories/arthritis-awareness-month 2024-08-19 always https://www.gilead.com/stories/at-the-forefront-of-hiv-health-and-healing-in-spain-ferran-story 2024-08-19 always https://www.gilead.com/stories/balancing-legal-work-at-gilead-and-family-life-with-triplets-joel-story 2024-08-19 always https://www.gilead.com/stories/believing-in-the-science-behind-car-t-cell-therapy-branden-story 2024-08-19 always https://www.gilead.com/stories/beyond-blood-cancers-new-explorations-in-car-t-cell-therapy 2025-06-02 daily 0.5 https://www.gilead.com/stories/bilal-piperdi-on-how-gilead-is-striving-to-create-new-possibilities-for-people-with-lung-cancer 2024-08-19 always https://www.gilead.com/stories/born-with-hiv-in-the-80s-kim-story-of-growing-up-as-a-dandelion 2025-06-05 daily 0.5 https://www.gilead.com/stories/breaking-barriers-to-breast-cancer-care-in-rural-areas 2026-02-04 always https://www.gilead.com/stories/breaking-down-barriers-to-access-in-hiv-and-beyond-a-perspective 2024-08-19 always https://www.gilead.com/stories/breast-cancer-journey-inspires-advocacy-for-healthcare-diversity-jamil-story 2025-09-08 always https://www.gilead.com/stories/bringing-pbc-into-focus-through-art-of-patient-stories 2025-05-07 daily 0.5 https://www.gilead.com/stories/building-a-bridge-to-a-healthier-world-for-youth-in-africa 2024-09-09 daily 0.5 https://www.gilead.com/stories/celebrating-national-black-hiv-aids 2024-08-19 always https://www.gilead.com/stories/championing-hiv-services-for-lgbtq-youth 2024-09-13 daily 0.5 https://www.gilead.com/stories/championing-hiv-support-in-italy-through-community-based-checkpoints 2026-01-29 always https://www.gilead.com/stories/channeling-her-passion-to-spread-awareness-about-tnbc-latoya-journey 2024-08-19 always https://www.gilead.com/stories/charting-a-career-to-help-reduce-health-inequity-porschas-story 2025-09-08 always https://www.gilead.com/stories/china-red-ribbon-school-provides-a-refuge-for-children-living-with-hiv 2024-08-19 always https://www.gilead.com/stories/claflin-university-deeply-rooted-commitment-to-social-justice 2025-09-09 always https://www.gilead.com/stories/closing-the-hiv-diagnosis-gap-in-germany 2024-09-09 daily 0.5 https://www.gilead.com/stories/closing-the-representation-gap-in-schools-one-black-male-teacher-at-a-time 2024-08-19 always https://www.gilead.com/stories/committed-to-reducing-greenhouse-gas-emissions-for-a-healthier-world 2025-09-09 always https://www.gilead.com/stories/connecting-breast-cancer-education-to-community-equal-hope 2025-09-08 always https://www.gilead.com/stories/cp-profile-tariro-makadzange 2026-02-19 always https://www.gilead.com/stories/cp-profiles-bismay-mishra 2026-02-19 always https://www.gilead.com/stories/cp-profiles-julie-dipaolo 2026-02-19 always https://www.gilead.com/stories/creating-possible 2024-08-19 always https://www.gilead.com/stories/david-malebranche-expands-career-in-hiv-care-to-help-bridge-the-divide-on-a-global-scale 2024-08-19 always https://www.gilead.com/stories/decades-of-achievements-gilead-35th-anniversary 2024-08-19 always https://www.gilead.com/stories/decades-long-effort-to-enact-universal-hiv-screening-for-pregnant-women-in-israel 2024-08-19 always https://www.gilead.com/stories/designing-inclusive-clinical-trials-in-an-effort-to-upend-the-hiv-epidemic 2025-01-08 daily 0.5 https://www.gilead.com/stories/developing-future-social-justice-leaders-at-tougaloo-college 2025-09-08 always https://www.gilead.com/stories/discovering-a-breakthrough-gilead-long-standing-commitment-to-helping-change-the-course-of-hiv 2025-02-07 daily 0.5 https://www.gilead.com/stories/dr-amelie-ramirez-seeks-to-end-disparities-in-latino-cancer-care 2024-08-19 always https://www.gilead.com/stories/drawing-inspiration-from-nature-olivier-nolan-stevaux-work-in-oncology-research 2025-08-14 daily 0.5 https://www.gilead.com/stories/driving-transformational-innovation-in-hiv-research 2024-08-19 always https://www.gilead.com/stories/empowering-and-inspiring-the-women-leaders-of-tomorrow 2024-08-19 always https://www.gilead.com/stories/ending-hiv-related-stigma-in-the-southern-united-states-gina-story 2024-08-19 always https://www.gilead.com/stories/expanding-our-cell-therapy-manufacturing-network-to-meet-the-needs-of-cancer-patients-in-europe 2025-09-08 always https://www.gilead.com/stories/experiencing-car-t-cell-therapy-and-empowering-others-through-peer-to-peer-support-chucks-story 2024-08-19 always https://www.gilead.com/stories/father-helps-build-gendercool-to-grow-awareness-around-trans-youth 2025-09-08 always https://www.gilead.com/stories/fifth-anniversary-of-compass-helping-address-the-hiv-epidemic-in-the-us-south 2024-08-19 always https://www.gilead.com/stories/first-delivery-of-gilead-twice-yearly-hiv-prevention-therapy-in-sub-saharan-africa-and-what-it-means-for-ending-the-hiv-epidemic 2025-11-24 daily 0.5 https://www.gilead.com/stories/four-questions-with-alphonso-david 2024-08-19 always https://www.gilead.com/stories/four-questions-with-anu-osinusi 2024-08-19 always https://www.gilead.com/stories/four-questions-with-behzad-kharabi-and-bijal-shah 2024-08-19 always https://www.gilead.com/stories/four-questions-with-betty-chiang 2024-08-19 always https://www.gilead.com/stories/four-questions-with-bill-guyer 2025-09-08 always https://www.gilead.com/stories/four-questions-with-cary-james 2024-08-19 always https://www.gilead.com/stories/four-questions-with-cleve-jones 2026-02-19 always https://www.gilead.com/stories/four-questions-with-daejin-abidoye 2024-08-19 always https://www.gilead.com/stories/four-questions-with-devang-bhuva 2025-09-09 always https://www.gilead.com/stories/four-questions-with-diana-brainard 2025-09-08 always https://www.gilead.com/stories/four-questions-with-douglas-brooks 2025-09-09 always https://www.gilead.com/stories/four-questions-with-dr-scott-tagawa-and-stephanie-chisolm-on-bladder-cancer 2024-08-19 always https://www.gilead.com/stories/four-questions-with-gilead-virology-clinical-research-team 2024-08-19 always https://www.gilead.com/stories/four-questions-with-jared-baeten 2024-08-19 always https://www.gilead.com/stories/four-questions-with-katrin-schoeneweis 2024-08-19 always https://www.gilead.com/stories/four-questions-with-ken-takeshita 2025-09-08 always https://www.gilead.com/stories/four-questions-with-louis-j-degennaro 2026-02-19 always https://www.gilead.com/stories/four-questions-with-maimah-karmo 2024-08-19 always https://www.gilead.com/stories/four-questions-with-mark-chao-and-mauro-avanzi 2024-08-19 always https://www.gilead.com/stories/four-questions-with-merdad-parsey 2024-08-19 always https://www.gilead.com/stories/four-questions-with-pankaj-bhargava 2025-09-09 always https://www.gilead.com/stories/four-questions-with-robin-barkins 2024-08-19 always https://www.gilead.com/stories/four-questions-with-sade-clacken-joseph 2024-08-19 always https://www.gilead.com/stories/four-questions-with-serengulam-govindan 2024-08-19 always https://www.gilead.com/stories/four-questions-with-shira-kogan 2026-02-04 always https://www.gilead.com/stories/four-questions-with-tomas-cihlar-committed-to-the-field-of-emerging-viruses 2025-09-09 always https://www.gilead.com/stories/four-questions-with-tracey-iraca 2024-08-19 always https://www.gilead.com/stories/four-questions-with-tram-tran 2024-08-19 always https://www.gilead.com/stories/four-questions-with-wayne-duffus 2024-08-19 always https://www.gilead.com/stories/from-the-lab-to-runway-hiv-unwrapped-helps-transform-stigma-by-giving-lab-coats-a-makeover 2025-11-24 daily 0.5 https://www.gilead.com/stories/from-the-margins-gilead-book-uniquely-captures-what-its-like-to-be-marginalized-by-disease 2025-07-30 always https://www.gilead.com/stories/funding-possibility-for-the-next-generation 2024-08-19 always https://www.gilead.com/stories/fundo-positivo 2024-08-19 always https://www.gilead.com/stories/gilead-and-forty-seven-committed-to-creating-possible-for-people-living-with-cancer 2026-02-19 always https://www.gilead.com/stories/gilead-and-kite-present-episode-4-delivering-possible 2024-08-19 always https://www.gilead.com/stories/gilead-and-the-morehouse-school-of-medicine-partner-to-study-covid-19-racial-health-inequities 2025-09-09 always https://www.gilead.com/stories/gilead-at-forefront-of-herculean-effort-to-combat-covid-19 2024-08-19 always https://www.gilead.com/stories/gilead-benefit-helps-employees-navigate-cancer-care 2024-09-09 daily 0.5 https://www.gilead.com/stories/gilead-campaign-aims-to-close-hiv-gender-gap-in-uk 2025-07-11 daily 0.5 https://www.gilead.com/stories/gilead-emphasizes-unique-ways-to-hire-top-talent 2024-08-19 always https://www.gilead.com/stories/gilead-employees-give-back-during-month-of-service 2025-08-06 daily 0.5 https://www.gilead.com/stories/gilead-employees-stitch-together-to-create-a-special-panel-of-the-aids-quilt 2024-08-19 always https://www.gilead.com/stories/gilead-focus-on-ending-the-hiv-epidemic-for-children-everywhere 2024-08-19 always https://www.gilead.com/stories/gilead-focus-program-helps-zero-in-on-early-hiv-detection 2024-08-19 always https://www.gilead.com/stories/gilead-hackathon-unearths-innovative-ways-to-improve-hiv-prevention 2025-09-09 always https://www.gilead.com/stories/gilead-helps-launch-turkiye-first-hiv-testing-week 2024-08-19 always https://www.gilead.com/stories/gilead-helps-pen-a-children-book-for-families-facing-breast-cancer 2024-10-15 daily 0.5 https://www.gilead.com/stories/gilead-helps-put-african-nation-on-path-to-eliminate-hepatitis-c 2024-08-19 always https://www.gilead.com/stories/gilead-oncology-grantee-provides-practical-support-for-patients-undergoing-breast-cancer-treatment 2025-10-01 daily 0.5 https://www.gilead.com/stories/gilead-path-to-equitable-global-covid-19-treatment-access 2024-08-19 always https://www.gilead.com/stories/gilead-pays-tribute-to-patient-advocacy-work-cara-story 2024-08-19 always https://www.gilead.com/stories/gilead-policy-papers-show-pandemic-impact-on-hiv-prevention-and-care 2024-08-19 always https://www.gilead.com/stories/gilead-presents-episode-1-defining-possible 2024-08-19 always https://www.gilead.com/stories/gilead-presents-episode-2-realizing-possible 2024-08-19 always https://www.gilead.com/stories/gilead-presents-episode-3-championing-possible 2024-08-19 always https://www.gilead.com/stories/gilead-presents-episode-5-assuring-possible 2024-08-19 always https://www.gilead.com/stories/gilead-research-scholar-profile-jennifer-downs-studies-the-link-between-hiv-and-a-common-parasite-in-tanzania 2026-02-04 always https://www.gilead.com/stories/gilead-research-scholar-profile-takahiro-kodama-discovers-gene-involved-in-the-progression-of-liver-cancer 2026-02-19 always https://www.gilead.com/stories/gilead-research-scholars-program-supports-new-investigations-into-rare-liver-disease 2025-11-05 daily 0.5 https://www.gilead.com/stories/gilead-s-lawyers-go-beyond-corporate-law-with-pro-bono-cases 2024-08-19 always https://www.gilead.com/stories/gilead-scientific-innovation-at-the-forefront-of-helping-end-the-hiv-epidemic 2024-12-02 daily 0.5 https://www.gilead.com/stories/gilead-seat-at-the-table-of-conversations-centered-around-hiv 2025-12-04 daily 0.5 https://www.gilead.com/stories/gilead-sets-sights-on-hepatitis-c-elimination-as-it-marks-10-years-of-curative-therapies 2024-08-19 always https://www.gilead.com/stories/gilead-supports-efforts-to-help-close-digital-divide-in-san-francisco-bay-area 2026-02-19 always https://www.gilead.com/stories/gileads-first-case-competition-seeks-to-expand-recruitment-efforts 2024-08-19 always https://www.gilead.com/stories/gileads-next-chapter 2024-08-19 always https://www.gilead.com/stories/giving-together-to-support-relief-efforts-of-california-wildfires 2024-08-19 always https://www.gilead.com/stories/glaad-and-gilead-release-inaugural-us-survey-on-hiv-stigma 2024-08-19 always https://www.gilead.com/stories/global-community-advisory-groups-pave-way-forward-for-inclusive-clinical-trials 2024-08-19 always https://www.gilead.com/stories/groups-around-the-world-work-to-eliminate-hepatitis-c-by-meeting-people-where-they-are 2024-08-19 always https://www.gilead.com/stories/helping-others-navigate-breast-cancer-wendys-story 2026-02-19 always https://www.gilead.com/stories/hiv-advisory-council-in-australia-taps-diverse-community-perspectives 2024-08-19 always https://www.gilead.com/stories/honoring-the-history-and-impact-of-the-aids-memorial-quilt 2025-09-09 always https://www.gilead.com/stories/how-gilead-pharmaceutical-development-and-manufacturing-team-delivers-transformative-medicines 2024-08-19 always https://www.gilead.com/stories/how-gilead-supportive-culture-helps-working-parents-lj-story 2024-08-19 always https://www.gilead.com/stories/how-luciana-preger-is-helping-advance-gileads-work-in-oncology 2024-09-10 daily 0.5 https://www.gilead.com/stories/how-one-school-has-transformed-education-for-first-generation-students 2024-08-19 always https://www.gilead.com/stories/imani-rupert-gordon-leads-nclr-into-new-era-of-lgbtq-justice 2026-02-19 always https://www.gilead.com/stories/india-efforts-to-help-end-hepatitis-c-starts-with-prison-population 2024-08-19 always https://www.gilead.com/stories/innovation-and-growth-in-immuno-oncology 2024-08-19 always https://www.gilead.com/stories/inside-the-innovation-oncology-leaders-discuss-life-at-gilead 2024-08-19 always https://www.gilead.com/stories/inside-the-innovation-pharmaceutical-development-and-manufacturing-leaders-share-experiences 2024-08-19 always https://www.gilead.com/stories/international-aids-society-leaders-on-the-future-of-hiv-prevention-and-treatment 2024-08-19 always https://www.gilead.com/stories/interns-help-facilitate-breast-cancer-conversations-among-young-black-women 2024-08-19 always https://www.gilead.com/stories/introducing-our-newsroom 2024-08-19 always https://www.gilead.com/stories/jasmine-davis-healthcare-and-transgender-advocate-empowering-the-community 2024-08-19 always https://www.gilead.com/stories/julies-car-t-cell-therapy-journey 2024-08-19 always https://www.gilead.com/stories/kay-yow-cancer-fund-works-to-bolster-research-increase-access-to-care 2024-08-19 always https://www.gilead.com/stories/kingmakers-of-oakland-aims-to-improve-the-lives-of-young-black-men 2025-09-09 always https://www.gilead.com/stories/lacing-up-for-health-after-beating-covid-19 2024-08-19 always https://www.gilead.com/stories/lance-toma-creates-safe-spaces-for-san-franciscos-lgbtq-aapi-community 2024-08-19 always https://www.gilead.com/stories/latinas-contra-cancer-empowers-patients-to-advocate-for-change 2024-08-19 always https://www.gilead.com/stories/leading-with-passion-and-purpose-sandra-story 2024-08-19 always https://www.gilead.com/stories/living-well-with-hepatitis-b-lai-journey 2024-08-19 always https://www.gilead.com/stories/living-with-a-rare-blood-cancer-marion-story 2024-08-19 always https://www.gilead.com/stories/living-with-a-rare-liver-disease-marias-journey 2024-09-09 daily 0.5 https://www.gilead.com/stories/living-with-metastatic-breast-cancer-esther-decades-long-journey 2024-08-19 always https://www.gilead.com/stories/looking-back-to-the-future-gilead-long-standing-commitment-to-help-end-the-hiv-epidemic 2025-06-20 daily 0.5 https://www.gilead.com/stories/making-medicines 2024-08-19 always https://www.gilead.com/stories/meet-gilead-covid-19-virus-variants-hunters 2024-08-19 always https://www.gilead.com/stories/mentoring-mothers-living-with-hiv-angelina-story 2024-08-19 always https://www.gilead.com/stories/message-to-our-employees-on-george-floyd-and-ongoing-protests 2024-08-19 always https://www.gilead.com/stories/message-to-our-employees-on-violence-against-asian-americans-and-pacific-islanders 2024-08-19 always https://www.gilead.com/stories/metastatic-breast-cancer-advocate-urges-black-individuals-to-join-clinical-trials 2024-08-19 always https://www.gilead.com/stories/mobile-clinics-expand-access-to-cancer-screenings-in-the-us-south 2025-09-09 always https://www.gilead.com/stories/morris-singletary-brings-forward-his-spirit-passion-and-vision-as-a-compass-grantee 2024-08-19 always https://www.gilead.com/stories/mother-of-three-shares-her-car-t-cell-therapy-journey-kelly-story 2024-08-19 always https://www.gilead.com/stories/nash-day 2025-09-09 always https://www.gilead.com/stories/national-hiv-aids-and-aging-awareness-day 2025-09-09 always https://www.gilead.com/stories/native-health-navigator-program-connects-tribes-to-cancer-care 2025-09-09 always https://www.gilead.com/stories/new-report-shows-every-country-in-the-world-must-do-more-to-end-the-hiv-epidemic 2024-09-30 daily 0.5 https://www.gilead.com/stories/on-world-aids-day-honoring-those-who-are-fearless-for-all 2024-08-19 always https://www.gilead.com/stories/open-letter-from-merdad-parsey 2025-09-09 always https://www.gilead.com/stories/our-partners-bamby-salcedo-focuses-on-supporting-transgender-latina-women 2026-02-19 always https://www.gilead.com/stories/our-partners-george-kalamitsis-helps-hard-to-reach-people-at-high-risk-for-hepatitis-c 2026-02-19 always https://www.gilead.com/stories/our-partners-princess-janae-place-helps-transgender-individuals-overcome-homelessness 2026-02-19 always https://www.gilead.com/stories/our-partners-shombi-ellis-connects-mothers-across-africa-to-promote-health 2024-08-19 always https://www.gilead.com/stories/our-partners-silvana-lesidrenska-uses-her-own-experience-to-advocate-for-viral-hepatitis-patients-in-bulgaria 2026-02-19 always https://www.gilead.com/stories/overcoming-blood-cancer-with-car-t-cell-therapy-eleonora-journey 2024-08-19 always https://www.gilead.com/stories/overcoming-covid-19-in-early-2020-keith-story 2024-08-19 always https://www.gilead.com/stories/paving-the-way-for-the-future-pipeline-gilead-builds-new-state-of-the-art-research-center 2025-09-02 daily 0.5 https://www.gilead.com/stories/playwright-lee-raines-shines-a-spotlight-on-the-criminalization-of-hiv 2024-08-19 always https://www.gilead.com/stories/portugal-positive-approach-to-teaching-teens-about-the-birds-bees-and-stis 2024-08-19 always https://www.gilead.com/stories/preserving-fertility-in-the-face-of-a-cancer-diagnosis 2024-10-09 always https://www.gilead.com/stories/prioritizing-hiv-studies-in-youth 2024-08-19 always https://www.gilead.com/stories/prioritizing-the-needs-of-the-black-lgbtq-community-in-an-innovative-hiv-trial 2024-08-19 always https://www.gilead.com/stories/profiles-in-creating-possible-jan-pineda-is-on-the-front-lines-of-genetically-engineering-t-cells-to-fight-cancer 2026-02-19 always https://www.gilead.com/stories/providing-health-and-wellness-support-for-women-in-chicago-with-breast-cancer 2024-08-19 always https://www.gilead.com/stories/psc-awareness-day 2024-08-19 always https://www.gilead.com/stories/public--and-private-sector-partnerships-are-key-to-ending-the-hiv-epidemic 2024-08-19 always https://www.gilead.com/stories/putting-a-spotlight-on-the-mental-health-needs-of-lgbtq-youth 2024-08-19 always https://www.gilead.com/stories/putting-faith-into-conversations-about-hiv-in-the-southern-united-states 2024-08-19 always https://www.gilead.com/stories/putting-patients-first-in-metastatic-triple-negative-breast-cancer-clinical-trials 2026-03-19 daily 0.5 https://www.gilead.com/stories/ramping-up-manufacturing-to-help-address-covid-19 2026-02-19 always https://www.gilead.com/stories/ravens-journey-living-with-hiv 2024-08-19 always https://www.gilead.com/stories/real-world-experiences-of-people-living-with-hiv-prioritizing-their-well-being 2025-09-04 daily 0.5 https://www.gilead.com/stories/recovering-from-covid-19-tobinas-story 2024-08-19 always https://www.gilead.com/stories/reducing-our-footprint-it-is-time-to-get-more-ambitious 2024-08-19 always https://www.gilead.com/stories/reflecting-on-treating-the-first-person-diagnosed-with-covid-19-in-the-united-states 2024-08-19 always https://www.gilead.com/stories/renewing-efforts-to-educate-new-communities-in-the-fight-against-hiv 2024-08-19 always https://www.gilead.com/stories/research-scholars-program-scientists-advancing-hiv-research 2024-08-19 always https://www.gilead.com/stories/robert-suttle-seeks-to-end-hiv-criminalization 2024-08-19 always https://www.gilead.com/stories/russian-foundation-for-teens-with-hiv 2024-08-19 always https://www.gilead.com/stories/sara-tolaney-on-gilead-research-scholars-program-and-the-importance-of-diversity-in-medicine 2025-09-09 always https://www.gilead.com/stories/shattering-stigma-breaking-down-barriers-and-creating-change 2024-08-19 always https://www.gilead.com/stories/shon-finds-new-hope-with-car-t-cell-therapy 2026-02-06 always https://www.gilead.com/stories/stacey-bledsoe-resolve-to-make-clinical-trials-available-to-everyone 2024-08-19 always https://www.gilead.com/stories/street-works-stays-focused-on-showing-up 2024-08-19 always https://www.gilead.com/stories/students-find-ways-to-learn-and-connect-during-gilead-and-kite-summer-internship-program 2026-02-04 always https://www.gilead.com/stories/supporting-nonprofits-focused-on-the-hiv-epidemic-and-lgbtq-equality 2025-09-09 always https://www.gilead.com/stories/supporting-the-lgbtq-community-in-oakland-love-is-the-answer 2024-08-19 always https://www.gilead.com/stories/taking-a-stand-against-asian-american-and-pacific-islander-hate-crimes 2024-08-19 always https://www.gilead.com/stories/taking-care-of-those-who-are-left-out-and-left-behind 2026-02-19 always https://www.gilead.com/stories/tarik-daniels-focuses-on-suicide-prevention 2025-09-09 always https://www.gilead.com/stories/tatiana-williams-leads-the-way-with-the-transinclusive-group 2025-09-09 always https://www.gilead.com/stories/the-fantastic-voyage-of-car-t-cells 2024-08-19 always https://www.gilead.com/stories/the-global-health-challenge-of-hiv-and-hepatitis-b-coinfections 2025-03-13 daily 0.5 https://www.gilead.com/stories/the-importance-of-family-benefits-for-a-first-time-mom-poonums-story 2024-08-19 always https://www.gilead.com/stories/the-importance-of-self-advocacy-in-breast-cancer 2024-08-19 always https://www.gilead.com/stories/the-next-wave-of-innovation-in-virology-research 2024-08-19 always https://www.gilead.com/stories/the-translatinx-network-helps-a-resilient-community-live-its-truth 2025-09-09 always https://www.gilead.com/stories/the-unprecedented-role-manufacturing-innovation-played-in-shaping-gilead-long-acting-hiv-prevention-therapy 2026-03-26 daily 0.5 https://www.gilead.com/stories/the-year-ahead 2024-08-19 always https://www.gilead.com/stories/thumbi-ndungu-on-thinking-beyond-lifelong-treatment-in-hiv 2024-08-19 always https://www.gilead.com/stories/us-military-veteran-battles-lymphoma-with-car-t-cell-therapy-marcus-story 2024-08-19 always https://www.gilead.com/stories/using-lessons-from-the-hiv-epidemic-to-help-reduce-stigma-around-lung-cancer 2025-02-20 daily 0.5 https://www.gilead.com/stories/volunteering-on-the-front-lines 2024-08-19 always https://www.gilead.com/stories/wake-forest-university-school-of-divinity-brings-faith-to-the-gilead-compass-initiative 2024-08-19 always https://www.gilead.com/stories/why-i-am-more-hopeful-than-ever-about-innovation-in-hiv-research-a-perspective 2024-08-19 always https://www.gilead.com/stories/women-living-with-hiv-help-redefine-long-term-treatment-success 2025-10-16 daily 0.5 https://www.gilead.com/stories/working-from-home-with-a-3-year-old-a-perspective 2026-02-06 always https://www.gilead.com/stories/working-to-build-next-generation-cancer-therapies 2024-09-17 daily 0.5 https://www.gilead.com/stories/working-to-improve-the-standard-of-care-in-ibd-across-europe 2024-08-19 always https://www.gilead.com/stories/world-aids-day 2026-02-04 always https://www.gilead.com/stories/world-cancer-day-2020-we-need-to-keep-going 2025-09-09 always https://www.gilead.com/stories/year-in-review-2019 2024-08-19 always https://www.gilead.com/stories/year-in-review-2021-moving-forward-and-onward-together 2025-09-09 always https://www.gilead.com/company/overview 2024-08-19 daily 0.5 https://www.gilead.com/company/leadership 2025-11-17 daily 0.5 https://www.gilead.com/company/board-of-directors 2025-11-17 daily 0.5 https://www.gilead.com/company/board-governance-and-committees 2024-08-29 daily 0.5 https://www.gilead.com/company/media 2024-10-30 daily 0.5 https://www.gilead.com/company/ethics-and-compliance 2025-05-29 daily 0.5 https://www.gilead.com/company/policies-and-procedures 2025-04-17 daily 0.5 https://www.gilead.com/company/disclosures 2024-08-29 daily 0.5 https://www.gilead.com/company/us-public-policy-engagement 2024-09-05 daily 0.5 https://www.gilead.com/company/investing-in-the-us 2025-12-05 daily 0.5 https://www.gilead.com/company/supplier-information 2025-09-23 daily 0.5 https://www.gilead.com/company/annual-impact-reports 2025-04-22 daily 0.5 https://www.gilead.com/company/awards-and-recognition 2026-03-13 daily 0.5 https://www.gilead.com/company/company-statements 2026-02-18 daily 0.5 https://www.gilead.com/company/us-locations 2024-08-19 daily 0.5 https://www.gilead.com/contact-us/partnership-request 2024-08-29 daily 0.5 https://www.gilead.com/contact-us/report-an-adverse-event 2025-08-26 daily 0.5 https://www.gilead.com/careers/overview 2024-08-22 daily 0.5 https://www.gilead.com/careers/life-at-gilead 2024-09-10 daily 0.5 https://www.gilead.com/careers/opportunities 2025-08-12 daily 0.5 https://www.gilead.com/careers/global-workforce 2024-09-10 daily 0.5 https://www.gilead.com/cookie-statement/french-translation 2024-04-20 daily 0.5 https://www.gilead.com/cookie-statement/spanish-translation 2024-04-20 daily 0.5 https://www.gilead.com/cookie-statement/german-translation 2024-04-20 daily 0.5 https://www.gilead.com/cookie-statement/italian-translation 2024-04-20 daily 0.5 https://www.gilead.com/cookie-statement/portuguese-translation 2024-04-20 daily 0.5 https://www.gilead.com/cookie-statement/greek-translation 2024-04-20 daily 0.5 https://www.gilead.com/cookie-statement/czech-translation 2024-04-20 daily 0.5 https://www.gilead.com/cookie-statement/dutch-translation 2024-04-20 daily 0.5 https://www.gilead.com/cookie-statement/polish-translation 2024-04-20 daily 0.5 https://www.gilead.com/cookie-statement/slovakian-translation 2024-04-20 daily 0.5 https://www.gilead.com/privacy-statements/consumer-health-data-privacy-policy 2024-10-28 daily 0.5 https://www.gilead.com/privacy-statements/french-translation 2024-08-29 daily 0.5 https://www.gilead.com/privacy-statements/spanish-translation 2024-08-29 daily 0.5 https://www.gilead.com/privacy-statements/german-translation 2024-08-29 daily 0.5 https://www.gilead.com/privacy-statements/italian-translation 2024-08-29 daily 0.5 https://www.gilead.com/privacy-statements/portuguese-translation 2024-08-29 daily 0.5 https://www.gilead.com/privacy-statements/czech-translation 2024-08-29 daily 0.5 https://www.gilead.com/privacy-statements/dutch-translation 2024-08-29 daily 0.5 https://www.gilead.com/privacy-statements/polish-translation 2024-08-29 daily 0.5 https://www.gilead.com/privacy-statements/slovakian-translation 2024-08-29 daily 0.5 https://www.gilead.com/privacy-statements/global-applicant-privacy-statement 2024-08-29 daily 0.5 https://www.gilead.com/privacy-statements/healthcare-professional-privacy-notice-us-only 2024-08-29 daily 0.5 https://www.gilead.com/privacy-statements/healthcare-professional-privacy-notice 2024-08-29 daily 0.5 https://www.gilead.com/science/therapeutic-areas/overview 2024-09-05 daily 0.5 https://www.gilead.com/science/therapeutic-areas/virology 2026-01-09 daily 0.5 https://www.gilead.com/science/therapeutic-areas/oncology 2026-01-09 daily 0.5 https://www.gilead.com/science/therapeutic-areas/inflammation 2026-01-09 daily 0.5 https://www.gilead.com/science/research/overview 2024-08-19 daily 0.5 https://www.gilead.com/science/research/our-r-and-d-approach 2024-08-19 daily 0.5 https://www.gilead.com/science/research/research-funding-programs 2025-03-18 daily 0.5 https://www.gilead.com/science/research/research-publications 2024-08-29 daily 0.5 https://www.gilead.com/medicines/patient-safety/overview 2025-06-19 daily 0.5 https://www.gilead.com/medicines/patient-safety/anti-counterfeiting 2024-09-06 daily 0.5 https://www.gilead.com/medicines/patient-safety/consumer-product-safety 2024-08-30 daily 0.5 https://www.gilead.com/medicines/patient-safety/report-an-adverse-event 2025-02-21 daily 0.5 https://www.gilead.com/medicines/medication-access/overview 2025-06-19 daily 0.5 https://www.gilead.com/medicines/medication-access/us-patient-access 2025-04-01 daily 0.5 https://www.gilead.com/medicines/medication-access/managed-access 2025-07-10 daily 0.5 https://www.gilead.com/responsibility/esg/overview 2024-08-19 daily 0.5 https://www.gilead.com/responsibility/esg/esg-performance 2026-03-12 daily 0.5 https://www.gilead.com/responsibility/esg/esg-focus-areas 2024-09-06 daily 0.5 https://www.gilead.com/responsibility/esg/esg-frameworks-and-reporting 2025-04-22 daily 0.5 https://www.gilead.com/responsibility/sustainability/overview 2024-08-20 daily 0.5 https://www.gilead.com/responsibility/sustainability/sustainability-focus-areas 2024-09-05 daily 0.5 https://www.gilead.com/responsibility/giving-at-gilead/overview 2024-08-19 daily 0.5 https://www.gilead.com/responsibility/giving-at-gilead/corporate-giving 2025-03-11 daily 0.5 https://www.gilead.com/responsibility/giving-at-gilead/gilead-foundation 2026-03-17 daily 0.5 https://www.gilead.com/responsibility/global-health-and-access/overview 2024-08-19 daily 0.5 https://www.gilead.com/responsibility/global-health-and-access/focus 2024-10-03 daily 0.5 https://www.gilead.com/responsibility/global-health-and-access/access-in-low--and-middle-income-countries 2025-01-16 daily 0.5 https://www.gilead.com/responsibility/inclusion-and-diversity/overview 2024-08-19 daily 0.5 https://www.gilead.com/responsibility/inclusion-and-diversity/employee-resource-groups 2025-11-13 daily 0.5 https://www.gilead.com/company/leadership/overview 2024-08-19 daily 0.5 https://www.gilead.com/company/leadership/daniel-oday 2024-09-05 daily 0.5 https://www.gilead.com/company/leadership/andrew-dickinson 2024-09-06 daily 0.5 https://www.gilead.com/company/leadership/stacey-ma 2024-09-06 daily 0.5 https://www.gilead.com/company/leadership/dietmar-berger 2024-12-19 daily 0.5 https://www.gilead.com/company/leadership/flavius-martin 2024-09-05 daily 0.5 https://www.gilead.com/company/leadership/jyoti-mehra 2024-09-06 daily 0.5 https://www.gilead.com/company/leadership/johanna-mercier 2024-09-06 daily 0.5 https://www.gilead.com/company/leadership/cindy-perettie 2024-09-06 daily 0.5 https://www.gilead.com/company/leadership/keeley-wettan 2026-02-26 daily 0.5 https://www.gilead.com/company/board-of-directors/overview 2024-08-19 daily 0.5 https://www.gilead.com/company/board-of-directors/daniel-oday 2024-09-13 daily 0.5 https://www.gilead.com/company/board-of-directors/jacqueline-barton 2024-09-05 daily 0.5 https://www.gilead.com/company/board-of-directors/jeffrey-bluestone 2024-09-05 daily 0.5 https://www.gilead.com/company/board-of-directors/sandra-horning 2024-09-05 daily 0.5 https://www.gilead.com/company/board-of-directors/kelly-kramer 2024-09-05 daily 0.5 https://www.gilead.com/company/board-of-directors/ted-love 2024-09-17 daily 0.5 https://www.gilead.com/company/board-of-directors/harish-manwani 2024-09-05 daily 0.5 https://www.gilead.com/company/board-of-directors/javier-rodriguez 2024-09-17 daily 0.5 https://www.gilead.com/company/board-of-directors/anthony-welters 2024-09-05 daily 0.5 https://www.gilead.com/company/policies-and-procedures/overview 2025-04-17 daily 0.5 https://www.gilead.com/company/policies-and-procedures/ai-principles 2025-02-21 daily 0.5 https://www.gilead.com/company/us-public-policy-engagement/overview 2024-08-19 daily 0.5 https://www.gilead.com/company/us-public-policy-engagement/political-contributions-archives 2024-08-29 daily 0.5 https://www.gilead.com/company/supplier-information/overview 2024-08-19 daily 0.5 https://www.gilead.com/company/supplier-information/supplier-enablement-resources-sap-ariba 2024-09-05 daily 0.5 https://www.gilead.com/company/supplier-information/supplier-inclusion 2025-05-06 daily 0.5 https://www.gilead.com/careers/life-at-gilead/overview 2024-08-22 daily 0.5 https://www.gilead.com/careers/life-at-gilead/inclusion-and-diversity-in-hiring 2025-03-04 daily 0.5 https://www.gilead.com/careers/opportunities/overview 2024-08-22 daily 0.5 https://www.gilead.com/careers/opportunities/early-career-opportunities 2024-09-05 daily 0.5 https://www.gilead.com/global-operations/africa/south-africa 2024-08-29 daily 0.5 https://www.gilead.com/global-operations/asia/india 2024-08-29 daily 0.5 https://www.gilead.com/global-operations/asia/singapore 2024-08-29 daily 0.5 https://www.gilead.com/global-operations/europe/portugal 2024-08-29 daily 0.5 https://www.gilead.com/global-operations/europe/czech-republic-and-slovakia 2024-08-29 daily 0.5 https://www.gilead.com/global-operations/europe/ireland 2024-08-29 daily 0.5 https://www.gilead.com/global-operations/europe/netherlands 2024-08-29 daily 0.5 https://www.gilead.com/global-operations/europe/poland 2024-08-29 daily 0.5 https://www.gilead.com/global-operations/europe/romania 2024-08-29 daily 0.5 https://www.gilead.com/global-operations/europe/russia 2024-08-29 daily 0.5 https://www.gilead.com/global-operations/middle-east/saudi-arabia 2024-08-29 daily 0.5 https://www.gilead.com/global-operations/middle-east/united-arab-emirates 2024-08-29 daily 0.5 https://www.gilead.com/global-operations/north-america/mexico 2024-08-29 daily 0.5 https://www.gilead.com/global-operations/south-america/argentina 2024-08-29 daily 0.5 https://www.gilead.com/global-operations/south-america/brazil 2024-08-29 daily 0.5 https://www.gilead.com/global-operations/south-america/colombia 2024-08-29 daily 0.5 https://www.gilead.com/science/therapeutic-areas/virology/overview 2024-09-05 daily 0.5 https://www.gilead.com/science/therapeutic-areas/virology/hiv 2025-09-29 daily 0.5 https://www.gilead.com/science/therapeutic-areas/virology/viral-hepatitis 2025-03-11 daily 0.5 https://www.gilead.com/science/therapeutic-areas/virology/neglected-and-emerging-viruses-and-pandemic-preparedness 2025-11-07 daily 0.5 https://www.gilead.com/science/research/research-funding-programs/overview 2024-08-20 daily 0.5 https://www.gilead.com/science/research/research-funding-programs/research-scholars-program 2024-09-24 daily 0.5 https://www.gilead.com/science/research/research-funding-programs/external-sponsored-research 2025-03-18 daily 0.5 https://www.gilead.com/science/research/research-funding-programs/community-based-participatory-research 2025-03-21 daily 0.5 https://www.gilead.com/news/news-details/1996/fda-grants-marketing-clearance-of-gileads-vistide-for-the-treatment-of-cmv-retinitis-in-patients-with-aids 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/1996/gilead-sciences-announces-discovery-of-orally-active-influenza-inhibitors 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/1996/gilead-sciences-announces-statistically-significant-antiviral-activity-against-hepatitis-b-virus 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/1996/gilead-sciences-commences-human-clinical-testing-of-systemic-pmpa-for-hiv 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/1996/gilead-sciences-hoffman-la-roche-announce-worldwide-influenza-collaboration 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/1996/hoffmann-la-roche-gilead-sciences-announce-collaboration-to-co-promote-potential-hepatitis-c-treatment-in-the-us 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/1996/pharmacia--upjohn-and-gilead-sciences-announce-marketing-collaboration-outside-of-the-us-for-new-aids-related-drug-vistide 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/1996/pharmacia--upjohn-and-gilead-sciences-receive-european-recommendation-for-vistide 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/1997/donald-h-rumsfeld-named-chairman-of-gilead-sciences 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/1997/gilead-announces-phase-iii-data-insufficient-for-marketing-clearance-of-forvadetm-topical-gel-to-treat-refractory-herpes-in-patients-with-aids 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/1997/gilead-begins-phase-ii-clinical-trials-of-oral-gs-840-for-chronic-hepatitis-b 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/1997/gilead-sciences-announces-start-of-expanded-access-program-for-preveon 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/1997/gilead-sciences-begins-human-testing-of-oral-pmpa-for-treatment-of-hiv 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/1997/gilead-sciences-receives-marketing-authorization-for-vistide-in-european-union 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/1997/gileads-pmpa-significantly-reduces-hiv-levels-in-phase-iii-study 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/1997/hoffmann-la-roche-and-gilead-sciences-initiate-human-testing-of-oral-influenza-drug-gs-4104 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/1997/hoffmann-la-roche-and-gilead-sciences-start-phase-ii-human-testing-of-oral-influenza-drug-gs-4104 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/1997/oral-influenza-compound-reduced-symptoms-and-prevented-illness-in-humans 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/1998/12th-world-aids-conference-to-be-broadcast-on-world-wide-web 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/1998/cidofovir-reported-to-have-activity-against-poxvirus-infection-in-primates 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/1998/dr-paul-berg-joins-gilead-sciences-board-of-directors 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/1998/flu-patients-in-united-states-may-now-have-access-to-experimental-oral-treatment-for-influenza 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/1998/gilead-announces-adefovir-dipivoxil-reduces-hepatitis-b-levels-by-more-than-99-percent-in-chronically-infected-patients 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/1998/gilead-announces-first-quarter-1998-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/1998/gilead-announces-fourth-quarter-and-1997-year-end-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/1998/gilead-announces-preliminary-results-from-phase-iiiii-studies-for-new-product-to-treat-or-prevent-influenza 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/1998/gilead-announces-presentation-of-phase-iii-study-results-of-oral-pmpa-for-hiv-at-upcoming-medical-conference 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/1998/gilead-announces-second-quarter-1998-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/1998/gilead-announces-that-partner-hoffmann-la-roche-discloses-gs-4104-phase-iii-study-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/1998/gilead-announces-third-quarter-1998-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/1998/gilead-broadens-hiv-expanded-access-program-for-preveon 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/1998/gilead-sciences-announces-termination-of-genetic-code-blocker-research-collaboration-with-glaxo-wellcome 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/1998/gilead-sciences-begins-phase-ii-human-testing-of-oral-pmpa-for-treatment-of-hiv-combinations-including-hydroxyurea-to-be-evaluated 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/1998/gilead-sciences-provides-update-on-preveon-clinical-program-for-the-treatment-of-hiv 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/1998/isis-acquires-antisense-patent-and-technology-estate-from-gilead-sciences 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/1999/1999-third-quarter-highlights 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/1999/ambisome-phase-iii-study-for-cryptococcal-meningitis 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/1999/first-approval-of-roches-tamiflu-a-new-flu-treatment 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/1999/gilead-acquisition-of-nexstar-completed 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/1999/gilead-announces-first-quarter-1999-financial-results 2024-09-10 daily 0.5 https://www.gilead.com/news/news-details/1999/gilead-announces-fourth-quarter-and-1998-year-end-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/1999/gilead-announces-second-quarter-1999-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/1999/gilead-announces-third-quarter-1999-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/1999/gilead-begins-multinational-phase-iii-trial-of-hepatitis-b-drug-adefovir-dipivoxil 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/1999/gilead-begins-multinational-phase-iii-trial-of-once-daily-oral-anti-hiv-drug-tenofovir-disoproxil-fumarate 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/1999/gilead-presents-preliminary-clinical-data-demonstrating-activity-of-adefovir-dipivoxil-against-lamivudine-resistant-hepatitis-b-virus 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/1999/gilead-sciences-amends-stockholder-rights-plan-19991022094200 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/1999/gilead-sciences-and-nexstar-pharmaceuticals-announce-date-for-special-stockholders-meetings-to-approve-merger 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/1999/gilead-sciences-and-nexstar-pharmaceuticals-to-merge 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/1999/gilead-sciences-announces-acceptance-of-late-breaker-abstract-at-upcoming-scientific-conference 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/1999/gilead-sciences-announces-changes-to-senior-management-team 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/1999/gilead-sciences-announces-results-of-fda-advisory-panel-on-anti-hiv-agent-adefovir-dipivoxil-60-mg 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/1999/gilead-sciences-announces-termination-of-its-us-development-program-for-adefovir-dipivoxil-for-hiv 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/1999/gilead-sciences-completes-european-marketing-authorisation-application-for-anti-hiv-agent-adefovir-dipivoxil-60-mg 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/1999/hoffmann-la-roche-submits-new-drug-application-to-market-new-flu-pill 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/1999/preliminary-phase-ii-clinical-results-for-once-daily-anti-hiv-agent-tenofovir-df-presented-at-icaac 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/1999/roche-announces-new-data-on-recently-approved-tamiflu-first-pill-to-treat-the-most-common-strains-of-influenza-a--b 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/1999/roche-receives-fda-approval-of-tamiflu-first-pill-to-treat-the-most-common-strains-of-influenza-ab 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2000/2000-first-quarter-highlights 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2000/canada-approves-antifungal-agent-ambisome 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2000/fda-approves-ambisome-for-the-treatment-of-cryptococcal-meningitis-in-aids-patients 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2000/gilead-and-virco-announce-us-collaboration-to-promote-one-of-the-first-pharmacogenomic-applications-for-hiv-resistance-tests-and-services 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2000/gilead-announces-data-demonstrating-that-single-dose-of-ambisome-safely-and-effectively-treats-visceral-leishmaniasis-in-india 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2000/gilead-announces-first-quarter-2000-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2000/gilead-begins-multinational-phase-iii-trial-of-once-daily-oral-anti-hiv-drug-tenofovir-disoproxil-fumarate-in-treatment-nave-patients 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2000/gilead-begins-phase-ii-study-of-nx-211-investigational-compound-for-the-treatment-of-patients-with-topotecan-resistant-ovarian-cancer 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2000/gilead-begins-second-pivotal-phase-iii-trial-of-once-daily-oral-hepatitis-b-drug-adefovir-dipivoxil-10-mg 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2000/gilead-presents-preliminary-clinical-data-describing-activity-of-adefovir-dipivoxil-against-lamivudine-resistant-hepatitis-b-virus 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2000/gilead-sciences-acquires-rights-to-novel-oncology-compound-from-southern-research-institute 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2000/gilead-sciences-and-eyetech-pharmaceuticals-announce-exclusive-license-of-potential-new-therapy-for-age-related-macular-degeneration 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2000/gilead-sciences-announces-changes-in-senior-management-team 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2000/gilead-sciences-announces-license-agreement-for-investigational-cancer-compound-with-glaxo-wellcome-plc 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2000/gilead-sciences-announces-preliminary-results-from-study-of-adefovir-dipivoxil-10-mg-for-the-treatment-of-patients-co-infected-with-hiv-and-chronic-hepatitis-b 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2000/gilead-sciences-announces-private-offering-of-convertible-subordinated-notes 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2000/gilead-sciences-announces-results-from-48-week-study-of-once-daily-anti-hiv-agent-tenofovir-df 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2000/gilead-sciences-announces-second-quarter-2000-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2000/gilead-sciences-announces-third-quarter-2000-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2000/gilead-sciences-board-of-directors-approves-proposed-increase-in-authorized-capital-for-planned-2-for-1-stock-split 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2000/gilead-sciences-calls-for-redemption-of-convertible-subordinated-notes-20000713164200 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2000/gilead-sciences-initiates-private-placement-of-convertible-subordinated-notes 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2000/gilead-sciences-presents-48-week-phase-ii-safety-and-efficacy-results-for-once-daily-anti-hiv-agent-tenofovir-df 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2000/gilead-sciences-presents-48-week-viral-resistance-data-from-phase-ii-study-of-investigational-anti-hiv-agent-tenofovir-df 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2000/gilead-sciences-receives-approval-to-initiate-clinical-trials-in-china-for-adefovir-dipivoxil-an-investigational-compound-for-the-treatment-of-chronic-hepatitis-b-infection 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2000/international-aids-conference-webcast-attracts-thousands-in-first-week-webcastaids2000com 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2000/new-ambisome-label-includes-claim-of-superior-safety-profile-compared-to-abelcet-in-febrile-neutropenic-cancer-patients 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2000/new-tamiflu-data-shows-early-treatment-optimizes-benefit-for-flu-sufferers 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2000/pharmacoeconomic-study-compares-total-hospital-costs-of-ambisome-to-abelcet-for-empirical-treatment-of-patients-with-febrile-neutropenia 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2000/roche-seeks-new-tamiflu-indication-for-the-prevention-of-influenza 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2000/roche-seeks-to-broaden-tamiflu-treatment-indication-with-pediatric-application 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2000/roches-oral-flu-drug-tamiflu-gets-approval-in-japan 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2000/roches-tamiflu-granted-fda-approval-for-the-prevention-of-influenza 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2000/roche-submits-tamiflu-for-regulatory-approval-in-japan-first-oral-neuraminidase-inhibitor-for-the-treatment-and-prevention-of-influenza 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2000/roche-to-submit-additional-data-on-tamiflu-for-the-treatment-of-influenza-to-the-european-regulatory-authorities 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2000/second-quarter-2000-highlights 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2000/study-results-published-in-journal-of-clinical-infectious-diseases-demonstrate-that-ambisome-has-an-improved-safety-profile-compared-to-abelcet 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2000/tamiflu-granted-fda-approval-for-treatment-of-flu-in-children 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2000/xiii-international-aids-conference-to-be-broadcast-on-world-wide-web-webcastaids2000com 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2001/cordell-w-hull-joins-gilead-sciences-board-of-directors 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2001/cubist-pharmaceuticals-and-gilead-sciences-announce-european-commercialization-agreement-for-investigational-antibacterial-agent-cidecin 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2001/european-cpmp-gives-positive-opinion-on-viread-gileads-new-once-daily-treatment-for-hiv-infection 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2001/fda-posts-background-documents-for-october-3-viread-advisory-committee-meeting 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2001/gayle-edlund-wilson-joins-gilead-sciences-board-of-directors 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2001/gilead-achieves-primary-endpoint-in-phase-iii-study-of-adefovir-dipivoxil-for-chronic-hepatitis-b-virus-infection 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2001/gilead-announces-data-from-studies-of-adefovir-dipivoxil-demonstrating-significant-improved-liver-function-and-viral-load-reduction-in-patients-with-chronic-hepatitis-b-virus-infection 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2001/gilead-announces-data-from-studies-of-adefovir-dipivoxil-in-patients-with-lamivudine-resistant-chronic-hepatitis-b-virus-infection 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2001/gilead-announces-fda-advisory-committee-supports-use-of-viread-in-treatment-experienced-patients-with-hiv-infection 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2001/gilead-announces-primary-endpoint-met-in-phase-iii-study-of-adefovir-dipivoxil-10-mg-in-patients-with-lamivudine-resistant-chronic-hepatitis-b-infection 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2001/gilead-announces-start-of-early-access-program-for-investigational-anti-hiv-agent-tenofovir-df-in-united-states-and-france 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2001/gilead-begins-phase-i-study-of-gs7836-an-investigational-anticancer-drug 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2001/gilead-begins-phase-i-study-of-gs7904l-an-investigational-anticancer-drug 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2001/gilead-board-of-directors-appoints-james-m-denny-as-chairman 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2001/gilead-board-of-directors-approves-two-for-one-stock-split-20010119085900 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2001/gilead-licenses-rights-under-its-selex-and-aptamer-patent-estate-to-archemix 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2001/gilead-sciences-and-glaxosmithkline-modify-terms-of-license-agreement-for-nx-211-gileads-investigational-compound-for-the-treatment-of-cancer 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2001/gilead-sciences-announces-acceptance-of-late-breaker-abstract-at-upcoming-icaac-meeting 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2001/gilead-sciences-announces-data-from-studies-of-adefovir-dipivoxil-investigational-agent-for-the-treatment-of-chronic-hepatitis-b-infection 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2001/gilead-sciences-announces-degussa-corporation-will-acquire-gileads-49-percent-interest-in-proligo-llc 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2001/gilead-sciences-announces-first-quarter-2001-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2001/gilead-sciences-announces-fourth-quarter-and-year-end-2000-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2001/gilead-sciences-announces-preliminary-results-from-phase-iii-study-of-investigational-anti-hiv-agent-tenofovir-df 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2001/gilead-sciences-announces-results-from-phase-iii-study-of-adefovir-dipivoxil-in-precore-mutant-chronic-hepatitis-b-virus-infection 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2001/gilead-sciences-announces-second-quarter-2001-financial-results 2026-02-10 daily 0.5 https://www.gilead.com/news/news-details/2001/gilead-sciences-announces-third-quarter-2001-financial-results 2026-02-10 daily 0.5 https://www.gilead.com/news/news-details/2001/gilead-sciences-broadens-entry-criteria-for-tenofovir-df-expanded-access-program-in-the-united-states 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2001/gilead-sciences-initiates-phase-i-study-in-china-of-adefovir-dipivoxil-investigational-compound-for-the-treatment-of-chronic-hepatitis-b-infection 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2001/gilead-sciences-presents-data-characterizing-resistance-profile-of-tenofovir-df-investigational-agent-for-the-treatment-of-hiv 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2001/gilead-sciences-stockholders-clear-the-way-for-2-for-1-stock-split 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2001/gilead-sciences-submits-marketing-authorisation-application-to-european-regulatory-authorities-for-tenofovir-df-for-the-treatment-of-hiv-infection 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2001/gilead-sciences-submits-new-drug-application-to-us-fda-for-tenofovir-df-for-the-treatment-of-hiv-infection 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2001/gilead-sciences-to-release-fourth-quarter-and-year-end-2000-earnings-on-thursday-january-25-2001 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2001/gileads-investigational-antiretroviral-agent-viread-reduces-viral-load-in-hiv-patients-with-resistant-virus-in-pivotal-phase-iii-study 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2001/gileads-viread-for-the-treatment-of-hiv-infection-to-be-reviewed-by-fda-antiviral-advisory-committee-on-october-3-2001 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2001/jama-study-reveals-roches-tamiflu-effective-in-protecting-people-exposed-to-influenza 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2001/osi-pharmaceuticals-acquires-oncology-assets-from-gilead-sciences 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2001/osi-pharmaceuticals-and-gilead-sciences-announce-closing-of-oncology-assets-deal 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2001/pharmacy-shelves-make-room-for-tamiflu-liquid-for-kids 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2001/roche-submits-oral-flu-drug-tamiflu-for-regulatory-approval-in-europe 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2001/us-fda-approves-gilead-sciences-anti-hiv-drug-viread 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2002/48-week-data-compare-viread-to-stavudine-when-used-as-part-of-patients-first-anti-hiv-regimen-data-presented-at-xiv-international-aids-conference-in-barcelona 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2002/48-week-data-demonstrate-ability-of-viread-to-suppress-viral-load-in-patients-with-multiple-treatment-resistant-hiv-mutations 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2002/92-week-data-from-clinical-study-of-gileads-adefovir-dipivoxil-in-patients-co-infected-with-hiv-and-lamivudine-resistant-hbv-presented-at-international-medical-meeting 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2002/anadys-forms-collaboration-with-gilead-to-discover-novel-antiviral-compounds-anadys-uhts-atlas-to-be-used-to-screen-important-and-challenging-viral-target 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2002/data-from-study-of-gileads-adefovir-dipivoxil-in-hepatitis-b-patients-with-lamivudine-resistant-virus-presented-at-international-medical-meeting 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2002/european-cpmp-gives-positive-opinion-on-hepsera-gileads-treatment-for-chronic-hepatitis-b-recommendation-granted-eight-months-after-filing 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2002/fda-advisory-committee-unanimously-supports-approval-of-gileads-adefovir-dipivoxil-to-treat-chronic-hepatitis-b 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2002/fda-approves-gileads-hepseratm-for-the-treatment-of-chronic-hepatitis-b 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2002/gilead-and-glaxosmithkline-announce-international-licensing-agreement-for-investigational-chronic-hepatitis-b-drug-adefovir-dipivoxil 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2002/gilead-announces-changes-to-senior-management-team-organization-positioned-for-continued-growth 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2002/gilead-announces-data-from-study-of-viread-in-patients-co-infected-with-hiv-and-hbv-data-presented-at-9th-conference-on-retroviruses-and-opportunistic-infections 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2002/gilead-announces-initiation-of-nih-sponsored-phase-i-trial-to-evaluate-tenofovir-topical-gel-as-preventive-for-vaginal-transmission-of-hiv 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2002/gilead-announces-posting-of-fda-briefing-documents-for-august-6-advisory-committee-review-of-adefovir-dipivoxil-for-chronic-hepatitis-b 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2002/gilead-announces-preliminary-48-week-study-results-showing-viread-comparable-to-stavudine-in-treatment-naive-hiv-patients 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2002/gilead-announces-presentation-of-data-from-phase-iii-study-of-adefovir-dipivoxil-in-patients-with-precore-mutant-chronic-hepatitis-b 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2002/gilead-board-of-directors-approves-two-for-one-stock-split-20020130165800 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2002/gilead-initiates-early-access-program-for-adefovir-dipivoxil-investigational-treatment-for-chronic-hepatitis-b-infection 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2002/gilead-launches-web-site-for-new-anti-hiv-drug-viread 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2002/gilead-sciences-and-triangle-pharmaceuticals-announce-expiration-of-hart-scott-rodino-waiting-period 2024-09-12 daily 0.5 https://www.gilead.com/news/news-details/2002/gilead-sciences-announces-acceptance-of-viread-late-breaker-abstracts-at-upcoming-14th-international-aids-conference 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2002/gilead-sciences-announces-first-quarter-2002-financial-results-product-revenues-include-272-million-in-viread-sales 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2002/gilead-sciences-announces-fourth-quarter-and-year-end-2001-financial-results-product-revenues-increased-57-percent-over-fourth-quarter-2000 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2002/gilead-sciences-announces-second-quarter-2002-financial-results-strong-viread-sales-push-total-revenues-past-100-million-lead-to-profitability 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2002/gilead-sciences-announces-third-quarter-2002-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2002/gilead-sciences-new-hiv-drug-viread-approved-for-marketing-in-european-union 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2002/gilead-sciences-to-acquire-triangle-pharmaceuticals-for-464-million 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2002/gilead-sciences-to-release-first-quarter-2002-financial-results-on-tuesday-april-30-2002-conference-call-and-webcast-to-follow 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2002/gilead-sciences-to-release-fourth-quarter-and-year-end-2001-financial-results-on-thursday-january-31-2002-conference-call-and-webcast-to-follow 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2002/gilead-sciences-to-release-second-quarter-2002-financial-results-on-wednesday-july-24-2002-conference-call-and-webcast-to-follow 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2002/gilead-sciences-to-release-third-quarter-2002-financial-results-on-thursday-october-31-2002-conference-call-and-webcast-to-follow 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2002/gilead-sciences-viread-suppresses-hiv-viral-load-through-48-weeks-in-phase-iii-clinical-trial 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2002/gilead-submits-marketing-authorisation-application-for-adefovir-dipivoxil-10-mg-for-treatment-of-chronic-hepatitis-b-eu-application-follows-submission-to-fda 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2002/gilead-submits-new-drug-application-to-us-fda-for-adefovir-dipivoxil-10-mg-for-the-treatment-of-chronic-hepatitis-b 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2002/gilead-to-raise-300-million-from-offering-of-convertible-notes 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2002/gilead-to-receive-300-million-from-offering-of-convertible-notes 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2002/hepsera-selected-as-us-trade-name-for-adefovir-dipivoxil 2024-08-20 daily 0.5 https://www.gilead.com/news/news-details/2002/new-data-demonstrate-antiviral-activity-of-gileads-hepsera-in-patients-with-lamivudine-resistant-chronic-hepatitis-b 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2002/phase-iii-study-of-viread-shows-favorable-lipid-and-mitochondrial-dna-profile-in-treatment-naive-hiv-patients-data-presented-in-late-breaker-session-at-42nd-icaac 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2002/roche-receives-approval-in-europe-for-tamiflur 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2002/roche-receives-positive-recommendation-in-europe-for-tamiflur 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2002/viread-demonstrates-anti-hiv-potency-similar-to-the-protease-inhibitor-ritonavir-in-short-term-study-of-treatment-naive-patients 2024-07-23 daily 0.5 https://www.gilead.com/news/news-details/2002/webcast-alert-gilead-sciences-inc-announces-its-annual-meeting-of-stockholders-conference-call-on-the-web 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2003/96-week-data-from-gileads-study-903-show-low-rate-of-virologic-failure-among-patients-taking-viread 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2003/96-week-data-from-phase-iii-study-show-long-term-efficacy-with-reduced-risk-of-lipid-and-metabolic-changes-for-viread-versus-stavudine-in-treatment-naive-hiv-patients 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2003/96-week-data-show-hepsera-reduces-liver-damage-and-improves-liver-function-in-more-than-70-percent-of-patients-with-hepatitis-b-e-antigen-negative-disease 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2003/cauley-geller-announces-class-action-lawsuit-against-gilead-sciences-inc-on-behalf-of-investors 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2003/european-commission-expands-the-indication-of-viread-gileads-once-daily-treatment-for-hiv-to-include-treatment-naive-patients 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2003/european-cpmp-gives-positive-opinion-on-emtriva-gileads-new-once-daily-treatment-for-hiv 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2003/european-cpmp-gives-positive-opinion-to-extend-the-indication-of-viread-gileads-once-daily-treatment-for-hiv-infection 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2003/gilead-and-bukwang-end-licensing-agreement-for-clevudine-investigational-agent-for-chronic-hepatitis-b 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2003/gilead-and-chiron-corporation-sign-non-exclusive-hcv-licensing-agreement-gilead-to-initiate-research-programs-in-hepatitis-c 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2003/gilead-and-japan-tobacco-sign-licensing-agreement-for-commercialization-of-gileads-hiv-products-in-japan 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2003/gilead-announces-144-week-data-of-hepsera-in-patients-co-infected-with-hiv-and-lamivudine-resistant-hbv 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2003/gilead-announces-preliminary-results-from-48-week-phase-iii-study-of-emtricitabine-in-patients-with-chronic-hepatitis-b 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2003/gilead-initiates-study-934-a-48-week-clinical-trial-evaluating-viread-and-emtriva-versus-combivir 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2003/gilead-launches-access-program-to-provide-anti-hiv-therapy-viread-in-68-developing-countries-at-no-profit 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2003/gilead-launches-web-site-for-hepsera-its-chronic-hepatitis-b-drug 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2003/gilead-purchases-foster-city-campus 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2003/gilead-sciences-amends-stockholder-rights-plan 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2003/gilead-sciences-announces-completion-of-redemption-of-5-convertible-subordinated-notes 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2003/gilead-sciences-announces-first-quarter-2003-financial-results-record-viread-sales-of-107-million-product-sales-of-156-million-up-121-percent-over-first-quarter-2002 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2003/gilead-sciences-announces-fourth-quarter-and-full-year-2002-financial-results-full-year-product-sales-of-424-million-up-122-percent-over-2001-net-income-of-72-million-for-2002 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2003/gilead-sciences-announces-second-quarter-2003-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2003/gilead-sciences-announces-selling-securityholder-registration-statement-declared-effective-by-sec 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2003/gilead-sciences-announces-third-quarter-2003-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2003/gilead-sciences-announces-third-quarter-2003-financial-results-20031028160300 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2003/gilead-sciences-calls-for-redemption-of-convertible-subordinated-notes-20031120163200 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2003/gilead-sciences-completes-acquisition-of-triangle-pharmaceuticals 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2003/gilead-sciences-expects-second-quarter-2003-financial-results-will-exceed-expectations-increase-driven-primarily-by-higher-viread-revenues 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2003/gilead-sciences-files-500-million-shelf-registration-statement 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2003/gilead-sciences-files-500-million-shelf-registration-statement-20031222185700 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2003/gilead-sciences-hepatitis-b-drug-hepsera-approved-for-marketing-in-european-union 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2003/gilead-sciences-hiv-drug-emtriva-approved-for-marketing-in-european-union 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2003/gilead-sciences-invites-investors-to-listen-to-webcast-of-presentation-at-goldman-sachs-healthcare-conference-webcast-available-through-gilead-corporate-website 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2003/gilead-sciences-successfully-completes-tender-offer-for-shares-of-triangle-pharmaceuticals-with-97-percent-of-shares-tendered 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2003/gilead-sciences-to-present-at-credit-suisse-first-boston-2003-healthcare-conference 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2003/gilead-sciences-to-present-at-credit-suisse-first-boston-2003-healthcare-conference-webcast-available-through-gilead-corporate-website 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2003/gilead-sciences-to-present-corporate-update-at-the-ubs-global-life-sciences-conference-on-tuesday-september-23-2003 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2003/gilead-sciences-to-release-first-quarter-financial-results-on-wednesday-april-23-2003-conference-call-and-webcast-to-follow 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2003/gilead-sciences-to-release-fourth-quarter-and-year-end-2002-financial-results-on-thursday-january-30-2003-conference-call-and-webcast-to-follow 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2003/gilead-sciences-to-release-second-quarter-financial-results-on-thursday-july-31-2003-conference-call-and-webcast-to-follow 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2003/gilead-sciences-to-release-third-quarter-financial-results-on-tuesday-october-28-2003-conference-call-and-webcast-to-follow 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2003/gilead-signs-agreement-to-acquire-foster-city-campus 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2003/intrabiotics-names-mark-l-perry-to-its-board-of-directors 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2003/mark-perry-joins-nuvelo-board-of-directors 2024-07-23 daily 0.5 https://www.gilead.com/news/news-details/2003/milberg-weiss-announces-the-filing-of-a-class-action-suit-against-gilead-sciences-inc-on-behalf-of-investors 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2003/new-data-highlight-safety-and-tolerability-profile-of-gileads-viread-for-periods-up-to-four-years-data-presented-at-european-aids-conference-in-warsaw 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2003/phase-iii-data-show-emtricitabine-maintains-viral-load-suppression-as-part-of-once-daily-protease-sparing-anti-hiv-regimen 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2003/phase-iii-trial-of-emtriva-new-once-daily-capsule-for-hiv-shows-continued-response-through-60-weeks 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2003/results-of-two-pivotal-studies-of-gileads-hepsera-published-in-the-new-england-journal-of-medicine 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2003/shareholder-class-action-filed-against-gilead-sciences-inc-by-the-law-firm-of-schiffrin--barroway-llp 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2003/us-fda-approves-gilead-sciences-emtriva-a-one-capsule-once-daily-medication-for-the-treatment-of-hiv 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2004/bristol-myers-squibb-and-gilead-sciences-establish-us-joint-venture-to-develop-and-commercialize-fixed-dose-combination-of-three-hiv-medicines 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2004/bristol-myers-squibb-gilead-sciences-and-merck--co-inc-announce-plans-to-develop-fixed-dose-combination-of-three-hiv-medicines 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2004/correcting-and-replacing-gilead-sciences-announces-acceptance-of-study-934-late-breaker-abstract-at-44th-annual-icaac-in-washington-dc 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2004/correcting-and-replacing-gilead-sciences-to-present-at-the-banc-of-america-securities-2004-healthcare-conference-on-friday-may-21st 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2004/european-chmp-gives-positive-opinion-on-gileads-truvada-as-part-of-combination-hiv-therapy 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2004/gilead-and-achillion-announce-collaboration-for-the-development-and-commercialization-of-achillions-hepatitis-c-compounds 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2004/gilead-and-genelabs-announce-research-collaboration-and-license-agreement-for-the-development-of-genelabs-novel-hepatitis-c-compounds 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2004/gilead-announces-data-from-landmark-three-year-clinical-trial-of-viread-144-week-data-highlight-viread-efficacy-safety-and-side-effect-profile 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2004/gilead-announces-long-term-safety-and-efficacy-data-through-144-weeks-for-hepsera-in-patients-with-chronic-hepatitis-b 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2004/gilead-announces-preliminary-24-week-data-from-study-934-comparing-viread-and-emtriva-to-combivir-both-in-combination-with-efavirenz-in-patients-with-hiv 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2004/gilead-board-of-directors-approves-two-for-one-stock-split-20040728162700 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2004/gilead-discontinues-development-of-gs-9005-and-gs-7340-company-continues-commitment-to-research-efforts-in-hiv 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2004/gilead-emory-university-and-the-university-of-georgia-research-foundation-end-licensing-agreement-for-amdoxovir-investigational-agent-for-hiv 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2004/gilead-expands-initiatives-providing-access-to-new-hiv-therapy-truvada-in-united-states-and-abroad 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2004/gilead-files-investigational-new-drug-application-for-its-novel-protease-inhibitor-anti-hiv-drug-developed-using-gileads-proprietary-prodrug-technology 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2004/gilead-reduces-price-of-viread-in-the-developing-world-by-37-percent-anti-hiv-medication-available-to-68-resource-limited-countries-through-the-gilead-access-program 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2004/gilead-sciences-announces-completion-of-redemption-of-2-convertible-senior-notes 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2004/gilead-sciences-announces-first-quarter-2004-financial-results-total-revenues-of-309-million-up-87-percent-over-first-quarter-2003 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2004/gilead-sciences-announces-fourth-quarter-and-full-year-2003-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2004/gilead-sciences-announces-new-commercial-structure-and-changes-to-senior-management-team-expansion-and-reorganization-of-commercial-group-to-support-anticipated-growth 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2004/gilead-sciences-announces-second-quarter-2004-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2004/gilead-sciences-announces-third-quarter-2004-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2004/gilead-sciences-board-member-establishes-rule-10b5-1-stock-trading-plan-20040503090400 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2004/gilead-sciences-board-member-establishes-rule-10b5-1-stock-trading-plan-20040817083200 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2004/gilead-sciences-calls-for-redemption-of-convertible-subordinated-notes 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2004/gilead-sciences-to-be-added-to-sp-500-index 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2004/gilead-sciences-to-present-at-2004-bio-ceo--investor-conference-webcast-available-through-gilead-corporate-website 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2004/gilead-sciences-to-present-at-the-22nd-annual-jpmorgan-healthcare-conference-on-monday-january-12th-webcast-available-through-gilead-corporate-website 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2004/gilead-sciences-to-present-at-the-24th-annual-sg-cowen-healthcare-conference-on-tuesday-march-9th-webcast-available-through-gilead-corporate-website 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2004/gilead-sciences-to-present-at-the-25th-annual-goldman-sachs-global-healthcare-conference-on-tuesday-june-8th-webcast-available-through-gilead-corporate-website 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2004/gilead-sciences-to-present-at-the-7th-annual-lehman-brothers-global-healthcare-conference-on-friday-march-5th-webcast-available-through-gilead-corporate-website 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2004/gilead-sciences-to-present-at-the-banc-of-america-securities-2004-healthcare-conference-on-friday-may-21st-webcast-available-through-gilead-corporate-website 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2004/gilead-sciences-to-present-at-the-biocentury-and-thomson-financial-newsmakers-in-the-biotech-industry-conference-on-thursday-september-9th 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2004/gilead-sciences-to-present-at-the-credit-suisse-first-boston-annual-healthcare-conference-on-thursday-november-18th-webcast-available-through-gilead-corporate-website 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2004/gilead-sciences-to-present-at-the-harris-nesbitt-4th-annual-investor-conference-on-wednesday-december-8th-webcast-available-through-gilead-corporate-website 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2004/gilead-sciences-to-present-at-the-lazard-1st-annual-life-sciences-conference-on-wednesday-december-1st-webcast-available-through-gilead-corporate-website 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2004/gilead-sciences-to-present-at-the-punk-ziegel--companys-investor-symposium-on-monday-november-22nd-webcast-available-through-gilead-corporate-website 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2004/gilead-sciences-to-present-at-the-thomas-weisel-partners-healthcare-tailwinds-2004-conference-on-wednesday-september-8th 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2004/gilead-sciences-to-present-at-the-ubs-global-life-sciences-conference-on-monday-september-27th-webcast-available-through-gilead-corporate-website 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2004/gilead-sciences-to-release-first-quarter-2004-financial-results-on-thursday-april-22-2004-conference-call-and-webcast-to-follow 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2004/gilead-sciences-to-release-fourth-quarter-and-year-end-2003-financial-results-on-thursday-january-29-2004-conference-call-and-webcast-to-follow 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2004/gilead-sciences-to-release-second-quarter-2004-financial-results-on-thursday-july-29-2004-conference-call-and-webcast-to-follow 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2004/gilead-sciences-to-release-third-quarter-2004-financial-results-on-thursday-october-21-2004-conference-call-and-webcast-to-follow 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2004/gilead-signs-inventory-management-agreements-with-the-three-major-us-wholesalers 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2004/gilead-submits-applications-to-us-and-european-regulatory-authorities-for-fixed-dose-co-formulation-of-viread-and-emtriva 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2004/interim-24-week-data-from-study-934-comparing-a-regimen-of-viread-and-emtriva-versus-combivir-both-in-combination-with-efavirenz-in-patients-with-hiv-presented-at-44th-icaac 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2004/kevin-young-joins-gilead-sciences-as-executive-vice-president-commercial-operations 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2004/new-data-support-hepseras-long-term-efficacy-against-chronic-hepatitis-b 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2004/nicholas-g-moore-joins-gilead-sciences-board-of-directors 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2004/pivotal-studies-of-gileads-viread-and-emtriva-published-in-special-international-aids-conference-issue-of-journal-of-the-american-medical-association 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2004/us-fda-approves-gileads-truvada-a-one-tablet-once-a-day-fixed-dose-co-formulation-of-viread-and-emtriva-as-part-of-hiv-combination-therapy 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2005/48-week-data-comparing-viread-versus-abacavir-as-replacement-for-thymidine-analogue-in-lipoatraphic-hiv-patients-presented-at-the-12th-conference-on-retroviruses-and-opportunistic-infections 2024-10-22 daily 0.5 https://www.gilead.com/news/news-details/2005/data-evaluating-long-term-therapy-with-hepsera-for-hepatitis-b-e-antigen-negative-chronic-hepatitis-b-published-in-the-new-england-journal-of-medicine 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2005/data-show-efficacy-of-standard-dosing-regimen-of-ambisomer-is-similar-to-high-loading-dose-for-patients-with-invasive-fungal-infections 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2005/dr-george-p-shultz-resigns-from-gilead-sciences-board-of-directors 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2005/european-commission-approves-truvada-a-once-a-day-tablet-containing-gilead-sciences-anti-hiv-drugs-emtriva-and-viread 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2005/five-year-data-evaluating-long-term-therapy-with-hepserar-for-hepatitis-b-e-antigen-negative-chronic-hepatitis-b-presented-at-aasld-annual-meeting 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2005/gilead-and-achillion-announce-initiation-of-phase-i-clinical-trial-evaluating-gs-9132-for-the-treatment-of-hepatitis-c 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2005/gilead-and-japan-tobacco-sign-licensing-agreement-for-novel-hiv-integrase-inhibitor 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2005/gilead-and-roche-end-tamiflur-dispute-expanded-collaboration-includes-gilead-role-in-oversight-of-manufacturing-and-commercialization 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2005/gilead-announces-initiation-of-phase-iii-clinical-trial-evaluating-hiv-integrase-inhibitor-gs-9137 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2005/gilead-announces-preliminary-48-week-data-from-study-934-comparing-viread-and-emtriva-to-combivir-both-in-combination-with-sustiva-in-patients-with-hiv 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2005/gilead-delivers-termination-notice-to-roche-for-tamiflu-development-and-licensing-agreement 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2005/gilead-expands-global-access-program-for-hiv-therapies-to-include-additional-countries-in-the-caribbean-and-latin-america-bahamas-manufacturing-plant-established 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2005/gilead-launches-an-educational-website-on-advances-in-combination-therapy-for-hiv 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2005/gilead-provides-update-on-development-of-fixed-dose-regimen-of-truvada--emtricitabine-and-tenofovir-disoproxil-fumarate--and-sustiva--efavirenz- 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2005/gilead-provides-update-on-development-of-fixed-dose-regimen-of-truvadar-emtricitabine-and-tenofovir-disoproxil-fumarate-and-sustivar-efavirenz 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2005/gilead-reduces-prices-for-vireadr-and-truvadar-in-the-developing-world 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2005/gilead-sciences-and-aspen-pharmacare-sign-letter-of-intent-to-establish-non-exclusive-licensing-and-distribution-agreement-for-antiretrovirals-truvada-and-viread-in-developing-world-countries 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2005/gilead-sciences-and-royalty-pharma-announce-525-million-agreement-with-emory-university-to-purchase-royalty-interest-for-emtricitabine 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2005/gilead-sciences-and-royalty-pharma-complete-525-million-purchase-from-emory-university-of-emtricitabine-royalty-interest 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2005/gilead-sciences-announces-early-termination-of-hart-scott-rodino-waiting-period-for-the-japan-tobacco-license-for-jtk-303 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2005/gilead-sciences-announces-first-quarter-2005-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2005/gilead-sciences-announces-fourth-quarter-and-full-year-2004-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2005/gilead-sciences-announces-initiation-of-phase-iii-clinical-program-evaluating-tenofovir-disoproxil-fumarate-for-the-treatment-of-chronic-hepatitis-b-virus 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2005/gilead-sciences-announces-management-promotions 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2005/gilead-sciences-announces-second-quarter-2005-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2005/gilead-sciences-announces-third-quarter-2005-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2005/gilead-sciences-board-member-amends-existing-rule-10b5-1-stock-trading-plan-20050818170300 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2005/gilead-sciences-board-member-establishes-rule-10b5-1-stock-trading-plan-20050429163200 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2005/gilead-sciences-to-present-at-the-2005-ubs-global-life-sciences-conference-on-tuesday-september-27th-webcast-available-through-gilead-corporate-website 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2005/gilead-sciences-to-present-at-the-23rd-annual-jpmorgan-healthcare-conference-on-monday-january-10th-webcast-available-through-gilead-corporate-website 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2005/gilead-sciences-to-present-at-the-banc-of-america-securities-health-care-conference-2005-on-tuesday-may-17th-webcast-available-through-gilead-corporate-website 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2005/gilead-sciences-to-present-at-the-cibc-world-markets-16th-annual-healthcare-conference-on-monday-november-7th-webcast-available-through-gilead-corporate-website 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2005/gilead-sciences-to-present-at-the-credit-suisse-first-boston-healthcare-conference-on-thursday-november-17th-webcast-available-through-gilead-corporate-website 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2005/gilead-sciences-to-present-at-the-goldman-sachs-26th-annual-global-healthcare-conference-on-wednesday-june-15th-webcast-available-through-gilead-corporate-website 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2005/gilead-sciences-to-present-at-the-lazard-capital-markets-life-sciences-conference-on-wednesday-november-30th-webcast-available-through-gilead-corporate-website 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2005/gilead-sciences-to-present-at-the-merrill-lynch-global-pharmaceutical-medical-device-and-biotechnology-conference-on-tuesday-february-8th 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2005/gilead-sciences-to-present-at-the-nasdaq-16th-investor-program-on-thursday-december-8th-webcast-available-through-gilead-corporate-website 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2005/gilead-sciences-to-present-at-the-sg-cowen--co-25th-annual-health-care-conference-on-tuesday-march-15th-webcast-available-through-gilead-corporate-website 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2005/gilead-sciences-to-present-at-two-upcoming-investor-conferences-20050328163100 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2005/gilead-sciences-to-present-at-two-upcoming-investor-conferences-20050527163200 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2005/gilead-sciences-to-present-at-two-upcoming-investor-conferences-20050902170900 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2005/gilead-sciences-to-release-first-quarter-2005-financial-results-on-tuesday-april-19-2005-conference-call-and-webcast-to-follow 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2005/gilead-sciences-to-release-fourth-quarter-and-year-end-2004-financial-results-on-thursday-january-27-2005-conference-call-and-webcast-to-follow 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2005/gilead-sciences-to-release-second-quarter-2005-financial-results-on-tuesday-july-19-2005-conference-call-and-webcast-to-follow 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2005/gilead-sciences-to-release-third-quarter-2005-financial-results-on-tuesday-october-18-2005-conference-call-and-webcast-to-follow 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2005/gilead-to-repatriate-funds-to-the-united-states 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2005/john-f-cogan-joins-gilead-sciences-board-of-directors 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2005/john-w-madigan-joins-gilead-sciences-board-of-directors 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2005/preliminary-24-week-data-evaluating-the-impact-of-switching-from-twice-daily-combivirr-to-once-daily-truvadar-in-patients-with-hiv-presented-at-10th-european-aids-conference 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2006/96-week-data-from-gileads-study-934-comparing-vireadr-and-emtrivar-to-combivirr-both-in-combination-with-sustivar-presented-at-xvi-international-aids-conference 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2006/96-week-data-from-gileads-study-934-comparing-vireadr-and-emtrivar-to-combivirr-both-in-combination-with-sustivar-published-in-journal-of-acquired-immune-deficiency-syndrome 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2006/bristol-myers-squibb-and-gilead-announce-data-supporting-bioequivalence-for-single-pill-fixed-dose-regimen-of-sustivar-efavirenz-and-truvadar-emtricitabine-and-tenofovir-disoproxil-fumarate 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2006/bristol-myers-squibb-and-gilead-sciences-establish-agreement-to-commercialize-atriplatm-efavirenz-600-mg-emtricitabine-200-mg-tenofovir-disoproxil-fumarate-300-mg-in-canada 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2006/bristol-myers-squibb-and-gilead-sciences-submit-new-drug-application-to-us-fda-for-a-once-daily-single-tablet-regimen-of-sustivar-efavirenz-and-truvadar-emtricitabine-and-tenofovir-disoproxi 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2006/bristol-myers-squibb-gilead-sciences-and-merck--co-submit-marketing-authorisation-application-for-atriplatm-efavirenz-600-mg-emtricitabine-200-mg-tenofovir-disoproxil-fumarate-300-mg-to-euro 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2006/data-comparing-vireadr-and-emtrivar-to-combivirr-as-part-of-combination-hiv-therapy-published-in-new-england-journal-of-medicine 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2006/gilead-announces-dismissal-of-securities-litigation 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2006/gilead-announces-licensing-agreements-with-eight-india-based-companies-for-manufacturing-and-distribution-of-generic-versions-of-viread-in-the-developing-world 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2006/gilead-announces-licensing-agreements-with-three-india-based-companies-for-manufacturing-and-distribution-of-generic-versions-of-viread-in-the-developing-world 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2006/gilead-announces-preliminary-results-from-phase-iii-study-of-aztreonam-lysine-for-inhalation-in-patients-with-cystic-fibrosis 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2006/gilead-announces-results-from-phase-iii-study-of-investigational-hiv-integrase-inhibitor-gs-9137 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2006/gilead-announces-the-advancement-of-hiv-integrase-inhibitor-gs-9137-to-a-phase-ii-clinical-trial 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2006/gilead-closes-sale-of-13-billion-convertible-senior-notes 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2006/gilead-grants-intellectual-property-rights-for-tenofovir-topical-gel-to-the-international-partnership-for-microbicides-and-conrad 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2006/gilead-invests-25-million-in-corus-pharma-establishes-equity-position-in-company-with-late-stage-product-candidate-for-cystic-fibrosis 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2006/gilead-offers-voluntary-licenses-for-manufacturing-of-viread-in-developing-world 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2006/gilead-prices-12-billion-convertible-senior-notes-company-to-repurchase-approximately-545-million-in-common-stock 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2006/gilead-sciences-agrees-to-exercise-its-option-to-acquire-corus-pharma-for-365-million 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2006/gilead-sciences-and-merck-establish-agreement-for-distribution-of-atriplatm-in-developing-countries 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2006/gilead-sciences-and-the-institute-of-organic-chemistry-and-biochemistry-iocb-establish-new-academic-research-centre-in-prague-donation-by-gilead-honors-leadership-of-dr-antonin-holy-in-antiv 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2006/gilead-sciences-announces-early-termination-of-hart-scott-rodino-waiting-period-20061026160300 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2006/gilead-sciences-announces-first-quarter-2006-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2006/gilead-sciences-announces-fourth-quarter-and-full-year-2005-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2006/gilead-sciences-announces-second-quarter-2006-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2006/gilead-sciences-announces-third-quarter-2006-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2006/gilead-sciences-board-member-amends-existing-rule-10b5-1-stock-trading-plan 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2006/gilead-sciences-completes-acquisition-of-corus-pharma 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2006/gilead-sciences-completes-acquisition-of-myogen 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2006/gilead-sciences-completes-acquisition-of-raylo-chemicals-inc 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2006/gilead-sciences-exercises-option-to-acquire-corus-pharma-for-365-million 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2006/gilead-sciences-extends-expiration-date-for-tender-offer-for-myogen-until-november-13-2006 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2006/gilead-sciences-launches-stop-hep-b-campaign-initiative-aims-to-combat-chronic-hepatitis-b-by-educating-and-empowering-at-risk-communities 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2006/gilead-sciences-president-and-chief-executive-officer-establishes-rule-10b5-1-stock-trading-plan 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2006/gilead-sciences-receives-subpoena-from-us-department-of-justice-20061207195700 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2006/gilead-sciences-successfully-completes-tender-offer-for-shares-of-myogen-with-over-913-percent-of-shares-tendered 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2006/gilead-sciences-to-acquire-degussas-raylo-chemicals-inc-purchase-to-expand-gileads-manufacturing-scale-up-capacity-for-investigational-therapies 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2006/gilead-sciences-to-acquire-myogen-inc-for-25-billion 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2006/gilead-sciences-to-present-at-the-22nd-annual-sanford-bernstein-strategic-decisions-conference-2006-on-wednesday-may-31st-webcast-available-through-gilead-corporate-website 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2006/gilead-sciences-to-present-at-the-24th-annual-jpmorgan-healthcare-conference-on-monday-january-9th-webcast-available-through-gilead-corporate-website 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2006/gilead-sciences-to-present-at-the-banc-of-america-2006-health-care-conference-on-thursday-may-18th-webcast-available-through-gilead-corporate-website 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2006/gilead-sciences-to-present-at-the-bear-stearns-19th-annual-healthcare-conference-on-tuesday-september-12th-webcast-available-through-gilead-corporate-website 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2006/gilead-sciences-to-present-at-the-citigroup-2006-healthcare-conference-on-tuesday-february-28th-webcast-available-through-gilead-corporate-website 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2006/gilead-sciences-to-present-at-the-credit-suisse-healthcare-conference-on-friday-november-17th 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2006/gilead-sciences-to-present-at-the-merrill-lynch-global-pharmaceutical-biotechnology--medical-device-conference-on-wednesday-february-8th-webcast-available-through-gilead-corporate-website 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2006/gilead-sciences-to-present-at-the-nasdaq-18th-investor-program-on-thursday-december-7 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2006/gilead-sciences-to-present-at-the-ubs-global-life-sciences-conference-on-monday-september-25th-webcast-available-through-gilead-corporate-website 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2006/gilead-sciences-to-present-at-the-william-blair--company-26th-annual-growth-stock-conference-on-wednesday-june-28th-webcast-available-through-gilead-corporate-website 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2006/gilead-sciences-to-present-at-two-upcoming-investor-conferences-20060303191900 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2006/gilead-sciences-to-present-at-two-upcoming-investor-conferences-20060428163100 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2006/gilead-sciences-to-present-at-two-upcoming-investor-conferences-20060609163200 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2006/gilead-sciences-to-present-at-two-upcoming-investor-conferences-20060901161700 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2006/gilead-sciences-to-present-at-two-upcoming-investor-conferences-20061122163300 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2006/gilead-sciences-to-release-first-quarter-2006-financial-results-on-tuesday-april-18-2006-conference-call-and-webcast-to-follow 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2006/gilead-sciences-to-release-fourth-quarter-and-year-end-2005-financial-results-on-monday-january-30-2006-conference-call-and-webcast-to-follow 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2006/gilead-sciences-to-release-second-quarter-2006-financial-results-on-thursday-july-20-2006-conference-call-and-webcast-to-follow 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2006/gilead-sciences-to-release-third-quarter-2006-financial-results-on-wednesday-october-18-2006 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2006/gilead-submits-new-drug-application-to-us-fda-for-ambrisentan-for-the-treatment-of-pulmonary-arterial-hypertension 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2006/gilead-to-offer-11-billion-convertible-senior-notes-company-to-repurchase-approximately-500-million-in-common-stock 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2006/kristen-m-metza-joins-gilead-as-vice-president-human-resources 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2006/landmark-five-year-data-on-gileads-anti-hiv-drug-vireadr-presented-at-8th-international-workshop-on-adverse-drug-reactions-and-lipodystrophy 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2006/us-fda-grants-traditional-approval-for-gileads-once-daily-hiv-medications-truvadar-and-vireadr-48-week-data-from-pivotal-study-934-added-to-us-prescribing-information-for-both-products 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2006/us-food-and-drug-administration-fda-approves-atriplatm-efavirenz-600-mg-emtricitabine-200-mg-tenofovir-disoproxil-fumarate-300-mg-the-first-once-daily-single-tablet-regimen-for-adults-with-h 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2007/144-week-data-from-gileads-study-934-comparing-truvadar-to-combivirr-both-in-combination-with-sustivar-presented-at-international-aids-society-meeting-in-sydney 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2007/bristol-myers-squibb-and-gilead-sciences-expand-their-alliance-to-include-commercialization-of-atriplar-efavirenz-600-mgemtricitabine-200-mgtenofovir-disoproxil-fumarate-300-mg-in-europe 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2007/carla-a-hills-joins-gilead-sciences-board-of-directors 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2007/caroline-dorsa-to-join-gilead-as-senior-vice-president-and-chief-financial-officer 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2007/data-from-phase-ii-study-of-gileads-darusentan-in-resistant-hypertension-published-in-journal-of-clinical-hypertension 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2007/data-from-preclinical-studies-of-gilead-nucleotide-compound-gs-9219-to-be-presented-at-aacr 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2007/european-chmp-issues-positive-opinion-for-atriplar-efavirenz-600-mg-emtricitabine-200-mgtenofovir-disoproxil-fumarate-300-mg 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2007/european-commission-approves-atriplar-efavirenz-600-mgemtricitabine-200-mgtenofovir-disoproxil-fumarate-300-mg-the-first-once-daily-single-tablet-regimen-for-virologically-suppressed-adults- 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2007/gilead-and-achillion-announce-positive-antiviral-activity-of-ns4a-antagonist-in-hcv-but-discontinue-gs-9132-ach-806-development 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2007/gilead-and-lg-life-sciences-announce-global-license-agreement-to-advance-novel-drug-candidates-for-treatment-of-fibrotic-diseases 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2007/gilead-announces-24-week-results-from-phase-ii-study-of-investigational-hiv-integrase-inhibitor-gs-9137 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2007/gilead-announces-48-week-data-evaluating-switching-from-combivirr-to-truvadar-among-virologically-suppressed-hiv-patients 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2007/gilead-announces-48-week-data-from-two-pivotal-phase-iii-studies-evaluating-vireadr-for-the-treatment-of-chronic-hepatitis-b 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2007/gilead-announces-achievement-of-primary-efficacy-endpoint-in-second-phase-iii-study-of-aztreonam-lysine-for-inhalation-in-patients-with-cystic-fibrosis 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2007/gilead-announces-completion-of-phase-ii-clinical-trial-of-novel-investigational-hiv-integrase-inhibitor-gs-9137 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2007/gilead-announces-detailed-results-of-phase-iii-study-of-aztreonam-lysine-for-inhalation-in-patients-with-cystic-fibrosis 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2007/gilead-announces-expanded-access-program-for-aztreonam-lysine-for-inhalation-for-patients-with-cystic-fibrosis 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2007/gilead-announces-new-letairistm-ambrisentan-data-for-the-treatment-of-patients-with-pulmonary-arterial-hypertension-who-group-1 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2007/gilead-announces-phase-i-data-for-gs-9190-an-investigational-compound-for-the-treatment-of-chronic-hepatitis-c 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2007/gilead-announces-presentation-of-long-term-data-for-ambrisentan-a-potential-treatment-for-patients-with-pulmonary-arterial-hypertension 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2007/gilead-announces-presentation-of-positive-phase-iii-data-on-aztreonam-lysine-for-inhalation-in-patients-with-cystic-fibrosis 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2007/gilead-announces-share-repurchase-program-20071022161600 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2007/gilead-board-of-directors-approves-two-for-one-stock-split 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2007/gilead-sciences-announces-first-quarter-2007-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2007/gilead-sciences-announces-fourth-quarter-and-full-year-2006-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2007/gilead-sciences-announces-new-appointments-within-executive-team 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2007/gilead-sciences-announces-second-quarter-2007-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2007/gilead-sciences-announces-senior-management-promotion 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2007/gilead-sciences-announces-senior-management-promotion-20070125170200 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2007/gilead-sciences-announces-third-quarter-2007-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2007/gilead-sciences-board-member-establishes-rule-10b5-1-stock-trading-plan-20070731161600 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2007/gilead-sciences-board-member-establishes-rule-10b5-1-stock-trading-plan-20071024161600 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2007/gilead-sciences-chief-operating-officer-and-chief-financial-officer-establishes-rule-10b5-1-stock-trading-plan 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2007/gilead-sciences-completes-1-billion-stock-repurchase-program 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2007/gilead-sciences-executive-vice-president-commercial-operations-establishes-rule-10b5-1-stock-trading-plan 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2007/gilead-sciences-to-host-conference-call-to-discuss-the-us-food-and-drug-administration-approval-of-letairistm 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2007/gilead-sciences-to-present-at-bank-of-americas-2007-healthcare-conference-on-wednesday-may-30 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2007/gilead-sciences-to-present-at-citigroups-2007-global-healthcare-conference-on-wednesday-may-23 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2007/gilead-sciences-to-present-at-the-19th-annual-piper-jaffray-healthcare-conference-on-tuesday-november-27 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2007/gilead-sciences-to-present-at-the-2007-credit-suisse-healthcare-conference-on-wednesday-november-14 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2007/gilead-sciences-to-present-at-the-2007-ubs-global-life-sciences-conference-on-tuesday-september-25 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2007/gilead-sciences-to-present-at-the-25th-annual-jpmorgan-healthcare-conference-on-monday-january-8th 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2007/gilead-sciences-to-present-at-the-bear-stearns-20th-annual-healthcare-conference-on-tuesday-september-11 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2007/gilead-sciences-to-present-at-the-cibc-world-markets-annual-biotechnology--specialty-pharmaceuticals-conference-on-thursday-april-12 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2007/gilead-sciences-to-present-at-the-cowen--company-27th-annual-health-care-conference-on-monday-march-12 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2007/gilead-sciences-to-present-at-the-goldman-sachs-28th-annual-healthcare-conference-on-wednesday-june-13 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2007/gilead-sciences-to-present-at-the-lehman-brothers-10th-annual-global-healthcare-conference-on-monday-march-19 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2007/gilead-sciences-to-present-at-the-merrill-lynch-global-pharmaceutical-biotechnology--medical-device-conference-on-wednesday-february-7 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2007/gilead-sciences-to-present-at-the-morgan-stanley-global-healthcare-unplugged-conference-on-wednesday-may-2 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2007/gilead-sciences-to-present-at-the-nasdaq-20th-investor-program-on-thursday-december-6 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2007/gilead-sciences-to-present-at-two-upcoming-investor-conferences-20070621163000 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2007/gilead-sciences-to-present-at-two-upcoming-investor-conferences-20070829163100 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2007/gilead-sciences-to-present-at-two-upcoming-investor-conferences-20071031161500 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2007/gilead-sciences-to-release-first-quarter-2007-financial-results-on-wednesday-april-18-2007 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2007/gilead-sciences-to-release-fourth-quarter-and-year-end-2006-financial-results-on-wednesday-january-31-2007 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2007/gilead-sciences-to-release-second-quarter-2007-financial-results-on-thursday-july-19-2007 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2007/gilead-sciences-to-release-third-quarter-2007-financial-results-on-thursday-october-18-2007 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2007/gileads-new-drug-application-for-ambrisentan-receives-priority-review-status 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2007/gilead-submits-marketing-applications-in-the-united-states-and-european-union-for-vireadr-tenofovir-disoproxil-fumarate-for-the-treatment-of-chronic-hepatitis-b 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2007/gilead-submits-new-drug-application-to-us-fda-for-aztreonam-lysine-for-inhalation-for-cystic-fibrosis 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2007/health-canada-approves-atriplar-efavirenz-600-mgemtricitabine-200-mgtenofovir-disoproxil-fumarate-300-mg-the-first-once-daily-single-tablet-regimen-for-hiv 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2007/marketing-authorisation-application-for-ambrisentan-validated-by-european-medicines-agency 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2007/parion-sciences-and-gilead-sciences-sign-agreement-to-advance-drug-candidates-for-pulmonary-disease 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2007/phase-iii-study-evaluating-gileads-vireadr-for-the-treatment-of-chronic-hepatitis-b-virus-meets-primary-endpoint 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2007/second-phase-iii-study-evaluating-gileads-vireadr-for-the-treatment-of-chronic-hepatitis-b-virus-meets-primary-endpoint 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2007/us-food-and-drug-administration-approves-gileads-letairistm-ambrisentan-5-mg-and-10-mg-tablets-for-the-once-daily-treatment-of-pulmonary-arterial-hypertension-who-group-1-in-patients-with-wh 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2008/data-demonstrating-significant-efficacy-of-vireadr-in-treating-chronic-hepatitis-b-published-in-new-england-journal-of-medicine 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2008/data-from-pivotal-phase-iii-studies-of-gileads-letairisr-ambrisentan-for-pulmonary-arterial-hypertension-who-group-1-in-patients-with-who-functional-class-ii-or-iii-symptoms-published-in-circulation 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2008/european-chmp-issues-positive-opinion-for-vireadr-for-the-treatment-of-chronic-hepatitis-b 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2008/european-commission-approves-vireadr-for-chronic-hepatitis-b 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2008/gilead-and-navitas-announce-agreement-for-cicletanine-for-the-treatment-of-pulmonary-arterial-hypertension 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2008/gilead-announces-500-million-accelerated-share-repurchase 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2008/gilead-announces-72-week-data-from-two-pivotal-phase-iii-studies-evaluating-vireadr-for-the-treatment-of-chronic-hepatitis-b 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2008/gilead-announces-departure-of-caroline-dorsa 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2008/gilead-announces-interim-12-month-phase-iii-study-results-for-aztreonam-lysine-for-inhalation-in-patients-with-cystic-fibrosis 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2008/gilead-announces-new-letairisr-ambrisentan-data-for-the-treatment-of-patients-with-pulmonary-arterial-hypertension-who-group-1-with-who-functional-class-ii-or-iii-symptoms 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2008/gilead-announces-two-year-clinical-data-for-letairisr-ambrisentan-for-the-treatment-of-pulmonary-arterial-hypertension-who-group-1 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2008/gilead-announces-two-year-data-from-pivotal-phase-iii-studies-evaluating-vireadr-for-chronic-hepatitis-b 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2008/gilead-appoints-dr-john-j-toole-as-senior-vice-president-corporate-development 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2008/gilead-appoints-john-c-martin-as-chairman-of-board-of-directors-names-john-f-milligan-president 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2008/gilead-initiates-letairisr-ambrisentan-phase-iv-program 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2008/gilead-initiates-phase-iii-clinical-trial-of-elvitegravir-an-investigational-integrase-inhibitor-for-hiv 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2008/gilead-receives-complete-response-letter-from-us-food-and-drug-administration-for-aztreonam-lysine-for-inhalation-an-investigational-treatment-for-cystic-fibrosis 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2008/gilead-sciences-and-merck--co-inc-enter-into-an-agreement-to-register-and-distribute-hiv-medication-atriplar-efavirenz-600-mg-emtricitabine-200-mg-tenofovir-disoproxil-fumarate-300-mg-in-twe 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2008/gilead-sciences-announces-first-quarter-2008-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2008/gilead-sciences-announces-fourth-quarter-and-full-year-2007-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2008/gilead-sciences-announces-notification-of-anda-filing-for-truvada 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2008/gilead-sciences-announces-second-quarter-2008-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2008/gilead-sciences-announces-third-quarter-2008-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2008/gilead-sciences-board-member-establishes-rule-10b5-1-stock-trading-plan 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2008/gilead-sciences-chairman-and-chief-executive-officer-establishes-rule-10b5-1-stock-trading-plan 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2008/gilead-sciences-files-patent-infringement-lawsuit-against-teva-pharmaceuticals 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2008/gilead-sciences-submits-marketing-authorisation-application-for-aztreonam-lysine-75-mg-powder-for-nebuliser-solution-a-potential-new-treatment-for-cystic-fibrosis-to-european-medicines-agency 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2008/gilead-sciences-to-present-at-the-2008-citi-investment-research-global-healthcare-conference-on-wednesday-may-21 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2008/gilead-sciences-to-present-at-the-26th-annual-jpmorgan-healthcare-conference-on-monday-january-7 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2008/gilead-sciences-to-present-at-the-29th-annual-goldman-sachs-global-healthcare-conference-on-wednesday-june-11 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2008/gilead-sciences-to-present-at-the-bank-of-america-2008-healthcare-conference-on-tuesday-may-13 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2008/gilead-sciences-to-present-at-the-merrill-lynch-global-pharmaceutical-biotechnology--medical-device-conference-on-tuesday-february-5 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2008/gilead-sciences-to-present-at-the-morgan-stanley-global-healthcare-unplugged-conference-on-wednesday-april-30 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2008/gilead-sciences-to-present-at-the-oppenheimer-19th-annual-healthcare-conference-on-tuesday-november-4 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2008/gilead-sciences-to-present-at-the-thomas-weisel-partners-healthcare-conference-on-wednesday-september-3 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2008/gilead-sciences-to-present-at-three-upcoming-investor-conferences-20081105161800 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2008/gilead-sciences-to-present-at-two-upcoming-investor-conferences-20080310163100 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2008/gilead-sciences-to-present-at-two-upcoming-investor-conferences-20080910173100 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2008/gilead-sciences-to-present-at-two-upcoming-investor-conferences-20081125161800 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2008/gilead-sciences-to-release-first-quarter-2008-financial-results-on-wednesday-april-16-2008 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2008/gilead-sciences-to-release-fourth-quarter-and-year-end-2007-financial-results-on-wednesday-january-23-2008 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2008/gilead-sciences-to-release-second-quarter-2008-financial-results-on-thursday-july-17-2008 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2008/gilead-sciences-to-release-third-quarter-2008-financial-results-on-thursday-october-16-2008 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2008/gilead-signs-agreement-with-efi-to-acquire-building-and-associated-land-bordering-gileads-foster-city-campus 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2008/richard-j-whitley-md-joins-gilead-sciences-board-of-directors 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2008/robin-l-washington-to-join-gilead-as-senior-vice-president-and-chief-financial-officer 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2008/seigo-izumo-md-joins-gilead-as-senior-vice-president-cardiovascular-therapeutics 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2008/us-food-and-drug-administration-approves-vireadr-for-chronic-hepatitis-b-in-adults 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2008/us-patent-office-confirms-first-of-four-vireadr-patents 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2008/us-patent-office-confirms-second-of-four-vireadr-patents 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2009/department-of-justice-declines-to-intervene-in-false-claims-act-lawsuits-against-gilead-sciences 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2009/european-chmp-adopts-negative-opinion-on-aztreonam-lysine 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2009/european-chmp-adopts-positive-opinion-for-aztreonam-lysine 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2009/european-commission-grants-conditional-marketing-authorization-to-caystonr-aztreonam-lysine-for-the-treatment-of-chronic-pulmonary-infections-due-to-pseudomonas-aeruginosa-in-patients-with-c 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2009/fda-advisory-committee-supports-use-of-aztreonam-for-inhalation-solution-for-patients-with-cystic-fibrosis 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2009/gilead-and-glaxosmithkline-announce-agreement-to-commercialize-vireadr-for-chronic-hepatitis-b-in-key-asian-countries 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2009/gilead-announces-data-demonstrating-pharmacokinetic-boosting-activity-of-gs-9350 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2009/gilead-announces-long-term-data-from-two-pivotal-phase-iii-studies-evaluating-vireadr-for-chronic-hepatitis-b 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2009/gilead-announces-senior-management-promotion 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2009/gilead-announces-senior-management-promotion-20090202140200 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2009/gilead-completes-acquisition-of-building-and-associated-land-from-efi 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2009/gilead-initiates-phase-ii-clinical-trial-of-cicletanine-for-the-treatment-of-pulmonary-arterial-hypertension 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2009/gilead-initiates-phase-ii-clinical-trial-of-integrase-based-single-tablet-once-daily-regimen-for-the-treatment-of-hiv 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2009/gilead-outlines-rd-priorities-for-2009 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2009/gilead-palo-alto-inc-announces-tender-offer-for-convertible-notes 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2009/gilead-receives-response-from-us-fda-on-companys-request-for-formal-dispute-resolution-for-aztreonam-for-inhalation-solution 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2009/gileads-aztreonam-for-inhalation-solution-to-be-reviewed-by-fda-anti-infective-drugs-advisory-committee-on-december-10-2009 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2009/gilead-sciences-agrees-to-acquire-cv-therapeutics-for-2000-per-share 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2009/gilead-sciences-announces-agreement-with-tibotec-pharmaceuticals-to-develop-and-commercialize-new-fixed-dose-combination-of-truvadar-and-tmc278 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2009/gilead-sciences-announces-changes-to-cardiovascular-rd-organization-leadership 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2009/gilead-sciences-announces-early-termination-of-hart-scott-rodino-waiting-period-20090331183100 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2009/gilead-sciences-announces-notification-of-anda-filing-for-atriplar 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2009/gilead-sciences-announces-plans-for-phase-iv-clinical-trial-evaluating-first-line-combination-therapy-versus-monotherapy-in-pulmonary-arterial-hypertension 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2009/gilead-sciences-announces-record-first-quarter-2009-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2009/gilead-sciences-announces-record-fourth-quarter-and-full-year-2008-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2009/gilead-sciences-announces-record-second-quarter-2009-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2009/gilead-sciences-announces-record-third-quarter-2009-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2009/gilead-sciences-completes-acquisition-of-cv-therapeutics 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2009/gilead-sciences-executive-vice-president-establishes-rule-10b5-1-stock-trading-plan 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2009/gilead-sciences-files-second-patent-infringement-lawsuit-against-teva-pharmaceuticals 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2009/gilead-sciences-marketing-authorisation-application-for-regadenoson-validated-by-european-medicines-agency 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2009/gilead-sciences-phase-iii-darusentan-data-show-significant-blood-pressure-reductions-in-resistant-hypertension-patients 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2009/gilead-sciences-receives-subpoena-from-us-department-of-health--human-services-regarding-ranexar 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2009/gilead-sciences-successfully-completes-tender-offer-for-shares-of-cv-therapeutics-with-over-88-percent-of-shares-tendered 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2009/gilead-sciences-to-present-at-the-11th-annual-bio-ceo-investor-conference-on-tuesday-february-10 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2009/gilead-sciences-to-present-at-the-18th-annual-credit-suisse-healthcare-conference-on-wednesday-november-11 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2009/gilead-sciences-to-present-at-the-27th-annual-jpmorgan-healthcare-conference-on-monday-january-12 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2009/gilead-sciences-to-present-at-the-barclays-capital-global-healthcare-conference-on-tuesday-march-10 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2009/gilead-sciences-to-present-at-the-cowen-and-company-29th-annual-healthcare-conference-on-monday-march-16 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2009/gilead-sciences-to-present-at-the-deutsche-bank-34th-annual-healthcare-conference-on-tuesday-may-19 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2009/gilead-sciences-to-present-at-the-lazard-capital-markets-6th-annual-healthcare-conference-on-tuesday-november-17 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2009/gilead-sciences-to-present-at-the-nasdaq-omx-23rd-investor-program 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2009/gilead-sciences-to-present-at-the-oppenheimer-20th-annual-healthcare-conference-on-tuesday-november-3 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2009/gilead-sciences-to-present-at-the-piper-jaffray-4th-annual-europe-conference-on-wednesday-june-24 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2009/gilead-sciences-to-present-at-the-thomas-weisel-partners-healthcare-conference-2009-on-wednesday-september-9 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2009/gilead-sciences-to-present-at-the-ubs-global-life-sciences-conference-on-monday-september-21 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2009/gilead-sciences-to-present-at-three-upcoming-investor-conferences 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2009/gilead-sciences-to-present-at-two-upcoming-investor-conferences-20090602163000 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2009/gilead-sciences-to-release-first-quarter-2009-financial-results-on-tuesday-april-21-2009 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2009/gilead-sciences-to-release-fourth-quarter-and-year-end-2008-financial-results-on-tuesday-january-27-2009 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2009/gilead-sciences-to-release-second-quarter-2009-financial-results-on-tuesday-july-21-2009 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2009/gilead-sciences-to-release-third-quarter-2009-financial-results-on-tuesday-october-20-2009 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2009/kevin-e-lofton-joins-gilead-sciences-board-of-directors 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2009/landmark-five-year-african-study-indicates-that-hiv-therapy-may-be-given-safely-in-resource-limited-settings-without-routine-laboratory-monitoring 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2009/new-data-for-gilead-sciences-ambrisentan-show-clinical-improvements-in-a-diverse-pulmonary-hypertension-ph-population 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2009/phase-iii-data-for-gilead-sciences-darusentan-accepted-as-late-breaker-presentation-at-ash-2009 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2009/phase-iii-study-of-gileads-darusentan-for-resistant-hypertension-meets-primary-endpoints 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2009/pivotal-data-demonstrating-efficacy-of-darusentan-in-treating-resistant-hypertension-published-in-the-lancet 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2009/second-pivotal-phase-iii-study-of-gileads-darusentan-for-resistant-hypertension-misses-primary-endpoints 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2010/aya-jakobovits-phd-named-president-and-ceo-of-kite-pharma-inc 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2010/department-of-justice-declines-to-intervene-in-lawsuit-against-gilead--sciences-regarding-ranexar 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2010/dr-paul-berg-to-retire-from-gilead-sciences-board-of-directors 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2010/gilead-announces-5-billion-share-repurchase-program-20100511083300 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2010/gilead-announces-share-repurchase-program 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2010/gilead-closes-sale-of-22-billion-of-convertible-senior-notes 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2010/gilead-finalizes-selection-of-bioequivalent-formulation-for-the--fixed-dose-regimen-of-truvadar-and-tibotec--pharmaceuticals-tmc278 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2010/gilead-initiates-phase-iii-clinical-program-evaluating-single-tablet--once-daily-quad-regimen-for-hiv 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2010/gilead-prices-22-billion-of-convertible-senior-notes-company-to--repurchase-1-billion-in-common-stock 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2010/gilead-provides-update-on-5-billion-stock-repurchase-program 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2010/gilead-provides-update-on-development-of-fixed-dose-regimen-of-truvadar--and-tibotec-pharmaceuticals-tmc278 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2010/gileads-caystonr-superior-to-tobramycin--inhalation-solution-in-six-month-head-to-head-cystic-fibrosis-study 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2010/gilead-sciences-and-adap-crisis-task-force-announce-new-initiatives--to-support-aids-drug-assistance-programs-adaps 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2010/gilead-sciences-announces-notification-of-anda-filing-for-hepserar 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2010/gilead-sciences-announces-notification-of-anda-filing-for-ranexar 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2010/gilead-sciences-announces-notification-of-anda-filing-for-viread 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2010/gilead-sciences-announces-record-first-quarter-2010-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2010/gilead-sciences-announces-record-fourth-quarter-and-full-year-2009-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2010/gilead-sciences-announces-second-quarter-2010-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2010/gilead-sciences-announces-third-quarter-2010-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2010/gilead-sciences-files-patent-infringement-lawsuit-against-lupin-limited 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2010/gilead-sciences-submits-european-marketing-application-for-once-daily-single-tablet-regimen-of-truvadar-and-tmc278-for-the-treatment-of-hiv-infection 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2010/gilead-sciences-submits-new-drug-application-to-us-fda-for--once-daily-single-tablet-regimen-of-truvadar--and-tmc278-for-hiv 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2010/gilead-sciences-to-acquire-arresto-biosciences-for-225-million 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2010/gilead-sciences-to-acquire-cgi-pharmaceuticals-for-up-to-120-million 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2010/gilead-sciences-to-present-at-the-12th--annual-bio-ceo-investor-conference-on-tuesday-february-9 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2010/gilead-sciences-to-present-at-the-2010-citi-investment-research--global-health-care-conference-on-wednesday-may-26 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2010/gilead-sciences-to-present-at-the-2010-creditsuisse-healthcare-conference-on-thursday-november-11 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2010/gilead-sciences-to-present-at-the-22nd-annual-piper-jaffray-healthcare-conference-on-tuesday-november-30 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2010/gilead-sciences-to-present-at-the-banc-of-america-merrill-lynch-2010--healthcare-conference-on-thursday-may-13 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2010/gilead-sciences-to-present-at-the-barclays-capital-2010-global--healthcare-conference-on-wednesday-march-24 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2010/gilead-sciences-to-present-at-the-cowen-and-company-30th--annual-health-care-conference-on-thursday-march-11 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2010/gilead-sciences-to-present-at-the-jefferies-2010-global-life-sciences--conference-on-wednesday-june-9 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2010/gilead-sciences-to-present-at-the-nasdaq-omx-25th-investor-program 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2010/gilead-sciences-to-present-at-the-sanford-c-bernstein-26th--annual-strategic-decisions-conference-on-thursday-june-3 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2010/gilead-sciences-to-present-at-the-ubs-global-life-sciences-conference--on-monday-september-20 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2010/gilead-sciences-to-present-at-two-upcoming-investor-conferences-20100104163300 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2010/gilead-sciences-to-present-at-two-upcoming-investor-conferences-20100609163100 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2010/gilead-sciences-to-present-at-two-upcoming-investor-conferences-20100908163200 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2010/gilead-sciences-to-release-first-quarter-2010-financial-results-on--tuesday-april-20-2010 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2010/gilead-sciences-to-release-fourth-quarter-and-year-end-2009-financial-results-on-tuesday-january-26-2010 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2010/gilead-sciences-to-release-second-quarter-2010-financial-results-on--tuesday-july-20-2010 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2010/gilead-sciences-to-release-third-quarter-2010-financial-results-on--tuesday-october-19-2010 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2010/gileads-head-to-head-study-of-caystonr--versus-tobramycin-inhalation-solution-in-cystic-fibrosis-patients--achieves-co-primary-efficacy-endpoint-of-non-inferiority 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2010/gileads-investigational-hepatitis-c-compounds-gs-9190-and-gs-9256-in--combination-with-standard-of-care-therapies-achieve-substantial-viral--suppression-in-phase-ii-study 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2010/gileads-single-tablet-quad-hiv-regimen-maintains-high-viral--suppression-through-48-weeks-in-phase-ii-study 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2010/gileads-single-tablet-quad-regimen-for-hiv-achieves-a-high-rate-of--virologic-suppression-in-phase-ii-study 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2010/gilead-terminates-phase-ii-clinical-trial-of-gs-9450-in-patients-with--chronic-hepatitis-c 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2010/gilead-terminates-phase-iii-clinical-trial-of-ambrisentan-in-patients--with-idiopathic-pulmonary-fibrosis 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2010/gilead-to-offer-22-billion-of-convertible-senior-notes-company-to--repurchase-1-billion-in-common-stock 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2010/john-g-mchutchison-md-to-join-gilead-sciences-as-senior-vice--president-liver-disease-therapeutics 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2010/kite-pharma-appoints-dr-gloria-lee-chief-medical-officer 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2010/per-wold-olsen-joins-gilead-sciences-board-of-directors 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2010/phase-ii-clinical-trial-of-gileads-investigational-integrase-based-once-daily-fixed-dose-quad-regimen-meets-24-week-primary-objective 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2010/us-food-and-drug-administration-approves-caystonr--aztreonam-for-inhalation-solution-for-the-improvement-of-respiratory--symptoms-in-cystic-fibrosis-patients-with-pseudomonas-aeruginosa 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2010/vireadr-for-hepatitis-b-maintains-antiviral-suppression-with--no-development-of-resistance-through-four-years-of-treatment 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2011/bristol-myers-squibb-and-gilead-sciences-announce-licensing-agreement--for-development-and-commercialization-of-new-fixed-dose-combination-pill-for-people-living-with-hiv 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2011/european-chmp-adopts-positive-opinion-for-eviplerar--a-once-daily-single-tablet-regimen-for-the-treatment-of-hiv-infection 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2011/gilead-amends-study-design-for-ongoing-hepatitis-c-clinical-trials--that-include-gs-9190-pegylated-interferon-and-ribavirin-and-another--direct-acting-antiviral-agent 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2011/gilead-and-boehringer-ingelheim-sign-license-agreement-for-novel-hiv--non-catalytic-integrase-inhibitors 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2011/gilead-and-globeimmune-announce-license-and-collaboration-agreement--to-develop-therapeutic-vaccine-products-for-treatment-of-chronic--hepatitis-b-infection 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2011/gilead-and-microdose-therapeutx-announce-license-and-collaboration--agreement-to-develop-mdt-637-for-treatment-of-respiratory-syncytial--virus 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2011/gilead-announces-positive-five-year-data-showing-effect-of-vireadr-on--liver-fibrosis-and-cirrhosis-caused-by-chronic-hepatitis-b 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2011/gilead-announces-two-year-data-from-pivotal-phase-3-study-of-elvitegravir-an-integrase-inhibitor-for-hiv 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2011/gilead-appoints-dr-muzammil-m-mansuri-as-senior-vice-president--research-and-development-strategy-and-corporate-development 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2011/gilead-expands-access-program-for-medications-in-developing-world 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2011/gilead-extends-its-funding-support-for-the-gilead-sciences-research--centre-at-the-institute-of-organic-chemistry-and-biochemistry-in-prague 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2011/gilead-files-european-marketing-application-for-the-quad-a-once-daily-single-tablet-regimen-for-the-treatment-of-hiv-infection 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2011/gilead-prices-1-billion-of-senior-unsecured-notes 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2011/gilead-prices-37-billion-of-senior-unsecured-notes 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2011/gilead-receives-european-marketing-authorization-for-eviplerar-a-new-complete-once-daily-single-tablet-regimen-for-hiv-1-infection-in-treatment-naive-adults 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2011/gilead-recommends-rejection-of-mini-tender-offer-by-trc-capital--corporation 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2011/gileads-boosting-agent-cobicistat-meets-48-week-primary-objective-in-pivotal-phase-3-study 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2011/gilead-sciences-and-cardiovascular-research-foundation-initiate-phase--3-clinical-trial-with-ranolazine-in-patients-who-have-undergone-pci-with--a-history-of-prior-chronic-angina 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2011/gilead-sciences-and-world-health-organization-establish-new-five-year--initiative-to-prevent-deaths-from-visceral-leishmaniasis 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2011/gilead-sciences-announces-agreement-with-tibotec-pharmaceuticals-to--develop-and-commercialize-a-new-fixed-dose-combination-of-cobicistat-and--prezistar 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2011/gilead-sciences-announces-first-quarter-2011-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2011/gilead-sciences-announces-fourth-quarter-and-full-year-2010-financial--results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2011/gilead-sciences-announces-notification-of-anda-filing-for-tamiflur 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2011/gilead-sciences-announces-second-quarter-2011-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2011/gilead-sciences-announces-third-quarter-2011-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2011/gilead-sciences-executive-vice-president-kevin-young-appointed-a--commander-of-the-most-excellent-order-of-the-british-empire 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2011/gilead-sciences-finalizes-agreement-with-tibotec-pharmaceuticals-to--develop-and-commercialize-a-single-tablet-regimen-of-prezistar-with--emtrivar-gs-7340-and-cobicistat 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2011/gilead-sciences-receives-refuse-to-file-notification-from-us-fda-on-new-drug-application-for-single-tablet-regimen-of-truvadar-and-tmc278 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2011/gilead-sciences-receives-refuse-to-file-notification-from-us-fda-on--new-drug-application-for-single-tablet-regimen-of-truvadar--and-tmc278 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2011/gilead-sciences-receives-subpoena-from-us-department-of-justice 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2011/gilead-sciences-refiles-new-drug-application-with-the-fda-for--single-tablet-regimen-of-truvadar-and-tmc278 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2011/gilead-sciences-resolves-us-food-and-drug-administration-warning--letter-related-to-san-dimas-manufacturing-facility 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2011/gilead-sciences-submits-supplemental-new-drug-application-to-us-food-and-drug-administration-for-truvada-for-reducing-the-risk-of-acquiring-hiv 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2011/gilead-sciences-to-acquire-calistoga-pharmaceuticals-for-375-million 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2011/gilead-sciences-to-acquire-pharmasset-inc-for-11-billion 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2011/gilead-sciences-to-present-at-bairds-2011-health-care-conference-on--thursday-september-8 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2011/gilead-sciences-to-present-at-the-2011-credit-suisse-healthcare--conference-on-wednesday-november-9 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2011/gilead-sciences-to-present-at-the-23rd-annual-piper-jaffray-healthcare-conference-on-tuesday-november-29 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2011/gilead-sciences-to-present-at-the-29th--annual-jpmorgan-healthcare-conference-on-monday-january-10 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2011/gilead-sciences-to-present-at-the-31st--annual-william-blair--company-growth-stock-conference-on-wednesday--june-15 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2011/gilead-sciences-to-present-at-the-cowen--company-31st--annual-health-care-conference-on-monday-march-7 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2011/gilead-sciences-to-present-at-the-deutsche-bank-36th--annual-health-care-conference-on-tuesday-may-3 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2011/gilead-sciences-to-present-at-the-lazard-capital-markets-8th-annual-healthcare-conference-on-tuesday-november-15 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2011/gilead-sciences-to-present-at-the-ubs-global-life-sciences-conference--on-tuesday-september-20 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2011/gilead-sciences-to-present-at-two-upcoming-investor-conferences-20110223163000 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2011/gilead-sciences-to-present-at-two-upcoming-investor-conferences-20110307163000 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2011/gilead-sciences-to-present-at-two-upcoming-investor-conferences-20110531171000 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2011/gilead-sciences-to-present-at-two-upcoming-investor-conferences-20110614163000 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2011/gilead-sciences-to-purchase-biologics-process-research-and-clinical--manufacturing-facility-from-genentech 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2011/gilead-sciences-to-release-first-quarter-2011-financial-results-on--wednesday-april-20-2011 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2011/gilead-sciences-to-release-fourth-quarter-and-year-end-2010-financial--results-on-tuesday-january-25-2011 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2011/gilead-sciences-to-release-second-quarter-2011-financial-results-on--tuesday-july-26-2011 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2011/gilead-sciences-to-release-third-quarter-2011-financial-results-on--thursday-october-27-2011 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2011/gileads-investigational-antiretroviral-elvitegravir-once-daily--non-inferior-to-raltegravir-twice-daily-at-48-weeks 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2011/gileads-investigational-antiretroviral-quad-regimen-meets-48-week--primary-objective-in-pivotal-phase-3-clinical-study-102 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2011/gilead-submits-new-drug-application-to-us-fda-for-once-daily--single-tablet-quad-hiv-regimen 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2011/gilead-to-offer-senior-notes 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2011/kite-pharma-appoints-adrian-bot-md-phd-as-chief-scientific-officer 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2011/kite-pharma-raises-15-million-in-initial-round-of-financing-and-appoints-david-bonderman-to-board-of-directors 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2011/phase-iii-clinical-trial-of-gileads-investigational-elvitegravir--meets-48-week-primary-objective 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2011/us-fda-accepts-new-drug-application-for-gileads-once-daily-single-tablet-quad-hiv-regimen 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2011/us-fda-removes-warning-about-potential-liver-injury-from-boxed--warning-of-prescribing-information-for-gileads-letairis 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2011/us-food-and-drug-administration-approves-gilead-sciences--compleratm-a-new-complete-once-daily-single-tablet-regimen-for-hiv-1--infection-in-treatment-nave-adults 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2011/yale-and-gilead-sciences-announce-cancer-research-collaboration 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2012/data-show-gileads-quad-regimen-for-hiv-non-inferior-to-protease-based-regimen-at-48-weeks-in-second-pivotal-phase-3-study 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2012/european-commission-approves-viread-for-hiv-1-infection-in-children-and-adolescents-and-for-chronic-hepatitis-b-in-adolescents 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2012/european-medicines-agency-validates-gileads-marketing-application-for-elvitegravir-for-treatment-of-hiv-infection 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2012/fda-advisory-committee-supports-approval-of-gileads-once-daily-quad-single-tablet-regimen-for-hiv 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2012/fda-advisory-committee-supports-approval-of-gileads-truvada-for-reducing-the-risk-of-acquiring-hiv 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2012/gilead-announces-100-percent-sustained-virologic-response-rate-svr4-for-an-interferon-free-regimen-of-sofosbuvir-gs-7977-gs-5885-and-ribavirin-in-treatment-nave-genotype-1-hepatitis-c-infect 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2012/gilead-announces-data-for-genotype-1-null-responder-hepatitis-c-patients-enrolled-in-electron-study 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2012/gilead-announces-early-sustained-virologic-response-rates-for-gs-7977-plus-ribavirin-in-genotype-1-treatment-na-ve-hepatitis-c-patients 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2012/gilead-announces-early-sustained-virologic-response-rates-for-gs-7977--plus-ribavirin-in-genotype-1-treatment-nave-hepatitis-c-patients 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2012/gilead-announces-sustained-virologic-response-data-for-12-week--regimen-of-gs-7977-plus-pegylated-interferon-and-ribavirin-in-genotype-1--hepatitis-c-patients 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2012/gilead-announces-sustained-virologic-response-rate-of-78-from-phase-3-study-of-sofosbuvir-for-genotype-23-hepatitis-c-infected-patients 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2012/gilead-board-approves-two-for-one-stock-split 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2012/gilead-files-european-marketing-application-for-boosting-agent-cobicistat 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2012/gilead-initiates-phase-2-clinical-trial-evaluating-gs-7340-a-low-dose-novel-prodrug-of-tenofovir-for-the-treatment-of-hiv 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2012/gilead-initiates-phase-3-clinical-trial-evaluating-gs-1101-for-the--treatment-of-chronic-lymphocytic-leukemia 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2012/gileads-boosting-agent-cobicistat-for-hiv-therapy-as-effective-as-ritonavir-in-pivotal-phase-3-study 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2012/gilead-sciences-announces-early-termination-of-hart-scott-rodino-waiting-period 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2012/gilead-sciences-announces-first-quarter-2012-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2012/gilead-sciences-announces-fourth-quarter-and-full-year-2011-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2012/gilead-sciences-announces-new-collaboration-with-indian-partners-to-reduce-manufacturing-cost-and-improve-availability-of-emtricitabine-based-antiretroviral-therapy-in-developing-countries 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2012/gilead-sciences-announces-second-quarter-2012-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2012/gilead-sciences-appoints-two-new-members-to-health-policy-advisory-board 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2012/gilead-sciences-completes-acquisition-of-pharmasset-inc 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2012/gilead-sciences-completes-tender-offer-for-all-outstanding-shares-of-pharmasset-inc 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2012/gilead-sciences-quad-study-102-results-conference-call-on-wednesday-march-7-2012 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2012/gilead-sciences-to-acquire-ym-biosciences 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2012/gilead-sciences-to-present-at-the-2012-credit-suisse-healthcare-conference-on-wednesday-november-14 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2012/gilead-sciences-to-present-at-the-30th-annual-jpmorgan-healthcare-conference-on-monday-january-9 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2012/gilead-sciences-to-present-at-the-32nd-annual-william-blair--company-growth-stock-conference-on-wednesday-june-13 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2012/gilead-sciences-to-present-at-the-bank-of-america-merrill-lynch-2012--health-care-conference-on-wednesday-may-16 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2012/gilead-sciences-to-present-at-the-barclays-capital-2012-global-healthcare-conference-on-tuesday-march-13 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2012/gilead-sciences-to-present-at-the-cowen--company-32nd-annual-health-care-conference-on-wednesday-march-7 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2012/gilead-sciences-to-present-at-the-deutsche-bank-37th--annual-health-care-conference-on-tuesday-may-8 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2012/gilead-sciences-to-present-at-the-nasdaq-omx-29th-investor-program 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2012/gilead-sciences-to-present-at-two-upcoming-investor-conferences-20120224163100 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2012/gilead-sciences-to-present-at-two-upcoming-investor-conferences-20120529163100 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2012/gilead-sciences-to-present-new-hepatitis-b-and-c-data-at-european--conference-on-liver-disease-this-week 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2012/gilead-sciences-to-release-first-quarter-2012-financial-results-on--thursday-april-26-2012 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2012/gilead-sciences-to-release-fourth-quarter-and-year-end-2011-financial-results-on-thursday-february-2-2012 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2012/gilead-sciences-to-release-second-quarter-2012-financial-results-on-thursday-july-26-2012 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2012/gileads-complera-non-inferior-to-atripla-among-treatment-nave-hiv-patients 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2012/gileads-hiv-integrase-inhibitor-elvitegravir-dosed-once-daily-as-effective-as-twice-daily-raltegravir-over-two-years-of-therapy-in-pivotal-phase-3-study 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2012/gileads-once-daily-single-tablet-regimen-complera-maintains-hiv-suppression-among-patients-switching-from-protease-inhibitor-based-regimens 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2012/gileads-once-daily-single-tablet-regimen-stribild-maintains-high-viral-suppression-through-two-years-of-therapy-among-treatment-nave-hiv-patients 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2012/gileads-quad-single-tablet-regimen-for-hiv-non-inferior-to-atripla-in-pivotal-phase-3-study 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2012/gilead-submits-new-drug-application-to-us-fda-for-boosting-agent-cobicistat 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2012/gilead-submits-new-drug-application-to-us-fda-for-hiv-integrase-inhibitor-elvitegravir-for-treatment-experienced-patients 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2012/roy-d-baynes-md-phd-to-join-gilead-sciences-as-senior-vice-president-oncology-therapeutics 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2012/us-fda-grants-priority-review-for-truvada-for-reducing-the-risk-of-acquiring-hiv-infection 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2012/us-food-and-drug-administration-approves-gileads-truvada-for-reducing-the-risk-of-acquiring-hiv 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2012/us-food-and-drug-administration-approves-new-formulations-of-viread-for-use-by-children-living-with-hiv 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2013/data-from-phase-3-studies-of-gileads-sofosbuvir-for-hepatitis-c-to-be-presented-at-48th-annual-easl-meeting-findings-published-online-today-in-the-new-england-journal-of-medicine 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2013/european-chmp-adopts-positive-opinion-for-gilead-sciences-sovaldi-for-the-treatment-of-chronic-hepatitis-c-infection 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2013/european-chmp-adopts-positive-opinion-for-stribild-a-once-daily-integrase-inhibitor-based-single-tablet-regimen-for-the-treatment-of-hiv-1-infection 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2013/european-commission-approves-gilead-sciences-tybost-a-new-boosting-agent-for-hiv-therapy 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2013/european-commission-approves-gileads-vitekta-an-integrase-inhibitor-for-the-treatment-of-hiv-1-infection 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2013/european-commission-approves-stribild-a-new-single-tablet-regimen-for-the-treatment-of-hiv-1-infection 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2013/european-medicines-agency-validates-gileads-marketing-application-for-sofosbuvir-for-the-treatment-of-hepatitis-c 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2013/fda-advisory-committee-supports-approval-of-gileads-sofosbuvir-for-chronic-hepatitis-c-infection 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2013/gilead-and-teva-reach-settlement-agreement-in-viread-patent-litigation 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2013/gilead-announces-full-24-week-phase-2-results-for-once-daily-single-tablet-hiv-regimen-containing-novel-prodrug-tenofovir-alafenamide-taf 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2013/gilead-announces-interim-phase-2-data-for-idelalisib-showing-response-in-refractory-indolent-non-hodgkins-lymphoma 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2013/gilead-announces-interim-phase-2-results-for-gs-9973-in-previously-treated-chronic-lymphocytic-leukemia 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2013/gilead-announces-new-sustained-viral-response-data-for-sofosbuvir-based-regimens-in-genotype-3-infected-hepatitis-c-patients 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2013/gilead-announces-phase-2-results-for-sofosbuvir-based-regimens-in-hepatitis-c-patients-before-and-after-liver-transplantation 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2013/gilead-announces-phase-3-results-for-an-all-oral-sofosbuvir-based-regimen-for-the-treatment-of-hepatitis-c-in-patients-co-infected-with-hiv 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2013/gilead-announces-pivotal-phase-2-data-for-idelalisib-in-refractory--indolent-non-hodgkins-lymphoma 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2013/gilead-announces-response-data-from-phase-2-study-of-idelalisib-for-previously-untreated-chronic-lymphocytic-leukemia 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2013/gilead-announces-sustained-virologic-response-rates-from-two-phase-3-studies-of-sofosbuvir-for-hepatitis-c 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2013/gilead-announces-svr12-rates-from-three-phase-3-studies-evaluating-a-once-daily-fixed-dose-combination-of-sofosbuvir-and-ledipasvir-for-genotype-1-hepatitis-c-patients 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2013/gilead-announces-update-on-phase-3-study-of-oral-fixed-dose-combination-of-sofosbuvir-and-ledipasvir-for-genotype-1-hepatitis-c-patients 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2013/gilead-announces-us-fda-priority-review-designation-for-sofosbuvir-for-the-treatment-of-hepatitis-c 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2013/gilead-initiates-phase-3-clinical-program-for-tenofovir-alafenamide-a-novel-low-dose-prodrug-for-the-treatment-of-hiv 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2013/gilead-issues-a-voluntary-recall-of-one-lot-of-vistide-cidofovir-injection-due-to-presence-of-particulate-matter 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2013/gilead-provides-update-on-hepatitis-c-development-programs 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2013/gilead-receives-complete-response-letters-from-us-food-and-drug-administration-for-elvitegravir-and-cobicistat 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2013/gilead-reports-interim-data-from-phase-2-lonestar-study 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2013/gilead-sciences-announces-first-quarter-2013-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2013/gilead-sciences-announces-fourth-quarter-and-full-year-2012-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2013/gilead-sciences-announces-second-quarter-2013-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2013/gilead-sciences-announces-third-quarter-2013-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2013/gilead-sciences-completes-acquisition-of-ym-biosciences 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2013/gilead-sciences-to-present-at-the-2013-ubs-global-healthcare-conference-on-monday-may-20 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2013/gilead-sciences-to-present-at-the-31st-annual-jpmorgan-healthcare-conference-on-monday-january-7 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2013/gilead-sciences-to-present-at-the-bank-of-america-merrill-lynch-2013-health-care-conference-on-wednesday-may-15 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2013/gilead-sciences-to-present-at-the-cowen--company-33rd-annual-health-care-conference-on-monday-march-4 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2013/gilead-sciences-to-present-at-the-credit-suisse-2013-healthcare--conference-on-wednesday-november-13 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2013/gilead-sciences-to-present-at-the-deutsche-bank-38th-annual-health-care-conference-on-wednesday-may-29 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2013/gilead-sciences-to-present-at-the-goldman-sachs-34th-annual-healthcare-conference-on-tuesday-june-11 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2013/gilead-sciences-to-present-at-the-nasdaq-omx-30th-investor-program-on-tuesday-december-3 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2013/gilead-sciences-to-present-at-the-wells-fargo-securities-2013-healthcare-conference-on-tuesday-june-18 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2013/gilead-sciences-to-present-at-two-upcoming-investor-conferences-20130211163100 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2013/gilead-sciences-to-present-at-two-upcoming-investor-conferences-20130225163100 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2013/gilead-sciences-to-present-at-two-upcoming-investor-conferences-20130906163100 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2013/gilead-sciences-to-release-first-quarter-2013-financial-results-on-thursday-may-2-2013 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2013/gilead-sciences-to-release-fourth-quarter-and-year-end-2012-financial-results-on-monday-february-4-2013 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2013/gilead-sciences-to-release-second-quarter-2013-financial-results-on-thursday-july-25-2013 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2013/gilead-sciences-to-release-third-quarter-2013-financial-results-on-tuesday-october-29-2013 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2013/gileads-idelalisib-significantly-reduces-rate-of-disease-progression-or-death-in-phase-3-chronic-lymphocytic-leukemia-study 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2013/gileads-ranexa-reduces-angina-frequency-in-study-of-chronic-angina-patients-with-type-2-diabetes 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2013/gileads-single-tablet-hiv-regimen-stribild-demonstrates-durable-viral-suppression-through-three-years-of-therapy 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2013/gileads-sofosbuvir-for-hepatitis-c-meets-primary-endpoint-in-fourth-pivotal-phase-3-study 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2013/gileads-tenofovir-alafenamide-taf-based-single-tablet-hiv-regimen-maintains-high-viral-suppression-through-48-weeks-in-phase-2-study 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2013/gilead-submits-new-drug-application-to-us-fda-for-idelalisib-for-the-treatment-of-indolent-non-hodgkins-lymphoma 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2013/gilead-submits-new-drug-application-to-us-fda-for-sofosbuvir-for-the-treatment-of-hepatitis-c 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2013/gilead-to-present-data-on-oncology-pipeline-at-american-society-of-hematology-annual-meeting 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2013/gilead-to-stop-phase-3-study-116-of-idelalisib-in-chronic-lymphocytic-leukemia-early-because-of-positive-risk-benefit 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2013/health-canada-issues-notice-of-compliance-for-sovaldi-sofosbuvir-for-the-treatment-of-chronic-hepatitis-c 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2013/kite-pharma-appoints-keith-nolop-md-chief-medical-officer 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2013/kite-pharma-appoints-leading-cancer-immunotherapy-experts-to-its-scientific-advisory-board 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2013/kite-pharma-completes-35-million-series-a-preferred-stock-financing 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2013/kite-pharmas-lead-program-with-the-national-cancer-institute-nci-demonstrates-positive-results-in-patients-with-aggressive-non-hodgkins-lymphoma 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2013/kite-pharma-to-present-at-the-32nd-annual-jp-morgan-healthcare-conference 2024-07-23 daily 0.5 https://www.gilead.com/news/news-details/2013/new-studies-demonstrate-that-modified-t-cells-are-effective-in-treating-blood-borne-cancers 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2013/us-fda-approves-gileads-once-daily-single-tablet-hiv-1-regimen-complera-for-patients-switching-from-a-stable-regimen 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2013/us-food-and-drug-administration-approves-gileads-sovaldi-sofosbuvir-for-the-treatment-of-chronic-hepatitis-c 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2014/european-chmp-adopts-positive-opinion-for-gileads-harvoni-ledipasvirsofosbuvir-for-the-treatment-of-chronic-hepatitis-c-infection-in-adults 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2014/european-chmp-adopts-positive-opinion-for-gileads-zydelig-idelalisib-for-the-treatment-of-chronic-lymphocytic-leukemia-and-follicular-lymphoma 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2014/european-commission-grants-marketing-authorization-for-gileads-harvoni-ledipasvirsofosbuvir-the-first-single-tablet-regimen-to-treat-the-majority-of-chronic-hepatitis-c-patients-with-genotype-1-and-4 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2014/european-commission-grants-marketing-authorization-for-gileads-sovaldi-sofosbuvir-for-the-treatment-of-chronic-hepatitis-c-infection 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2014/european-commission-grants-marketing-authorization-for-gileads-zydelig-idelalisib-for-the-treatment-of-chronic-lymphocytic-leukemia-and-follicular-lymphoma 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2014/european-medicines-agency-validates-gileads-marketing-application-for-ledipasvirsofosbuvir-fixed-dose-combination-tablet-for-genotype-1-chronic-hepatitis-c-infection 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2014/first-line-combination-of-ambrisentan-and-tadalafil-reduces-risk-of-clinical-failure-compared-to-monotherapy-in-pulmonary-arterial-hypertension-outcomes-study 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2014/gilead-announces-5-billion-share-repurchase-program 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2014/gilead-announces-amended-agreements-with-janssen-to-develop-and-commercialize-tenofovir-alafenamide-based-single-tablet-regimens-for-hiv-treatment 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2014/gilead-announces-data-from-phase-2-study-of-simtuzumab-for-previously-untreated-pancreatic-cancer 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2014/gilead-announces-executive-promotions-20140127170100 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2014/gilead-announces-generic-licensing-agreements-to-increase-access-to-hepatitis-c-treatments-in-developing-countries 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2014/gilead-announces-harvoni-study-results-in-chronic-hepatitis-c-patients-with-advanced-liver-disease-and-those-who-failed-prior-treatment 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2014/gilead-announces-new-agreement-with-medicines-patent-pool-for-access-to-medicines-in-developing-world-countries 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2014/gilead-announces-phase-1-data-for-investigational-therapy-gs-6615-in-patients-with-long-qt-3-syndrome 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2014/gilead-announces-phase-2-data-for-investigational-all-oral-regimen-of-sofosbuvir-plus-gs-5816-for-the-treatment-of-chronic-hepatitis-c 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2014/gilead-announces-phase-2-results-for-two-investigational-all-oral-sofosbuvir-based-regimens-for-the-treatment-of-chronic-hepatitis-c 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2014/gilead-announces-phase-3-data-showing-that-the-fixed-dose-combination-of-ledipasvirsofosbuvir-achieved-100-percent-sustained-virologic-response-svr12-among-patients-with-chronic-hepatitis-c-in-japan 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2014/gilead-announces-results-from-phase-2-study-showing-reduction-in-atrial-fibrillation-burden-with-the-investigational-combination-of-ranolazine-and-low-dose-dronedarone 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2014/gilead-announces-results-from-phase-3-study-of-sofosbuvir-among-hepatitis-c-patients-in-japan 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2014/gilead-announces-results-from-study-of-sovaldi-for-retreatment-of-chronic-hepatitis-c-in-patients-not-cured-with-prior-antiviral-therapy 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2014/gilead-announces-settlement-method-for-100-convertible-senior-notes-due-2014 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2014/gilead-announcesupdated-phase-2-results-for-investigational-gs-9973-in-relapsed-chronic-lymphocytic-leukemia 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2014/gilead-announces-us-fda-priority-review-designation-for-ledipasvirsofosbuvir-fixed-dose-combination-tablet-for-chronic-hepatitis-c-genotype-1-infection 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2014/gilead-files-for-us-approval-of-ledipasvirsofosbuvir-fixed-dose-combination-tablet-for-genotype-1-hepatitis-c 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2014/gilead-presents-follow-up-data-from-zydelig-registrational-studies-in-patients-with-chronic-lymphocytic-leukemia-follicular-lymphoma-and-small-lymphocytic-lymphoma 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2014/gilead-prices-4-billion-of-senior-unsecured-notes 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2014/gilead-prices-4-billion-of-senior-unsecured-notes-20140304182000 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2014/gilead-sciences-announces-first-quarter-2014-financial-results 2024-08-20 daily 0.5 https://www.gilead.com/news/news-details/2014/gilead-sciences-announces-fourth-quarter-and-full-year-2013-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2014/gilead-sciences-announces-second-quarter-2014-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2014/gilead-sciences-announces-third-quarter-2014-financial-results 2024-08-20 daily 0.5 https://www.gilead.com/news/news-details/2014/gilead-sciences-kevin-young-cbe-executive-vice-president-commercial-operations-to-retire 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2014/gilead-sciences-new-drug-applications-for-cobicistat-and-elvitegravir-for-hiv-therapy-accepted-by-us-fda 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2014/gilead-sciences-to-present-at-the-2014-ubs-healthcare-conference-on-tuesday-may-20 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2014/gilead-sciences-to-present-at-the-32nd-annual-jpmorgan-healthcare-conference-on-monday-january-13 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2014/gilead-sciences-to-present-at-the-34th-cowen--co-healthcare-conference-on-monday-march-3 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2014/gilead-sciences-to-present-at-the-bank-of-america-merrill-lynch-2014-health-care-conference-on-wednesday-may-14 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2014/gilead-sciences-to-present-at-the-rbc-capital-markets-2014-global-healthcare-conference-on-wednesday-february-26 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2014/gilead-sciences-to-present-at-the-wells-fargo-healthcare-conference-on-tuesday-june-17 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2014/gilead-sciences-to-present-at-two-upcoming-investor-conferences-20140210170100 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2014/gilead-sciences-to-present-at-two-upcoming-investor-conferences-in-september 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2014/gilead-sciences-to-present-at-two-upcoming-investor-conferences-on-tuesday-june-10 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2014/gilead-sciences-to-release-first-quarter-2014-financial-results-on-tuesday-april-22-2014 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2014/gilead-sciences-to-release-fourth-quarter-and-year-end-2013-financial-results-on-tuesday-february-4-2014 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2014/gilead-sciences-to-release-second-quarter-2014-financial-results-on-wednesday-july-23-2014 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2014/gilead-sciences-to-release-third-quarter-2014-financial-results-on-tuesday-october-28-2014 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2014/gileads-investigational-gs-5806-reduces-viral-load-and-clinical-symptoms-in-phase-2-respiratory-syncytial-virus-rsv-challenge-study-in-adults 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2014/gileads-investigational-tenofovir-alafenamide-taf-based-single-tablet-hiv-regimen-meets-48-week-primary-objective-in-two-phase-3-studies 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2014/gileads-sovaldi-demonstrates-efficacy-and-safety-among-chronic-hepatitis-c-patients-with-advanced-liver-disease 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2014/gilead-submits-new-drug-application-to-japans-pharmaceutical-and-medical-devices-agency-for-fixed-dose-combination-of-ledipasvirsofosbuvir-for-chronic-hepatitis-c-genotype-1-infection 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2014/gilead-submits-new-drug-application-to-japans-pharmaceutical-and-medical-devices-agency-for-sofosbuvir-for-chronic-hepatitis-c 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2014/gilead-submits-new-drug-application-to-us-food-and-drug-administration-for-tenofovir-alafenamide-taf-based-single-tablet-regimen-for-hiv 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2014/health-canada-issues-notice-of-compliance-for-gileads-harvoni-ledipasvirsofosbuvir-the-first-once-daily-single-tablet-regimen-for-the-treatment-of-genotype-1-chronic-hepatitis-c 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2014/kite-pharma-added-to-the-nasdaq-biotechnology-index 2024-07-23 daily 0.5 https://www.gilead.com/news/news-details/2014/kite-pharma-announces-exclusive-license-with-the-national-institutes-of-health-for-t-cell-receptor-tcr-based-products-targeting-ny-eso-1-for-multiple-cancer-indications 2024-07-23 daily 0.5 https://www.gilead.com/news/news-details/2014/kite-pharma-announces-fda-orphan-drug-designation-for-anti-cd19-t-cell-cancer-immunotherapy-product 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2014/kite-pharma-announces-full-exercise-of-underwriters-option-to-purchase-additional-shares-20140623193000 2024-07-23 daily 0.5 https://www.gilead.com/news/news-details/2014/kite-pharma-announces-full-exercise-of-underwriters-option-to-purchase-additional-shares-20141230190100 2024-07-23 daily 0.5 https://www.gilead.com/news/news-details/2014/kite-pharma-announces-patients-with-aggressive-non-hodgkins-lymphoma-experience-positive-results-after-receiving-anti-cd19-chimeric-antigen-receptor-car-t-cells-at-the-national-cancer-institute-nci 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2014/kite-pharma-announces-patients-with-relapsed-or-refractory-acute-lymphoblastic-leukemia-all-experience-positive-results-after-receiving-anti-cd19-chimeric-antigen-receptor-car-t-cells 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2014/kite-pharma-announces-presentations-at-the-upcoming-56th-american-society-of-hematology-annual-meeting 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2014/kite-pharma-announces-pricing-of-follow-on-offering 2024-07-23 daily 0.5 https://www.gilead.com/news/news-details/2014/kite-pharma-announces-pricing-of-initial-public-offering 2024-07-23 daily 0.5 https://www.gilead.com/news/news-details/2014/kite-pharma-announces-the-appointment-of-arie-belldegrun-md-as-president-and-chief-executive-officer 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2014/kite-pharma-appoints-cynthia-m-butitta-as-chief-financial-officer 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2014/kite-pharma-appoints-rizwana-f-sproule-phd-as-vice-president-regulatory-affairs 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2014/kite-pharma-expands-companys-board-of-directors-with-the-appointment-of-jonathan-m-peacock 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2014/kite-pharma-expands-leadership-team-and-announces-senior-management-promotions 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2014/kite-pharma-expands-rd-team-appoints-dr-william-y-go-as-senior-director-clinical-development-and-jeff-aycock-as-senior-director-clinical-operations 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2014/kite-pharma-files-registration-statement-for-proposed-follow-on-offering 2024-07-23 daily 0.5 https://www.gilead.com/news/news-details/2014/kite-pharma-files-registration-statement-for-proposed-initial-public-offering 2024-07-23 daily 0.5 https://www.gilead.com/news/news-details/2014/kite-pharma-inc-appoints-jeffrey-s-wiezorek-md-ms-as-vice-president-clinical-development 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2014/kite-pharma-inc-completes-50-million-mezzanine-private-financing 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2014/kite-pharma-names-david-chang-md-phd-to-lead-rd-programs 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2014/kite-pharma-receives-positive-opinion-for-orphan-drug-designation-in-the-european-union-for-kte-c19-kites-lead-investigational-cancer-immunotherapy 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2014/kite-pharma-reports-second-quarter-2014-results 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2014/kite-pharma-reports-third-quarter-2014-results 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2014/kite-pharma-submits-investigational-new-drug-application-for-phase-12-trial-of-kte-c19-anti-cd19-chimeric-antigen-receptor-car-t-cell-therapy-for-the-treatment-of-refractory-aggressive-non-h 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2014/kite-pharma-to-highlight-cancer-immunotherapy-t-cell-manufacturing-process-at-2014-asco-annual-meeting 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2014/kite-pharma-to-participate-in-gene-therapy-panel-at-the-bio-investor-forum 2024-07-23 daily 0.5 https://www.gilead.com/news/news-details/2014/kite-pharma-to-participate-in-three-upcoming-investor-conferences-in-november-2014 2024-07-23 daily 0.5 https://www.gilead.com/news/news-details/2014/kite-pharma-to-present-at-the-21st-annual-newsmakers-in-the-biotech-industry-investment-conference-on-friday-september-26 2024-07-23 daily 0.5 https://www.gilead.com/news/news-details/2014/kite-pharma-to-present-at-the-citi-9th-annual-biotech-conference-on-wednesday-september-3-20140826113500 2024-07-23 daily 0.5 https://www.gilead.com/news/news-details/2014/neostems-subsidiary-progenitor-cell-therapy-pct-to-provide-process-development-and-manufacturing-services-to-kite-pharma 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2014/ono-and-gilead-announce-exclusive-license-agreement-to-develop-btk-inhibitor-ono-4059-for-the-treatment-of-b-cell-malignancies-and-other-diseases 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2014/philippe-c-bishop-md-to-join-gilead-as-senior-vice-president-hematology-and-oncology-therapeutics 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2014/us-fda-accepts-new-drug-application-for-gileads-idelalisib-for-the-treatment-of-refractory-indolent-non-hodgkins-lymphoma 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2014/us-food-and-drug-administration-approves-gileads-harvoni-ledipasvirsofosbuvir-the-first-once-daily-single-tablet-regimen-for-the-treatment-of-genotype-1-chronic-hepatitis-c 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2014/us-food-and-drug-administration-approves-gileads-zydelig-idelalisib-for-relapsed-chronic-lymphocytic-leukemia-follicular-lymphoma-and-small-lymphocytic-lymphoma 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/amgen-and-kite-pharma-announce-strategic-cancer-immunotherapy-collaboration-to-advance-the-application-of-novel-chimeric-antigen-receptor-car-t-cell-therapies 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/european-chmp-adopts-positive-opinion-for-gileads-single-tablet-regimen-genvoya-elvitegravir-cobicistat-emtricitabine-and-tenofovir-alafenamide-for-the-treatment-of-hiv 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/european-commission-grants-marketing-authorization-for-gileads-single-tablet-regimen-genvoya-elvitegravir-cobicistat-emtricitabine-and-tenofovir-alafenamide-for-the-treatment-of-hiv-1-infection 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/european-medicines-agency-validates-gileads-marketing-application-for-fixed-dose-combination-of-emtricitabine-and-tenofovir-alafenamide-for-hiv-treatment 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/european-medicines-agency-validates-gileads-marketing-application-for-fixed-dose-combination-of-sofosbuvirvelpatasvir-for-the-treatment-of-hepatitis-c 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/european-medicines-agency-validates-gileads-marketing-application-for-single-tablet-regimen-containing-rilpivirine-emtricitabine-and-tenofovir-alafenamide-rftaf-for-hiv-treatment 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/franz-b-humer-former-chairman-and-ceo-of-roche-group-appointed-to-kite-pharmas-board-of-directors 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/galapagos-and-gilead-announce-global-partnership-to-develop-filgotinib-for-the-treatment-of-rheumatoid-arthritis-and-other-inflammatory-diseases 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/gilead-announces-data-for-investigational-all-oral-pan-genotypic-three-drug-regimen-of-sofosbuvir-gs-5816-and-gs-9857-for-chronic-hepatitis-c 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/gilead-announces-executive-promotions 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/gilead-announces-executive-promotions-20150128163100 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/gilead-announces-phase-3-results-for-genvoya-elvitegravir-cobicistat-emtricitabine-and-tenofovir-alafenamide-an-investigational-once-daily-single-tablet-regimen-for-hiv 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/gilead-announces-phase-3-results-for-investigational-once-daily-single-tablet-hiv-regimen-containing-tenofovir-alafenamide-taf 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/gilead-announces-phase-3-results-from-the-first-study-to-evaluate-switching-from-tdf-based-regimens-to-a-taf-based-regimen-containing-elvitegravir-cobicistat-emtricitabine-and-tenofovir-alaf 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/gilead-announces-preclinical-data-for-an-investigational-tlr7-agonist-in-siv-infected-virally-suppressed-monkeys 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/gilead-announces-results-from-studies-evaluating-sofosbuvir-based-regimens-in-chronic-hepatitis-c-patients-with-genotypes-2-5 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/gilead-announces-svr12-rates-from-four-phase-3-studies-evaluating-a-once-daily-fixed-dose-combination-of-sofosbuvir-sof-and-velpatasvir-vel-gs-5816-for-the-treatment-of-all-six-hepatitis-c-genotypes 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/gilead-announces-svr12-rates-from-phase-3-study-evaluating-harvoni-for-the-treatment-of-chronic-hepatitis-c-in-patients-co-infected-with-hiv 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/gilead-expands-hepatitis-c-generic-licensing-agreements-to-include-investigational-pan-genotypic-agent 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/gilead-presents-new-data-at-the-liver-meeting-2015 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/gilead-prices-10-billion-of-senior-unsecured-notes 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/gilead-provides-update-on-investigational-compound-gs-5734-for-the-treatment-of-ebola-virus-disease 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/gilead-sciences-acquires-epitherapeutics 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/gilead-sciences-announces-43-cents-quarterly-dividend-program-and-15-billion-share-buyback-program 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/gilead-sciences-announces-acquisition-of-phenex-pharmaceuticals-development-program-for-non-alcoholic-steatohepatitis-nash-and-other-liver-diseases 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/gilead-sciences-announces-first-quarter-2015-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/gilead-sciences-announces-fourth-quarter-2015-dividend 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/gilead-sciences-announces-fourth-quarter-and-full-year-2014-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/gilead-sciences-announces-second-quarter-2015-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/gilead-sciences-announces-third-quarter-2015-dividend 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/gilead-sciences-announces-third-quarter-2015-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/gilead-sciences-declares-first-quarterly-cash-dividend 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/gilead-sciences-to-present-at-the-33rd-annual-jp-morgan-healthcare-conference-on-tuesday-january-13 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/gilead-sciences-to-present-at-the-baird-2015-healthcare-conference-on-wednesday-september-9 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/gilead-sciences-to-present-at-the-bank-of-america-merrill-lynch-2015-health-care-conference-on-wednesday-may-13 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/gilead-sciences-to-present-at-the-barclays-global-healthcare-conference-on-wednesday-march-11 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/gilead-sciences-to-present-at-the-bernstein-31st-annual-strategic-decisions-conference-on-thursday-may-28 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/gilead-sciences-to-present-at-the-cowen-and-company-35th-annual-health-care-conference-on-tuesday-march-3 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/gilead-sciences-to-present-at-the-credit-suisse-24th-annual-healthcare-conference-on-tuesday-november-10 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/gilead-sciences-to-present-at-the-morgan-stanley-global-healthcare-conference-on-wednesday-september-16 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/gilead-sciences-to-present-at-the-rbc-capital-markets-2015-healthcare-conference-on-wednesday-february-25 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/gilead-sciences-to-present-at-the-ubs-2015-global-healthcare-conference-on-tuesday-may-19 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/gilead-sciences-to-present-at-two-upcoming-investor-conferences 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/gilead-sciences-to-present-at-two-upcoming-investor-conferences-on-tuesday-december-1 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/gilead-sciences-to-present-at-two-upcoming-investor-conferences-on-tuesday-june-9 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/gilead-sciences-to-release-first-quarter-2015-financial-results-on-thursday-april-30-2015 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/gilead-sciences-to-release-fourth-quarter-and-full-year-2014-financial-results-on-tuesday-february-3-2015 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/gilead-sciences-to-release-second-quarter-2015-financial-results-on-tuesday-july-28-2015 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/gilead-sciences-to-release-third-quarter-2015-financial-results-on-tuesday-october-27-2015 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/gileads-harvoni-and-sovaldi-demonstrate-efficacy-and-safety-among-chronic-hepatitis-c-patients-with-advanced-liver-disease 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/gileads-investigational-fixed-dose-combination-of-emtricitabinetenofovir-alafenamide-ftaf-meets-primary-48-week-objective-in-phase-3-study 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/gilead-submits-new-drug-application-to-us-food-and-drug-administration-for-fixed-dose-combination-of-emtricitabinetenofovir-alafenamide-for-hiv-treatment 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/gilead-submits-new-drug-application-to-us-food-and-drug-administration-for-fixed-dose-combination-of-sofosbuvirvelpatasvir-for-treatment-of-all-six-genotypes-of-hepatitis-c 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/gilead-submits-new-drug-application-to-us-food-and-drug-administration-for-single-tablet-regimen-for-hiv-containing-rilpivirine-emtricitabine-and-tenofovir-alafenamide-rftaf 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/gileads-zydelig-combined-with-bendamustine-and-rituximab-shows-superior-efficacy-to-bendamustinerituximab-in-phase-3-study-of-patients-with-relapsed-chronic-lymphocytic-leukemia 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/japans-ministry-of-health-labour-and-welfare-approves-gileads-harvoni-the-first-once-daily-single-tablet-regimen-for-the-treatment-of-genotype-1-chronic-hepatitis-c 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/japans-ministry-of-health-labour-and-welfare-approves-gileads-sovaldi-sofosbuvir-for-the-treatment-of-genotype-2-chronic-hepatitis-c 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/kite-pharma-and-alpine-immune-sciences-announce-research-collaboration-and-license-agreement-to-enhance-immune-response-in-the-tumor-microenvironment 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/kite-pharma-and-bluebird-bio-announce-strategic-collaboration-to-advance-second-generation-tcr-cell-therapy-products-to-treat-hpv-associated-cancers 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/kite-pharma-and-ge-global-research-announce-strategic-collaboration-to-automate-manufacturing-of-engineered-t-cell-therapies 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/kite-pharma-and-the-leukemia--lymphoma-societyr-enter-into-collaboration-to-enhance-the-development-of-kte-c19-in-refractory-aggressive-non-hodgkin-lymphoma-and-launch-car-t-cell-therapy-edu 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/kite-pharma-announces-addition-of-scott-n-bernstein-as-vice-president-of-intellectual-property-law 2024-08-20 daily 0.5 https://www.gilead.com/news/news-details/2015/kite-pharma-announces-clinical-biomarker-results-of-anti-cd19-car-t-cell-therapy-at-the-57th-american-society-of-hematology-annual-meeting-ash 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2015/kite-pharma-announces-exclusive-license-with-the-national-institutes-of-health-for-t-cell-receptor-tcr-based-products-to-treat-hpv-associated-cancers 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/kite-pharma-announces-exclusive-license-with-the-national-institutes-of-health-for-t-cell-receptor-tcr-based-products-to-treat-tumors-expressing-mage 2024-07-23 daily 0.5 https://www.gilead.com/news/news-details/2015/kite-pharma-announces-expanded-agreement-with-tel-aviv-sourasky-medical-center-and-pioneering-researcher-professor-zelig-eshhar-to-develop-novel-chimeric-antigen-receptor-car-approaches-for- 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2015/kite-pharma-announces-full-exercise-of-underwriters-option-to-purchase-additional-shares 2024-07-23 daily 0.5 https://www.gilead.com/news/news-details/2015/kite-pharma-announces-peer-reviewed-publication-of-t-cell-receptor-based-product-candidate-to-treat-hpv-associated-cancers 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/kite-pharma-announces-presentations-highlighting-cancer-immunotherapy-t-cell-manufacturing-process 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/kite-pharma-announces-pricing-of-public-offering-of-common-stock 2024-07-23 daily 0.5 https://www.gilead.com/news/news-details/2015/kite-pharma-announces-proposed-public-offering-of-common-stock 2024-07-23 daily 0.5 https://www.gilead.com/news/news-details/2015/kite-pharma-announces-publication-in-science-of-cancer-immunotherapy-articles-authored-by-lead-collaborators-at-the-national-cancer-institute-and-the-netherlands-cancer-institute 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2015/kite-pharma-announces-that-the-first-patient-in-its-phase-12-clinical-trial-has-been-treated-with-kte-c19-anti-cd19-chimeric-antigen-receptor-car-t-cell-therapy-for-refractory-aggressive-non 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2015/kite-pharma-appoints-industry-leader-shawn-cline-tomasello-as-chief-commercial-officer 2024-07-23 daily 0.5 https://www.gilead.com/news/news-details/2015/kite-pharma-commends-honors-conferred-to-drs-owen-witte-and-steven-a-rosenberg-at-the-2015-american-association-for-cancer-research-aacr-annual-meeting 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2015/kite-pharma-commends-honors-conferred-to-scientific-advisory-board-members-for-their-significant-contributions-to-medicine 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/kite-pharma-commends-steven-a-rosenberg-md-phd-on-the-prestigious-medal-of-honor-award-from-the-american-cancer-society 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/kite-pharma-establishes-manufacturing-capabilities-to-support-development-and-commercialization-of-car-and-tcr-cancer-immunotherapy-products 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2015/kite-pharma-expands-and-strengthens-leadership-team 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2015/kite-pharma-expands-collaboration-with-netherlands-cancer-institute-nki 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2015/kite-pharma-expands-its-research-and-development-collaboration-with-the-national-cancer-institute-to-develop-a-next-generation-of-cancer-immunotherapy-products-for-solid-tumors 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2015/kite-pharma-expands-senior-management-team-with-appointment-of-claudine-prowse-phd-as-svp-corporate-communications-and-investor-relations 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2015/kite-pharma-granted-orphan-drug-designation-in-the-european-union-for-kte-c19-kites-lead-anti-cd19-chimeric-antigen-receptor-car-t-cell-therapy 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/kite-pharma-initiates-phase-2-clinical-study-of-kte-c19-zuma-2-in-patients-with-relapsed-or-refractory-mantle-cell-lymphoma-rr-mcl-to-support-registration-for-a-second-indication 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/kite-pharma-initiates-the-zuma-3-study-to-support-registration-of-kte-c19-for-relapsed-or-refractory-rr-acute-lymphoblastic-leukemia-all-in-adult-subjects 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/kite-pharma-initiates-the-zuma-4-study-to-support-registration-of-kte-c19-for-relapsed-or-refractory-rr-acute-lymphoblastic-leukemia-all-in-children-and-young-adults 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/kite-pharma-initiates-zuma-1-phase-2-in-patients-with-aggressive-refractory-non-hodgkins-lymphoma-nhl-to-support-registration-of-kte-c19 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2015/kite-pharma-presents-clinical-biomarker-results-in-patients-treated-with-anti-cd19-chimeric-antigen-receptor-t-cell-therapy-at-the-2015-asco-annual-meeting 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2015/kite-pharma-presents-phase-1-results-from-zuma-1-at-the-57th-american-society-of-hematology-ash-annual-meeting 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2015/kite-pharma-provides-update-on-kte-c19-clinical-trial 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2015/kite-pharma-receives-fda-breakthrough-therapy-designation-for-kte-c19-for-the-treatment-of-refractory-aggressive-non-hodgkin-lymphoma-nhl 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2015/kite-pharma-receives-positive-opinion-for-orphan-drug-designation-in-the-european-union-for-kte-c19-kites-lead-cancer-t-cell-immunotherapy 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/kite-pharma-receives-positive-opinions-for-orphan-drug-designation-in-the-european-union-eu-for-kte-c19-in-three-additional-hematological-indications 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2015/kite-pharma-reports-first-quarter-2015-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/kite-pharma-reports-full-year-and-fourth-quarter-2014-financial-results 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2015/kite-pharma-reports-second-quarter-2015-financial-results 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2015/kite-pharma-reports-third-quarter-2015-financial-results-and-provides-business-update 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2015/kite-pharma-strengthens-its-t-cell-receptor-tcr-cancer-gene-therapy-platform-through-acquisition-of-t-cell-factory-bv-tcftm 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/kite-pharma-to-hold-conference-call-to-provide-a-corporate-update-on-monday-august-17-2015 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2015/kite-pharma-to-host-investor-day-on-june-23-2015 2024-07-23 daily 0.5 https://www.gilead.com/news/news-details/2015/kite-pharma-to-host-second-quarter-2015-financial-results-conference-call-and-webcast 2024-07-03 daily 0.5 https://www.gilead.com/news/news-details/2015/kite-pharma-to-host-third-quarter-2015-financial-results-conference-call-and-webcast 2024-07-03 daily 0.5 https://www.gilead.com/news/news-details/2015/kite-pharma-to-participate-in-upcoming-investor-conferences-in-may-2015 2024-07-03 daily 0.5 https://www.gilead.com/news/news-details/2015/kite-pharma-to-participate-in-upcoming-investor-conferences-in-september-2015 2024-07-03 daily 0.5 https://www.gilead.com/news/news-details/2015/kite-pharma-to-present-at-ibc-life-sciences-immuno-oncology-advancing-the-next-generation-of-cancer-immunotherapies-conference 2024-07-03 daily 0.5 https://www.gilead.com/news/news-details/2015/kite-pharma-to-present-at-the-17th-annual-bio-ceo--investor-conference 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2015/kite-pharma-to-present-at-the-2015-barclays-global-healthcare-conference 2024-07-03 daily 0.5 https://www.gilead.com/news/news-details/2015/kite-pharma-to-present-at-the-2015-jefferies-immuno-oncology-summit-in-boston 2024-07-03 daily 0.5 https://www.gilead.com/news/news-details/2015/kite-pharma-to-present-at-the-33rd-annual-jp-morgan-healthcare-conference 2024-07-03 daily 0.5 https://www.gilead.com/news/news-details/2015/kite-pharma-to-present-at-the-canaccord-genuity-35th-annual-growth-conference 2024-07-03 daily 0.5 https://www.gilead.com/news/news-details/2015/kite-pharma-to-present-at-the-cowen-and-company-35th-annual-health-care-conference 2024-07-03 daily 0.5 https://www.gilead.com/news/news-details/2015/kite-pharma-to-present-at-the-jefferies-2015-global-healthcare-conference 2024-07-03 daily 0.5 https://www.gilead.com/news/news-details/2015/kite-pharma-to-present-at-upcoming-investor-conferences-in-november-2015 2024-07-03 daily 0.5 https://www.gilead.com/news/news-details/2015/kite-pharma-to-present-clinical-biomarkers-from-patients-treated-with-anti-cd19-chimeric-antigen-receptor-t-cell-therapy-at-the-2015-asco-annual-meeting 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2015/kite-pharma-to-present-four-abstracts-including-safety-and-efficacy-data-from-the-kte-c19-phase-1-study-in-patients-with-refractory-aggressive-nhl-zuma-1-at-the-57th-american-society-of-hema 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2015/kite-pharma-to-report-first-quarter-financial-results-on-friday-may-15-2015 2024-07-03 daily 0.5 https://www.gilead.com/news/news-details/2015/kite-pharma-to-report-fourth-quarter-and-full-year-2014-financial-results-on-march-26th-2015 2024-07-03 daily 0.5 https://www.gilead.com/news/news-details/2015/multiple-scientific-presentations-at-the-liver-meeting-2015-further-highlight-the-utility-of-sofosbuvir-based-hepatitis-c-therapies 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/phase-3-results-for-zydelig-with-bendamustine-and-rituximab-for-relapsed-chronic-lymphocytic-leukemia-cll-presented-at-american-society-of-hematology-annual-meeting 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/results-from-the-ambition-study-of-first-line-treatment-with-letairis-and-tadalafil-in-pulmonary-arterial-hypertension-published-in-the-new-england-journal-of-medicine 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/us-fda-approves-new-indications-for-harvoni-gileads-once-daily-single-tablet-regimen-for-chronic-hepatitis-c 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/us-food-and-drug-administration-approves-gileads-single-tablet-regimen-genvoya-elvitegravir-cobicistat-emtricitabine-and-tenofovir-alafenamide-for-treatment-of-hiv-1-infection 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/us-food-and-drug-administration-approves-new-treatment-combination-of-gileads-letairis-with-tadalafil-for-pulmonary-arterial-hypertension-who-group-1 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2015/zydelig-in-combination-with-ofatumumab-improves-progression-free-survival-in-previously-treated-patients-with-chronic-lymphocytic-leukemia 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/european-chmp-adopts-positive-opinion-for-gileads-epclusa-sofosbuvirvelpatasvir-for-the-treatment-of-all-genotypes-of-chronic-hepatitis-c 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/european-chmp-adopts-positive-opinion-for-gileads-fixed-dose-combination-descovy-emtricitabinetenofovir-alafenamide-for-the-treatment-of-hiv 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/european-chmp-adopts-positive-opinion-for-gileads-taf-based-single-tablet-regimen-odefsey-emtricitabine-rilpivirine-tenofovir-alafenamide-for-treatment-of-hiv 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/european-chmp-adopts-positive-opinion-for-gileads-vemlidy-tenofovir-alafenamide-taf-for-the-treatment-of-chronic-hepatitis-b-virus-infection 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/european-chmp-adopts-positive-opinion-on-gileads-type-ii-variation-application-for-truvada-for-reducing-the-risk-of-sexually-acquired-hiv 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/european-commission-grants-marketing-authorization-for-gileads-epclusa-sofosbuvirvelpatasvir-for-the-treatment-of-all-genotypes-of-chronic-hepatitis-c 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/european-commission-grants-marketing-authorization-for-gileads-fixed-dose-combination-descovy-emtricitabine-tenofovir-alafenamide-for-treatment-of-hiv 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/european-commission-grants-marketing-authorization-for-gileads-once-daily-truvada-for-reducing-the-risk-of-sexually-acquired-hiv-1 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/european-commission-grants-marketing-authorization-for-gileads-single-tablet-regimen-odefsey-emtricitabine-rilpivirine-tenofovir-alafenamide-for-the-treatment-of-hiv 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/european-medicines-agency-validates-gileads-marketing-application-for-tenofovir-alafenamide-taf-for-the-treatment-of-chronic-hepatitis-b 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/european-medicines-agency-validates-gileads-type-ii-variation-application-for-truvada-for-reducing-the-risk-of-sexually-acquired-hiv 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/galapagos-and-gilead-cleared-by-us-federal-trade-commission-to-close-global-partnership-on-filgotinib 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/galapagos-and-gilead-complete-closing-of-their-global-collaboration-for-filgotinib 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/gilead-announces-data-from-new-preclinical-study-evaluating-an-investigational-tlr7-agonist-in-siv-infected-monkeys 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/gilead-announces-full-48-week-results-from-two-phase-3-studies-evaluating-tenofovir-alafenamide-taf-for-patients-with-chronic-hepatitis-b-infection 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/gilead-announces-multiple-scientific-presentations-demonstrating-broad-utility-of-sofosbuvir-based-hepatitis-c-therapies 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/gilead-announces-promotion-of-katie-watson-to-executive-vice-president-human-resources 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/gilead-announces-results-from-first-study-to-evaluate-switching-to-ftaf-based-regimens-from-truvada-ftdf-based-regimens 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/gilead-announces-svr12-rates-from-four-phase-3-studies-of-a-once-daily-fixed-dose-combination-of-sofosbuvir-velpatasvir-and-voxilaprevir-in-treatment-nave-and-treatment-experienced-genotype- 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/gilead-announces-top-line-phase-2-results-for-gs-4997-selonsertib-in-nonalcoholic-steatohepatitis-nash-pulmonary-arterial-hypertension-pah-and-diabetic-kidney-disease-dkd 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/gilead-announces-top-line-results-from-two-phase-3-studies-evaluating-momelotinib-for-patients-with-myelofibrosis 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/gilead-announces-top-line-results-from-two-phase-3-studies-evaluating-tenofovir-alafenamide-taf-for-patients-with-chronic-hepatitis-b-infection 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/gilead-announces-us-fda-priority-review-designation-for-sofosbuvirvelpatasvir-for-treatment-of-all-genotypes-of-chronic-hepatitis-c-infection 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/gilead-launches-new-grants-program-to-support-hiv-cure 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/gilead-presents-new-data-highlighting-progress-in-liver-fibrosis 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/gilead-presents-preliminary-data-on-bictegravir-an-investigational-integrase-strand-transfer-inhibitor-for-the-treatment-of-hiv 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/gilead-presents-results-from-phase-3-studies-evaluating-switching-to-descovy-ftctaf-based-regimens-from-truvada-ftctdf-based-regimens 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/gilead-prices-5-billion-of-senior-unsecured-notes 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/gilead-sciences-and-the-world-health-organization-announce-five-year-visceral-leishmaniasis-collaboration 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/gilead-sciences-announces-acquisition-of-nimbus-therapeutics-acetyl-coa-carboxylase-acc-program-for-nash-and-other-liver-diseases 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/gilead-sciences-announces-appointment-of-kevin-young-cbe-as-chief-operating-officer-and-martin-silverstein-md-as-executive-vice-president-strategy 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/gilead-sciences-announces-declaration-of-q1-cash-dividend-and-increases-to-shareholder-return-programs 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/gilead-sciences-announces-first-quarter-2016-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/gilead-sciences-announces-fourth-quarter-2016-dividend 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/gilead-sciences-announces-fourth-quarter-and-full-year-2015-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/gilead-sciences-announces-promotion-of-james-r-meyers-to-executive-vice-president-worldwide-commercial-operations 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/gilead-sciences-announces-second-quarter-2016-dividend 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/gilead-sciences-announces-second-quarter-2016-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/gilead-sciences-announces-settlement-method-for-1625-convertible-senior-notes-due-2016 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/gilead-sciences-announces-third-quarter-2016-dividend 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/gilead-sciences-announces-third-quarter-2016-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/gilead-sciences-to-participate-in-two-upcoming-investor-conferences 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/gilead-sciences-to-present-at-the-34th-annual-jp-morgan-healthcare-conference-on-monday-january-11 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/gilead-sciences-to-present-at-the-35th-annual-jp-morgan-healthcare-conference-on-monday-january-9 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/gilead-sciences-to-present-at-the-36th-annual-william-blair-growth-stock-conference-on-tuesday-june-14 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/gilead-sciences-to-present-at-the-annual-piper-jaffray-healthcare-conference-on-tuesday-november-29 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/gilead-sciences-to-present-at-the-bank-of-america-merrill-lynch-healthcare-conference-on-tuesday-may-10 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/gilead-sciences-to-present-at-the-barclays-global-healthcare-conference-on-tuesday-march-15 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/gilead-sciences-to-present-at-the-cowen--company-36th-annual-health-care-conference-on-monday-march-7 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/gilead-sciences-to-present-at-the-credit-suisse-25th-annual-healthcare-conference-on-monday-november-7 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/gilead-sciences-to-present-at-the-goldman-sachs-37th-annual-global-healthcare-conference-on-wednesday-june-8 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/gilead-sciences-to-present-at-the-jefferies-2016-healthcare-conference-on-friday-june-10 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/gilead-sciences-to-present-at-the-rbc-capital-markets-2016-healthcare-conference-on-wednesday-february-24 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/gilead-sciences-to-present-at-the-ubs-global-healthcare-conference-on-monday-may-23 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/gilead-sciences-to-present-at-three-upcoming-investor-conferences-in-september 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/gilead-sciences-to-release-first-quarter-2016-financial-results-on-thursday-april-28-2016 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/gilead-sciences-to-release-fourth-quarter-and-full-year-2015-financial-results-on-tuesday-february-2-2016 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/gilead-sciences-to-release-second-quarter-2016-financial-results-on-monday-july-25-2016 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/gilead-sciences-to-release-third-quarter-2016-financial-results-on-tuesday-november-1-2016 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/gileads-john-c-martin-phd-to-assume-role-of-executive-chairman-of-the-board-john-f-milligan-phd-to-be-appointed-chief-executive-officer-and-director 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/gileads-odefsey-emtricitabine-rilpivirine-tenofovir-alafenamide-meets-primary-48-week-objective-in-two-phase-3b-studies 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/gilead-submits-new-drug-application-to-japans-pharmaceutical-and-medical-devices-agency-for-tenofovir-alafenamide-taf-for-patients-with-chronic-hepatitis-b-infection 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/gilead-submits-new-drug-application-to-us-food-and-drug-administration-for-tenofovir-alafenamide-taf-for-the-treatment-of-chronic-hepatitis-b 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/gilead-submits-new-drug-application-to-us-food-and-drug-administration-for-the-investigational-single-tablet-regimen-sofosbuvirvelpatasvirvoxilaprevir 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/gilead-terminates-phase-23-study-of-gs-5745-in-patients-with-ulcerative-colitis 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/gilead-terminates-phase-2-study-of-simtuzumab-in-patients-with-idiopathic-pulmonary-fibrosis 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/japans-ministry-of-health-labour-and-welfare-approves-gileads-vemlidy-for-patients-with-chronic-hepatitis-b-virus-infection 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/kelly-a-kramer-joins-gilead-sciences-board-of-directors 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/kitenci-anti-cd19-car-t-cell-therapy-demonstrates-durable-complete-remissions-in-advanced-non-hodgkin-lymphoma 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/kite-pharma-advisors-and-scientific-pioneers-in-cancer-immunotherapy-receive-prestigious-cellular-immune-therapy-award 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/kite-pharma-and-cell-design-labs-announce-exclusive-research-collaboration-using-molecular-onoff-switches-for-car-t-cell-immunotherapies 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/kite-pharma-and-vitruvian-networks-enter-strategic-partnership-to-develop-best-in-class-logistics-and-data-analytics-software-for-engineered-t-cell-therapies-at-commercial-scale 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/kite-pharma-announces-clinical-and-manufacturing-updates-on-kte-c19-and-mage-a3-product-candidates-at-the-annual-meeting-of-the-american-association-for-cancer-research-aacr 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/kite-pharma-announces-clinical-collaboration-to-evaluate-two-novel-immunotherapies-for-patients-with-non-hodgkin-lymphoma 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2016/kite-pharma-announces-exclusive-license-with-the-national-institutes-of-health-for-fully-human-anti-cd19-chimeric-antigen-receptor-car-product-candidate-to-treat-b-cell-malignancies 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2016/kite-pharma-announces-exclusive-license-with-the-national-institutes-of-health-for-multiple-neoantigen-directed-t-cell-receptor-tcr-product-candidates-to-treat-solid-tumors-expressing-mutated-kras 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2016/kite-pharma-announces-fda-orphan-drug-designations-for-kte-c19-in-five-additional-indications 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/kite-pharma-announces-key-presentations-on-kte-c19-and-engineered-cell-therapy-pipeline-programs-at-the-annual-meeting-of-the-american-association-for-cancer-research-aacr 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2016/kite-pharma-announces-positive-topline-kte-c19-data-from-zuma-1-pivotal-trial-in-patients-with-aggressive-non-hodgkin-lymphoma-nhl 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/kite-pharma-announces-presentations-at-the-annual-meeting-of-the-american-society-of-gene--cell-therapy-asgct 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/kite-pharma-announces-publication-of-t-cell-therapy-targeting-mutant-kras-in-cancer-by-the-national-cancer-institute-nci-in-new-england-journal-of-medicine 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2016/kite-pharma-announces-review-of-national-cancer-institutes-manufacturing-facilities 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2016/kite-pharma-announces-successful-defense-of-roberts-patent-and-intent-to-appeal-us-patent-and-trademark-office-decision-on-a-narrow-patent-focused-on-select-cd28-car-t-products 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/kite-pharma-announces-the-first-meta-analysis-of-outcomes-in-chemorefractory-diffuse-large-b-cell-lymphoma-scholar-1 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/kite-pharma-appoints-chris-nowers-as-head-of-europe-to-lead-commercial-operations-and-advance-the-companys-cartcr-therapy-portfolio-in-the-region 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2016/kite-pharma-appoints-jian-irish-phd-as-senior-vice-president-of-supply-chain 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2016/kite-pharma-augments-commercial-leadership-team 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/kite-pharma-commends-scientific-advisory-board-members-on-awards-received-from-the-american-association-of-cancer-research-aacr 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/kite-pharma-completes-enrollment-of-all-patients-with-diffuse-large-b-cell-lymphoma-dlbcl-in-pivotal-multi-center-phase-2-study-of-kte-c19-zuma-1 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/kite-pharma-deepens-cell-manufacturing-and-operations-expertise-with-appointment-of-tim-moore 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2016/kite-pharma-details-kte-c19-launch-preparedness-and-near-term-next-generation-cartcr-product-candidates-at-investor-day 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/kite-pharma-expands-development-of-t-cell-receptor-tcr-therapies-targeting-hpv-associated-cancers-in-partnership-with-the-national-cancer-institute-nci 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/kite-pharma-expands-its-clinical-and-research-partnership-with-the-national-cancer-institute-nci-for-next-generation-car-programs-to-treat-b-cell-malignancies 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2016/kite-pharma-expands-leadership-team-appoints-paul-l-jenkinson-as-chief-financial-officer 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/kite-pharma-granted-access-to-priority-medicines-prime-regulatory-support-for-kte-c19-in-the-treatment-of-chemorefractory-diffuse-large-b-cell-lymphoma-dlbcl 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/kite-pharma-initiates-phase-1b2-combination-study-for-kte-c19-and-atezolizumab-in-patients-with-refractory-diffuse-large-b-cell-lymphoma-dlbcl 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/kite-pharma-initiates-rolling-submission-of-us-biologics-license-application-bla-for-kte-c19-its-investigational-anti-cd19-car-t-therapy-for-the-treatment-of-patients-with-relapsedrefractory 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2016/kite-pharma-licenses-enabling-technology-for-the-development-of-off-the-shelf-allogeneic-t-cell-therapies 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/kite-pharma-names-christine-cassiano-as-senior-vice-president-of-corporate-communications-and-investor-relations 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2016/kite-pharma-opens-state-of-the-art-t-cell-therapy-manufacturing-facility 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/kite-pharma-presents-12-month-follow-up-data-from-zuma-1-phase-1-at-the-european-society-for-medical-oncology-esmo-annual-congress 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/kite-pharma-presents-ongoing-complete-responses-at-9-months-in-phase-1-of-zuma-1-in-patients-with-chemorefractory-non-hodgkin-lymphoma 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/kite-pharma-presents-results-of-multi-center-pivotal-zuma-1-trial-of-axicabtagene-ciloleucel-kte-c19-in-aggressive-non-hodgkin-lymphoma-as-late-breaking-abstract-at-annual-meeting-of-america 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/kite-pharma-presents-updated-phase-1-results-from-zuma-1-at-the-american-association-of-cancer-research-aacr-annual-meeting 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/kite-pharma-reports-first-quarter-2016-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/kite-pharma-reports-fourth-quarter-and-full-year-2015-financial-results 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2016/kite-pharma-reports-second-quarter-2016-financial-results 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2016/kite-pharma-reports-third-quarter-2016-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/kite-pharma-to-highlight-key-data-from-car-t-cell-therapy-pipeline-in-oral-presentations-at-the-2016-european-hematology-association-eha-annual-congress 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/kite-pharma-to-highlight-key-data-from-engineered-car-t-cell-therapy-pipeline-at-the-2016-american-society-of-clinical-oncology-annual-meeting 2024-09-10 daily 0.5 https://www.gilead.com/news/news-details/2016/kite-pharma-to-host-investor-day-on-october-18-2016-spotlighting-an-industry-leading-cartcr-pipeline-next-generation-research-and-development-and-kte-c19-launch-readiness 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2016/kite-pharma-to-participate-in-september-2016-investor-conferences 2024-07-03 daily 0.5 https://www.gilead.com/news/news-details/2016/kite-pharma-to-participate-in-the-2016-rbc-capital-markets-global-healthcare-conference 2024-07-03 daily 0.5 https://www.gilead.com/news/news-details/2016/kite-pharma-to-present-at-june-2016-investor-conferences 2024-07-03 daily 0.5 https://www.gilead.com/news/news-details/2016/kite-pharma-to-present-at-march-2016-investor-conferences 2024-07-03 daily 0.5 https://www.gilead.com/news/news-details/2016/kite-pharma-to-present-at-november-2016-investor-conferences 2024-07-03 daily 0.5 https://www.gilead.com/news/news-details/2016/kite-pharma-to-present-at-the-34th-annual-jp-morgan-healthcare-conference 2024-07-03 daily 0.5 https://www.gilead.com/news/news-details/2016/kite-pharma-to-present-at-the-canaccord-genuity-36th-annual-growth-conference 2024-07-03 daily 0.5 https://www.gilead.com/news/news-details/2016/kite-pharma-to-present-interim-results-from-the-zuma-1-pivotal-trial-of-kte-c19-in-a-late-breaking-session-at-the-2016-american-society-of-hematology-annual-meeting 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/kite-pharma-to-present-kte-c19-data-from-interim-analysis-of-the-zuma-1-pivotal-trial-in-patients-with-chemorefractory-primary-mediastinal-b-cell-lymphoma-pmbcl-and-transformed-follicular-ly 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/kite-pharma-to-report-first-quarter-2016-financial-results-on-may-9-2016 2024-07-03 daily 0.5 https://www.gilead.com/news/news-details/2016/kite-pharma-to-report-fourth-quarter-and-full-year-2015-financial-results-on-february-29-2016 2024-07-03 daily 0.5 https://www.gilead.com/news/news-details/2016/kite-pharma-to-report-second-quarter-2016-financial-results-on-august-8-2016 2024-07-03 daily 0.5 https://www.gilead.com/news/news-details/2016/kite-pharma-to-report-third-quarter-2016-financial-results-on-november-9-2016 2024-07-03 daily 0.5 https://www.gilead.com/news/news-details/2016/phase-2-data-for-selonsertib-in-nonalcoholic-steatohepatitis-nash-presented-at-the-liver-meeting-2016 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/santa-monica-calif-jan-13-2016-globe-newswire----kite-pharma-inc-nasdaqkite-today-announced-that-its-european-subsidiary-has-entered-into-a-research-and-license-agreement-with-leiden-univers 2024-08-26 daily 0.5 https://www.gilead.com/news/news-details/2016/us-fda-approves-two-supplemental-indications-for-harvoni-in-chronic-hepatitis-c-patients-with-advanced-liver-disease 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/us-food-and-drug-administration-approves-descovy-emtricitabine-tenofovir-alafenamide-gileads-third-taf-based-hiv-therapy 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/us-food-and-drug-administration-approves-gileads-epclusa-sofosbuvirvelpatasvir-for-the-treatment-of-all-genotypes-of-chronic-hepatitis-c 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/us-food-and-drug-administration-approves-gileads-second-taf-based-single-tablet-regimen-odefsey-emtricitabine-rilpivirine-tenofovir-alafenamide-for-the-treatment-of-hiv-1-infection 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2016/us-food-and-drug-administration-approves-gileads-vemlidy-tenofovir-alafenamide-for-the-treatment-of-chronic-hepatitis-b-virus-infection 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/alessandro-riva-md-to-join-gilead-as-senior-vice-president-hematology-and-oncology-therapeutic-area-head 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/china-food-and-drug-administration-approves-gileads-sovaldi-sofosbuvir-for-treatment-of-chronic-hepatitis-c-virus-infection 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/european-chmp-adopts-positive-opinion-for-gileads-vosevi-sofosbuvirvelpatasvirvoxilaprevir-for-the-treatment-of-all-chronic-hepatitis-c-genotypes 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/european-commission-grants-marketing-authorization-for-gileads-vemlidy-tenofovir-alafenamide-taf-for-the-treatment-of-chronic-hepatitis-b-virus-infection 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/european-commission-grants-marketing-authorization-for-gileads-vosevi-sofosbuvirvelpatasvirvoxilaprevir-for-the-treatment-of-all-genotypes-of-chronic-hepatitis-c 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/european-medicines-agency-validates-gileads-marketing-application-for-fixed-dose-combination-of-bictegravir-emtricitabine-and-tenofovir-alafenamide-for-treatment-of-hiv 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/european-medicines-agency-validates-gileads-marketing-authorization-application-for-investigational-chronic-hepatitis-c-therapy-sofosbuvirvelpatasvirvoxilaprevir-sofvelvox 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/gilead-announces-10-year-100-million-commitment-to-address-the-hivaids-epidemic-in-the-southern-united-states 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/gilead-announces-144-week-data-evaluating-safety-and-efficacy-of-genvoya-for-treatment-of-hiv-1-in-treatment-nave-adults 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/gilead-announces-findings-from-new-preclinical-study-evaluating-novel-class-of-hiv-capsid-inhibitors 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/gilead-announces-multiple-scientific-presentations-demonstrating-high-cure-rates-in-difficult-to-cure-hcv-patients-and-improved-long-term-bone-and-renal-safety-of-vemlidy-in-hbv-patients-swi 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/gilead-announces-new-license-agreement-with-the-medicines-patent-pool-for-access-to-bictegravir 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/gilead-announces-phase-2-results-for-gs-0976-in-nonalcoholic-steatohepatitis-nash 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/gilead-announces-phase-3-results-for-investigational-fixed-dose-combination-of-bictegravir-emtricitabine-and-tenofovir-alafenamide-for-treatment-of-hiv 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/gilead-announces-scientific-presentations-demonstrating-efficacy-of-harvoni-ledipasvirsofosbuvir-in-special-patient-populations-with-hcv-infection 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/gilead-announces-us-fda-priority-review-designation-for-fixed-dose-combination-of-bictegravir-emtricitabine-and-tenofovir-alafenamide-for-treatment-of-hiv 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/gilead-awards-75-million-in-second-round-of-grants-to-advance-hiv-cure-research 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/gilead-awards-more-than-22-million-in-grants-to-support-hiv-cure-research 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/gilead-presents-data-at-the-international-liver-congress-2017-supporting-the-efficacy-and-safety-of-vemlidy-in-patients-with-chronic-hepatitis-b-after-96-weeks-and-also-after-switching-from-viread 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/gilead-presents-new-phase-2-data-on-bictegravir-an-investigational-integrase-strand-transfer-inhibitor-for-the-treatment-of-hiv 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/gilead-presents-proof-of-concept-data-for-gs-0976-in-nonalcoholic-steatohepatitis-nash-at-the-international-liver-congress-2017 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/gilead-presents-results-from-phase-3-study-evaluating-patients-who-switched-to-investigational-fixed-dose-combination-of-bictegravir-emtricitabine-and-tenofovir-alafenamide-from-boosted-prot 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/gilead-prices-3-billion-of-senior-unsecured-notes 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/gilead-sciences-and-kite-pharma-announce-expiration-of-hart-scott-rodino-waiting-period 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/gilead-sciences-and-kite-to-acquire-cell-design-labs 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/gilead-sciences-announces-10-percent-increase-in-first-quarter-2017-dividend 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/gilead-sciences-announces-first-quarter-2017-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/gilead-sciences-announces-fourth-quarter-2017-dividend 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/gilead-sciences-announces-fourth-quarter-and-full-year-2016-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/gilead-sciences-announces-promotion-of-alessandro-riva-to-executive-vice-president-oncology-therapeutics 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/gilead-sciences-announces-second-quarter-2017-dividend 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/gilead-sciences-announces-second-quarter-2017-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/gilead-sciences-announces-that-john-c-martin-phd-will-transition-from-executive-chairman-to-chairman-of-the-board-of-directors 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/gilead-sciences-announces-third-quarter-2017-dividend 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/gilead-sciences-announces-third-quarter-2017-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/gilead-sciences-completes-acquisition-of-kite-pharma-inc 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/gilead-sciences-completes-tender-offer-for-all-outstanding-shares-of-kite-pharma-inc 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/gilead-sciences-to-acquire-kite-pharma-for-119-billion 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/gilead-sciences-to-present-at-citis-12th-annual-biotech-conference-on-wednesday-september-6 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/gilead-sciences-to-present-at-the-36th-annual-jp-morgan-healthcare-conference-on-monday-january-8 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/gilead-sciences-to-present-at-the-37th-annual-william-blair-growth-stock-conference-on-tuesday-june-13 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/gilead-sciences-to-present-at-the-bank-of-america-merrill-lynch-healthcare-conference-on-thursday-may-18 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/gilead-sciences-to-present-at-the-barclays-global-healthcare-conference-on-tuesday-march-14 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/gilead-sciences-to-present-at-the-credit-suisse-26th-annual-healthcare-conference-on-tuesday-november-7 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/gilead-sciences-to-present-at-the-goldman-sachs-38th-annual-global-healthcare-conference-on-thursday-june-15 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/gilead-sciences-to-present-at-the-morgan-stanley-global-healthcare-conference-on-monday-september-11 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/gilead-sciences-to-present-at-the-nasdaq-37th-investor-program-on-wednesday-december-6 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/gilead-sciences-to-present-at-the-rbc-capital-markets-2017-global-healthcare-conference-on-wednesday-february-22 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/gilead-sciences-to-release-first-quarter-2017-financial-results-on-tuesday-may-2-2017 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/gilead-sciences-to-release-fourth-quarter-and-full-year-2016-financial-results-on-tuesday-february-7-2017 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/gilead-sciences-to-release-second-quarter-2017-financial-results-on-wednesday-july-26-2017 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/gilead-sciences-to-release-third-quarter-2017-financial-results-on-thursday-october-26-2017 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/gileads-investigational-fixed-dose-combination-of-bictegravir-emtricitabine-and-tenofovir-alafenamide-for-the-treatment-of-hiv-1-meets-primary-endpoint-in-four-phase-3-studies 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/gilead-submits-new-drug-application-to-us-food-and-drug-administration-for-fixed-dose-combination-of-bictegravir-emtricitabine-and-tenofovir-alafenamide-for-hiv-treatment 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/gilead-to-present-clinical-and-preclinical-data-on-nonalcoholic-steatohepatitis-nash-at-the-international-liver-congress-2017 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/kevin-young-cbe-gileads-chief-operating-officer-to-retire 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/kite-announces-appointment-of-renowned-cancer-researcher-owen-n-witte-md-to-its-board-of-directors 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2017/kite-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-underwriters-option-to-purchase-additional-shares 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2017/kite-announces-commencement-of-public-offering-of-common-stock 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2017/kite-announces-data-from-zuma-3-study-of-kte-c19-in-adult-patients-with-relapsed-or-refractory-acute-lymphoblastic-leukemia 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/kite-announces-initiation-of-axicabtagene-ciloleucel-car-t-clinical-program-in-the-european-union 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2017/kite-announces-landmark-study-of-refractory-aggressive-non-hodgkin-lymphoma-scholar-1-outcomes-published-in-the-journal-blood 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/kite-announces-long-term-data-from-pivotal-zuma-1-study-of-yescarta-axicabtagene-ciloleucel-in-patients-with-refractory-large-b-cell-lymphoma 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/kite-announces-positive-topline-primary-results-of-axicabtagene-ciloleucel-from-first-pivotal-car-t-trial-in-patients-with-aggressive-non-hodgkin-lymphoma 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/kite-announces-presentations-on-its-lead-car-t-therapy-development-program-at-the-2017-american-society-of-clinical-oncology-annual-meeting 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2017/kite-announces-pricing-of-public-offering-of-common-stock 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2017/kite-completes-submission-of-us-biologics-license-application-bla-for-axicabtagene-ciloleucel-as-the-first-car-t-therapy-for-the-treatment-of-patients-with-aggressive-non-hodgkin-lymphoma-nhl 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2017/kite-doses-first-patient-in-the-phase-2-trial-of-axicabtagene-ciloleucel-in-indolent-b-cell-non-hodgkin-lymphoma-zuma-5 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/kite-files-the-industrys-first-car-t-marketing-authorization-application-in-europe-for-axicabtagene-ciloleucel 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2017/kite-highlights-durable-complete-remissions-up-to-56-months-in-patients-with-chemorefractory-aggressive-non-hodgkin-lymphoma-nhl-after-anti-cd19-car-t-cell-therapy-at-the-national-cancer-institute 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2017/kite-highlights-publication-from-the-national-cancer-institute-demonstrating-responses-in-patients-with-metastatic-solid-tumors-treated-with-t-cell-receptor-tcr-therapy-targeting-mage-a3 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2017/kite-named-to-the-mit-technology-reviews-annual-50-smartest-companies-list-in-recognition-for-its-leadership-in-establishing-car-t-therapy 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2017/kite-pharma-and-fosun-pharma-establish-joint-venture-in-china-to-develop-and-commercialize-autologous-t-cell-therapies-to-treat-cancer 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2017/kite-pharma-enhances-commercial-expertise-with-the-appointment-of-ian-t-clark-to-its-board-of-directors 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2017/kite-pharma-establishes-a-strategic-partnership-with-daiichi-sankyo-to-develop-and-commercialize-axicabtagene-ciloleucel-kte-c19-in-japan 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/kite-pharma-highlights-publication-from-the-national-cancer-institute-demonstrating-durable-complete-remissions-in-patients-with-relapsedrefractory-non-hodgkin-lymphoma-following-low-dose-co 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/kite-pharma-submits-investigational-new-drug-ind-application-for-kite-718-an-investigational-next-generation-t-cell-receptor-tcr-therapy-targeting-cancer-antigens-mage-a3-and-mage-a6 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2017/kite-pharma-to-present-at-the-35th-annual-jp-morgan-healthcare-conference 2024-07-23 daily 0.5 https://www.gilead.com/news/news-details/2017/kite-presents-ongoing-response-rate-in-plenary-session-from-its-pivotal-car-t-trial-of-axicabtagene-ciloleucel-in-patients-with-aggressive-non-hodgkin-lymphoma-at-the-2017-american-associati 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/kite-presents-promising-preclinical-data-from-kite-585-a-fully-human-anti-bcma-car-t-cell-product-candidate-at-the-2017-american-association-of-cancer-research-aacr-annual-meeting 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/kite-receives-us-food-and-drug-administration-priority-review-for-axicabtagene-ciloleucel 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/kite-reports-73-percent-of-patients-achieved-mrd-negative-complete-remission-in-updated-analysis-from-phase-1-zuma-3-car-t-trial-of-kte-c19-in-adult-patients-with-high-burden-relapsedrefract 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/kite-reports-first-quarter-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/kite-reports-fourth-quarter-and-full-year-2016-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/kite-reports-second-quarter-2017-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/kite-submits-investigational-new-drug-ind-application-for-kite-585-anti-bcma-car-t-therapy-candidate-for-multiple-myeloma 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/kites-yescarta-axicabtagene-ciloleucel-becomes-first-car-t-therapy-approved-by-the-fda-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-large-b-cell-lymphoma-after-two-or-more 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/kite-to-present-at-august-2017-investor-conference 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2017/kite-to-present-at-june-2017-investor-conferences 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2017/kite-to-present-at-march-2017-investor-conferences 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2017/kite-to-present-two-plenary-presentations-from-the-zuma-1-pivotal-trial-of-axicabtagene-ciloleucel-at-the-2017-american-association-of-cancer-research-annual-meeting 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/kite-to-report-first-quarter-2017-financial-results-on-may-8-2017 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2017/kite-to-report-fourth-quarter-and-full-year-2016-financial-results-on-february-28-2017 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2017/kite-to-report-second-quarter-2017-financial-results-on-august-8-2017 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2017/kite-wins-clinical-trial-result-of-the-year-for-its-pivotal-car-t-trial-of-axicabtagene-ciloleucel-in-patients-with-aggressive-non-hodgkin-lymphoma-at-the-2017-clinical-and-research-excellence-awards 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/richard-l-wang-named-chief-executive-officer-of-fosun-kite-biotechnology-co-ltd-a-joint-venture-to-lead-development-of-axicabtagene-ciloleucel-and-other-engineered-t-cell-therapies-for-treat 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2017/us-fda-approves-expanded-labeling-for-epclusa-sofosbuvirvelpatasvir-for-the-treatment-of-chronic-hepatitis-c-in-patients-co-infected-with-hiv 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/us-fda-approves-new-indications-for-harvoni-and-sovaldi-in-pediatric-patients-12-years-and-older-with-chronic-hepatitis-c-infection 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/us-food-and-drug-administration-approves-gileads-vosevi-sofosbuvirvelpatasvirvoxilaprevir-for-re-treatment-of-adults-with-chronic-hepatitis-c-virus 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2017/us-patent-office-to-confirm-kites-seminal-eshhar-car-t-patent 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2018/china-drug-administration-approves-epclusa-sofosbuvirvelpatasvir-gileads-pan-genotypic-treatment-for-chronic-hepatitis-c-virus-infection 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2018/china-national-drug-administration-approves-gileads-genvoya-elvitegravir-cobicistat-emtricitabine-and-tenofovir-alafenamide-a-single-tablet-regimen-for-the-treatment-of-hiv-1-infection 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2018/china-national-medical-products-administration-approves-descovy-emtricitabine-tenofovir-alafenamide-for-the-treatment-of-hiv-1-infection 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2018/china-national-medical-products-administration-nmpa-approves-gileads-vemlidy-tenofovir-alafenamide-for-chronic-hepatitis-b-virus-hbv-infection 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2018/chinas-national-medical-products-administration-approves-harvoni-ledipasvirsofosbuvir-for-treatment-of-chronic-hepatitis-c-virus-genotype-1-6 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2018/european-chmp-adopts-positive-opinion-for-gileads-biktarvy-bictegravir-emtricitabine-tenofovir-alafenamide 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2018/european-chmp-adopts-positive-opinion-for-yescarta-axicabtagene-ciloleucel-for-the-treatment-of-relapsed-or-refractory-dlbcl-and-pmbcl-after-two-or-more-lines-of-systemic-therapy 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2018/european-commission-grants-marketing-authorization-for-gileads-biktarvy-bictegravir-emtricitabine-tenofovir-alafenamide-for-the-treatment-of-hiv-1-infection 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2018/gilead-and-agenus-enter-into-collaboration-to-develop-immuno-oncology-therapies 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2018/gilead-and-galapagos-announce-filgotinib-meets-primary-and-all-key-secondary-endpoints-in-first-phase-3-study-in-rheumatoid-arthritis 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2018/gilead-and-galapagos-announce-results-with-filgotinib-in-the-phase-2-equator-study-in-psoriatic-arthritis-and-progression-into-phase-3-for-the-selection-study-in-ulcerative-colitis 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2018/gilead-and-galapagos-announce-tortuga-phase-2-study-of-filgotinib-in-ankylosing-spondylitis-achieves-primary-endpoint 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2018/gilead-and-verily-announce-scientific-collaboration-to-identify-and-understand-immunological-and-molecular-drivers-of-inflammatory-diseases 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2018/gilead-announces-96-week-results-from-phase-3-study-of-biktarvy-bictegravir-emtricitabine-tenofovir-alafenamide-for-the-treatment-of-hiv-1-in-adults-new-to-hiv-therapy 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2018/gilead-announces-96-week-results-from-phase-3-study-of-biktarvy-bictegravir-emtricitabine-tenofovir-alafenamide-for-the-treatment-of-hiv-1-in-adults-new-to-hiv-therapy-20181003083000 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2018/gilead-announces-data-from-new-preclinical-study-evaluating-a-combination-of-an-investigational-tlr7-agonist-and-an-investigational-hiv-envelope-targeting-antibody-in-shiv-infected-virally-s 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2018/gilead-announces-new-data-on-the-impact-of-truvada-emtricitabine-and-tenofovir-disoproxil-fumarate-for-pre-exposure-prophylaxis-prep-on-the-number-of-hiv-diagnoses-in-the-united-states 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2018/gilead-announces-positive-phase-2-results-for-gs-9674-in-primary-sclerosing-cholangitis-psc-at-the-liver-meeting-2018 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2018/gilead-enters-licensing-agreement-with-trianni-for-use-of-trianni-transgenic-human-monoclonal-antibody-discovery-platform 2024-07-23 daily 0.5 https://www.gilead.com/news/news-details/2018/gilead-presents-data-from-nonalcoholic-steatohepatitis-nash-development-program-for-advanced-fibrosis-at-the-liver-meeting-2018 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2018/gilead-presents-data-from-phase-3-study-evaluating-women-who-switched-to-biktarvy-bictegravir-emtricitabine-and-tenofovir-alafenamide-from-a-boosted-protease-inhibitor-based-regimen-or-boost 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2018/gilead-presents-data-on-multiple-investigational-regimens-for-the-treatment-of-patients-with-nonalcoholic-steatohepatitis-nash-and-advanced-fibrosis-at-the-international-liver-congress-2018 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2018/gilead-presents-latest-data-from-viral-hepatitis-research-programs-at-the-liver-meeting-2018 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2018/gilead-presents-results-from-phase-3-study-evaluating-patients-who-switched-to-biktarvy-bictegravir-emtricitabine-and-tenofovir-alafenamide-from-regimen-containing-abacavir-dolutegravir-and- 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2018/gilead-sciences-and-precision-biosciences-announce-collaboration-to-develop-therapies-against-hepatitis-b-virus-using-arcus-genome-editing 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2018/gilead-sciences-and-scholar-rock-announce-strategic-collaboration-to-develop-novel-therapies-for-fibrotic-diseases 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2018/gilead-sciences-and-tango-therapeutics-announce-strategic-collaboration-to-develop-next-generation-targeted-immuno-oncology-therapies 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2018/gilead-sciences-announces-10-percent-increase-in-first-quarter-2018-dividend 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2018/gilead-sciences-announces-ceo-john-f-milligan-to-step-down 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2018/gilead-sciences-announces-executive-promotions 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2018/gilead-sciences-announces-first-quarter-2018-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2018/gilead-sciences-announces-fourth-quarter-2018-dividend 2024-07-23 daily 0.5 https://www.gilead.com/news/news-details/2018/gilead-sciences-announces-fourth-quarter-and-full-year-2017-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2018/gilead-sciences-announces-leadership-changes-in-corporate-development-and-strategy 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2018/gilead-sciences-announces-second-quarter-2018-dividend 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2018/gilead-sciences-announces-second-quarter-2018-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2018/gilead-sciences-announces-senior-management-change 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2018/gilead-sciences-announces-third-quarter-2018-dividend 2024-07-23 daily 0.5 https://www.gilead.com/news/news-details/2018/gilead-sciences-announces-third-quarter-2018-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2018/gilead-sciences-appoints-laura-hamill-as-executive-vice-president-worldwide-commercial-operations 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2018/gilead-sciences-chief-scientific-officer-john-mchutchison-appointed-officer-of-the-order-of-australia 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2018/gilead-sciences-names-daniel-oday-chairman-and-chief-executive-officer 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2018/gilead-sciences-norbert-bischofberger-phd-to-step-down-john-mchutchison-md-appointed-chief-scientific-officer-and-andrew-cheng-md-phd-appointed-chief-medical-officer 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2018/gilead-sciences-to-present-at-the-bank-of-america-merrill-lynch-healthcare-conference-on-wednesday-may-16 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2018/gilead-sciences-to-present-at-the-evercore-isi-healthconx-conference-on-tuesday-november-27 2024-07-23 daily 0.5 https://www.gilead.com/news/news-details/2018/gilead-sciences-to-present-at-the-goldman-sachs-39th-annual-global-healthcare-conference-on-wednesday-june-13 2024-07-23 daily 0.5 https://www.gilead.com/news/news-details/2018/gilead-sciences-to-present-at-the-jefferies-2018-healthcare-conference-on-wednesday-june-6 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2018/gilead-sciences-to-present-at-the-morgan-stanley-global-healthcare-conference-on-wednesday-september-12 2024-07-23 daily 0.5 https://www.gilead.com/news/news-details/2018/gilead-sciences-to-present-at-the-rbc-capital-markets-2018-global-healthcare-conference-on-wednesday-february-21 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2018/gilead-sciences-to-release-first-quarter-2018-financial-results-on-tuesday-may-1-2018 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2018/gilead-sciences-to-release-fourth-quarter-and-full-year-2017-financial-results-on-tuesday-february-6-2018 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2018/gilead-sciences-to-release-second-quarter-2018-financial-results-on-wednesday-july-25-2018 2024-07-23 daily 0.5 https://www.gilead.com/news/news-details/2018/gilead-sciences-to-release-third-quarter-2018-financial-results-on-thursday-october-25-2018 2024-07-23 daily 0.5 https://www.gilead.com/news/news-details/2018/gilead-subsidiary-to-launch-authorized-generics-of-epclusa-sofosbuvirvelpatasvir-and-harvoni-ledipasvirsofosbuvir-for-the-treatment-of-chronic-hepatitis-c 2024-08-20 daily 0.5 https://www.gilead.com/news/news-details/2018/gilead-to-present-latest-scientific-research-in-hematologic-malignancies-and-solid-tumors-at-ash-2018 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2018/gilead-to-present-wide-ranging-new-data-on-treatment-and-diagnosis-of-liver-diseases-at-the-liver-meeting-2018 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2018/harish-manwani-joins-gilead-sciences-board-of-directors 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2018/hookipa-and-gilead-enter-into-a-collaboration-and-license-agreement-to-develop-immunotherapies-against-hiv-and-hepatitis-b 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2018/jacqueline-k-barton-phd-joins-gilead-sciences-board-of-directors 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2018/kite-a-gilead-company-and-sangamo-therapeutics-announce-collaboration-to-develop-next-generation-engineered-cell-therapies-for-the-treatment-of-cancer 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2018/kite-and-gadeta-announce-strategic-collaboration-to-advance-gamma-delta-t-cell-receptor-technology-for-solid-tumors 2024-07-23 daily 0.5 https://www.gilead.com/news/news-details/2018/kite-and-hifibio-therapeutics-announce-a-research-collaboration-to-develop-technology-for-the-potential-discovery-of-neoantigen-reactive-t-cell-receptors-tcrs-for-the-treatment-of-cancer 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2018/kite-announces-clinical-collaboration-to-evaluate-investigational-combination-of-yescarta-axicabtagene-ciloleucel-and-pfizers-utomilumab-in-large-b-cell-lymphoma 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2018/kite-announces-initial-results-from-a-phase-1-study-of-t-cell-receptor-tcr-cell-therapy-in-hpv-16-positive-solid-tumors 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2018/kite-announces-new-data-analyses-for-car-t-therapy-in-patients-with-blood-cancers-at-the-2018-american-society-of-clinical-oncology-meeting 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2018/kite-announces-new-worldwide-facilities-and-expanded-collaboration-with-national-cancer-institute-to-support-cell-therapy-pipeline 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2018/kite-announces-two-year-data-for-yescarta-axicabtagene-ciloleucel-in-patients-with-refractory-large-b-cell-lymphoma 2024-08-20 daily 0.5 https://www.gilead.com/news/news-details/2018/kite-announces-updated-data-from-zuma-3-study-of-kte-x19-in-adult-patients-with-relapsed-or-refractory-acute-lymphoblastic-leukemia 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2018/michael-amoroso-to-join-kite-as-senior-vice-president-and-head-of-worldwide-commercial-cell-therapy 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2018/phase-3-data-on-filgotinib-in-biologic-experienced-rheumatoid-arthritis-to-be-presented-at-2018-acrarhp-annual-meeting 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2018/positive-trial-results-with-filgotinib-in-psoriatic-arthritis-and-ankylosing-spondylitis-both-published-in-the-lancet 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2018/us-food-and-drug-administration-approves-expanded-indication-for-truvada-emtricitabine-and-tenofovir-disoproxil-fumarate-for-reducing-the-risk-of-acquiring-hiv-1-in-adolescents 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2018/us-food-and-drug-administration-approves-gileads-biktarvy-bictegravir-emtricitabine-tenofovir-alafenamide-for-treatment-of-hiv-1-infection 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2018/yescarta-axicabtagene-ciloleucel-receives-european-marketing-authorization-for-the-treatment-of-relapsed-or-refractory-dlbcl-and-pmbcl-after-two-or-more-lines-of-systemic-therapy 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2019/china-national-medical-products-administration-approves-biktarvy-bictegravir-emtricitabine-and-tenofovir-alafenamide-for-treatment-of-hiv-1-infection 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/china-national-medical-products-administration-approves-vosevi-sofosbuvir-velpatasvir-and-voxilaprevir-for-people-with-chronic-hepatitis-c-infection-who-require-re-treatment 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/data-showing-potential-for-machine-learning-to-advance-understanding-of-nonalcoholic-steatohepatitis-nash-presented-at-the-liver-meeting-2019 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/european-medicines-agency-validates-marketing-application-for-filgotinib-for-the-treatment-of-rheumatoid-arthritis 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-and-carna-biosciences-announce-research-and-development-collaboration-to-develop-novel-immuno-oncology-therapies 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-and-eisai-enter-into-agreement-in-japan-for-the-co-promotion-of-the-investigational-rheumatoid-arthritis-therapy-filgotinib-pending-regulatory-approval 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-and-galapagos-announce-efficacy-and-safety-results-of-filgotinib-through-52-weeks-in-finch-1-and-finch-3-studies-in-rheumatoid-arthritis 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-and-galapagos-announce-filgotinib-meets-primary-and-key-secondary-endpoints-in-the-phase-3-finch-1-rheumatoid-arthritis-study 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-and-galapagos-announce-filgotinib-meets-primary-endpoint-in-the-phase-3-finch-3-study-in-methotrexate-nave-rheumatoid-arthritis-patients 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-and-galapagos-complete-closing-of-their-transformative-research-and-development-collaboration 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-and-galapagos-enter-into-transformative-research-and-development-collaboration 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-and-galapagos-report-updated-safety-information-for-filgotinib-in-rheumatoid-arthritis-ra 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-and-galapagos-to-present-latest-data-on-filgotinib-at-the-annual-european-congress-of-rheumatology-eular-2019 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-and-galapagos-to-present-new-data-on-filgotinib-at-2019-acrarp-annual-meeting 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-and-glympse-bio-announce-strategic-collaboration-for-use-of-biomarker-technology-in-nash-clinical-development 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-and-insitro-announce-strategic-collaboration-to-discover-and-develop-novel-therapies-for-nonalcoholic-steatohepatitis 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-and-nurix-establish-strategic-collaboration-to-develop-novel-therapies-for-cancer-and-other-diseases 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-announces-data-demonstrating-non-inferiority-of-once-daily-descovy-vs-once-daily-truvada-for-prevention-of-hiv-infection 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-announces-data-from-two-studies-supporting-further-development-of-gs-6207-a-novel-investigational-hiv-1-capsid-inhibitor-as-a-component-of-future-long-acting-hiv-therapies 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-announces-intent-to-submit-new-drug-application-for-filgotinib-to-us-food-and-drug-administration-this-year 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-announces-latest-data-in-ongoing-hiv-cure-research-program 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-announces-new-data-from-viral-hepatitis-research-programs-at-the-liver-meeting-2019 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-announces-new-grant-programs-supporting-investigator-sponsored-research-in-liver-diseases 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-announces-senior-management-change 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-announces-topline-data-from-phase-3-stellar-3-study-of-selonsertib-in-bridging-fibrosis-f3-due-to-nonalcoholic-steatohepatitis-nash 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-announces-topline-data-from-phase-3-stellar-4-study-of-selonsertib-in-compensated-cirrhosis-f4-due-to-nonalcoholic-steatohepatitis-nash 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-announces-topline-results-from-phase-2-atlas-study-in-patients-with-bridging-fibrosis-f3-and-compensated-cirrhosis-f4-due-to-nonalcoholic-steatohepatitis-nash 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-appoints-christi-l-shaw-as-chief-executive-officer-of-kite 2024-07-23 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-launches-hepconnect-initiative-to-reduce-hepatitis-c-infections-in-greater-appalachia 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-presents-96-week-discover-trial-data-supporting-non-inferior-efficacy-and-key-safety-differences-of-descovy-for-prep-compared-with-truvada-for-prep 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-presents-data-on-biktarvy-bictegravir-emtricitabine-and-tenofovir-alafenamide-in-virologically-suppressed-adults-including-those-with-pre-existing-nrti-resistance 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-presents-data-on-investigational-hiv-1-capsid-inhibitor-gs-6207-as-a-potential-component-of-long-acting-hiv-therapy 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-presents-new-data-from-the-companys-hiv-clinical-development-program-and-latest-findings-on-the-impact-of-hiv-pre-exposure-prophylaxis-prep-at-idweek-2019 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-presents-new-data-in-nonalcoholic-steatohepatitis-nash-at-the-international-liver-congress-2019 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-presents-new-data-on-biktarvy-bictegravir-emtricitabine-and-tenofovir-alafenamide-and-taf-based-regimens-for-the-treatment-of-hiv-1-in-children-older-adults-and-women 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-presents-new-data-on-biktarvy-for-the-treatment-of-hiv-in-women-and-in-virologically-suppressed-patients-with-known-resistance 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-presents-new-data-on-viral-hepatitis-at-the-international-liver-congress-2019 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-presents-new-findings-on-profile-of-descovy-for-potential-use-as-hiv-pre-exposure-prophylaxis-compared-with-truvada 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-presents-proof-of-concept-data-for-gs-6207-a-first-in-class-capsid-inhibitor-in-people-living-with-hiv 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/gileads-biktarvy-maintained-high-efficacy-with-no-cases-of-treatment-emergent-resistance-through-three-years-in-phase-3-hiv-clinical-trials 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-sciences-and-goldfinch-bio-announce-strategic-collaboration-to-develop-novel-therapies-for-kidney-disease 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-sciences-and-novo-nordisk-announce-intent-to-initiate-a-clinical-collaboration-in-nash 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-sciences-and-renown-institute-for-health-innovation-announce-strategic-collaboration-to-advance-understanding-of-nonalcoholic-steatohepatitis-nash 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-sciences-and-the-elton-john-aids-foundation-launch-radian-initiative-to-address-hiv-in-eastern-europe-and-central-asia-eeca 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-sciences-and-yuhan-corporation-announce-collaboration-and-license-agreement-to-develop-novel-investigational-treatments-for-advanced-fibrosis-due-to-nonalcoholic-steatohepatitis 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-sciences-announces-11-percent-increase-in-first-quarter-2019-dividend 2024-07-23 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-sciences-announces-changes-to-senior-leadership-team 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-sciences-announces-first-quarter-2019-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-sciences-announces-fourth-quarter-2019-dividend 2024-07-23 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-sciences-announces-fourth-quarter-and-full-year-2018-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-sciences-announces-second-quarter-2019-dividend 2024-07-23 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-sciences-announces-second-quarter-2019-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-sciences-announces-third-quarter-2019-dividend 2024-07-23 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-sciences-announces-third-quarter-2019-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-sciences-appoints-andrew-dickinson-as-chief-financial-officer 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-sciences-appoints-johanna-mercier-as-chief-commercial-officer 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-sciences-appoints-merdad-parsey-md-phd-as-chief-medical-officer 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-sciences-chief-financial-officer-robin-washington-to-step-down-in-early-2020 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-sciences-chief-scientific-officer-john-mchutchison-to-leave-the-company 2024-08-20 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-sciences-launches-age-positively-initiative-to-address-unique-challenges-of-aging-population-living-with-hiv 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-sciences-licenses-respiratory-and-herpes-antiviral-research-programs-from-novartis 2024-08-20 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-sciences-statement-on-us-food-and-drug-administration-advisory-committees-recommendation-on-descovy-for-prep 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-sciences-submits-new-drug-application-for-filgotinib-for-the-treatment-of-adults-with-rheumatoid-arthritis-in-japan 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-sciences-to-present-at-the-37th-annual-jp-morgan-healthcare-conference-on-monday-january-7 2024-07-23 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-sciences-to-present-at-the-38th-annual-jp-morgan-healthcare-conference-on-monday-january-13-2020 2024-07-23 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-sciences-to-present-at-the-bank-of-america-merrill-lynch-2019-health-care-conference-on-tuesday-may-14 2024-07-23 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-sciences-to-present-at-the-barclays-global-healthcare-conference-on-tuesday-march-12 2024-07-23 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-sciences-to-present-at-the-jefferies-2019-global-healthcare-conference-on-wednesday-june-5 2024-07-23 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-sciences-to-present-at-the-morgan-stanley-global-healthcare-conference-on-tuesday-september-10 2024-07-23 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-sciences-to-provide-free-truvada-for-prep-to-support-us-initiative-to-end-the-hiv-epidemic 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-sciences-to-release-first-quarter-2019-financial-results-on-thursday-may-2-2019 2024-07-23 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-sciences-to-release-fourth-quarter-and-full-year-2018-financial-results-on-monday-february-4-2019 2024-07-23 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-sciences-to-release-second-quarter-2019-financial-results-on-tuesday-july-30-2019 2024-07-23 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-sciences-to-release-third-quarter-2019-financial-results-on-thursday-october-24-2019 2024-07-23 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-submits-filgotinib-new-drug-application-to-us-food-and-drug-administration-under-priority-review-for-rheumatoid-arthritis-treatment 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-submits-supplemental-new-drug-application-to-us-food-and-drug-administration-for-once-daily-descovy-for-hiv-pre-exposure-prophylaxis 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-to-present-new-data-from-multiple-liver-disease-research-and-development-programs-at-the-international-liver-congress-2019 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/gilead-to-present-new-data-on-hiv-prevention-treatment-and-cure-research-at-ias-2019 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/industry-veterans-appointed-to-head-the-global-technical-operations-and-clinical-development-organizations-at-kite 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/japans-ministry-of-health-labour-and-welfare-approves-gileads-biktarvy-bictegravir-emtricitabine-and-tenofovir-alafenamide-for-treatment-of-hiv-1-infection 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/japans-ministry-of-health-labour-and-welfare-approves-gileads-epclusa-sofosbuvirvelpatasvir 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/kite-and-humanigen-announce-clinical-collaboration-to-evaluate-investigational-combination-of-yescarta-axicabtagene-ciloleucel-with-lenzilumab-in-relapsedrefractory-diffuse-large-b-cell-lymphoma 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/kite-and-kiniksa-pharmaceuticals-announce-clinical-collaboration-evaluating-investigational-combination-of-yescarta-and-mavrilimumab-in-relapsed-or-refractory-large-b-cell-lymphoma 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/kite-and-the-cibmtr-present-positive-findings-from-real-world-use-of-yescarta-axicabtagene-ciloleucel-in-relapsed-or-refractory-large-b-cell-lymphoma 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/kite-announces-end-of-phase-1-zuma-3-results-for-kte-x19-in-adult-patients-with-relapsed-or-refractory-acute-lymphoblastic-leukemia 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/kite-announces-long-term-data-from-zuma-1-showing-approximately-half-of-refractory-large-b-cell-lymphoma-patients-were-alive-three-years-after-yescarta-treatment 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/kite-announces-new-yescarta-data-from-zuma-1 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/kite-announces-plans-for-new-state-of-the-art-facility-to-expand-cell-therapy-production-capabilities 2024-08-20 daily 0.5 https://www.gilead.com/news/news-details/2019/kite-announces-plans-to-bolster-industry-leading-cell-therapy-manufacturing-capabilities-with-new-viral-vector-facility 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/kite-presents-positive-results-from-pivotal-zuma-2-trial-in-relapsed-or-refractory-mantle-cell-lymphoma 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/kite-submits-biologics-license-application-to-us-food-and-drug-administration-for-companys-second-car-t-cell-therapy 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/kite-to-present-new-data-from-industry-leading-cell-therapy-portfolio-at-ash-2019 2024-08-20 daily 0.5 https://www.gilead.com/news/news-details/2019/kite-to-present-new-data-from-leading-cell-therapy-portfolio-at-asco-2019 2024-08-20 daily 0.5 https://www.gilead.com/news/news-details/2019/louisiana-launches-hepatitis-c-innovative-payment-model-with-asegua-therapeutics-aiming-to-eliminate-the-disease 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/national-aids-memorial-receives-24-million-donation-from-gilead-sciences-to-support-the-aids-memorial-quilt-as-it-moves-home-to-san-francisco 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/new-data-on-filgotinib-in-rheumatoid-arthritis-ra-demonstrate-durable-efficacy-and-safety-profile 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2019/us-food-and-drug-administration-approves-descovy-for-hiv-pre-exposure-prophylaxis-prep 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/an-open-letter-from-daniel-oday-chairman--ceo-gilead-sciences 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/anthony-welters-joins-gilead-sciences-board-of-directors 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/china-national-medical-products-administration-approves-truvada-for-hiv-pre-exposure-prophylaxis-prep 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/data-on-53-patients-treated-with-investigational-antiviral-remdesivir-through-the-compassionate-use-program-published-in-new-england-journal-of-medicine 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/european-chmp-adopts-positive-opinion-for-kites-kte-x19-for-the-treatment-of-relapsed-or-refractory-mantle-cell-lymphoma 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/european-commission-grants-conditional-marketing-authorization-for-gileads-veklury-remdesivir-for-the-treatment-of-covid-19 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/european-commission-grants-marketing-authorization-for-jyseleca--filgotinib-for-the-treatment-of-adults-with-moderate-to-severe-active-rheumatoid-arthritis 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/european-medicines-agency-validates-kites-marketing-application-for-companys-second-car-t-cell-therapy 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/european-medicines-agency-validates-marketing-application-for-filgotinib-for-the-treatment-of-ulcerative-colitis 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/filgotinib-demonstrates-durable-efficacy-and-consistent-safety-profile-at-52-weeks-in-finch-1-and-3-studies-in-rheumatoid-arthritis 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/final-results-of-national-institute-of-allergy-and-infectious-diseases-actt-1-trial-published-in-new-england-journal-of-medicine-expand-clinical-benefits-of-veklury-remdesivir-for-the-treatm 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/gilead-advances-oncology-portfolio-with-new-data-from-phase-3-ascent-trial-of-trodelvy-in-metastatic-triple-negative-breast-cancer 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/gilead-and-galapagos-announce-new-commercialization-and-development-agreement-for-jyseleca-filgotinib 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/gilead-and-galapagos-announce-positive-european-chmp-opinion-for-jyseleca-filgotinib-for-the-treatment-of-adults-with-moderate-to-severe-rheumatoid-arthritis 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/gilead-and-galapagos-announce-positive-topline-results-of-phase-2b3-trial-of-filgotinib-in-moderately-to-severely-active-ulcerative-colitis 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/gilead-and-kite-continue-to-advance-next-generation-cancer-therapies-at-2020-american-society-of-clinical-oncology-annual-meeting 2024-08-20 daily 0.5 https://www.gilead.com/news/news-details/2020/gilead-and-kite-to-share-latest-scientific-advances-in-hematologic-malignancies-at-ash-2020 2024-08-20 daily 0.5 https://www.gilead.com/news/news-details/2020/gilead-and-novo-nordisk-present-new-data-from-proof-of-concept-trial-in-nash 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/gilead-announces-20-million-philanthropic-fund-to-support-nonprofit-organizations-impacted-by-the-covid-19-crisis 2024-08-20 daily 0.5 https://www.gilead.com/news/news-details/2020/gilead-announces-approval-of-veklury-remdesivir-in-japan-for-patients-with-severe-covid-19 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/gilead-announces-expiration-of-hart-scott-rodino-waiting-period-for-forty-seven-tender-offer 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2020/gilead-announces-investigational-long-acting-hiv-1-capsid-inhibitor-lenacapavir-achieves-primary-endpoint-in-phase-23-study-in-heavily-treatment-experienced-people-living-with-hiv 2024-07-23 daily 0.5 https://www.gilead.com/news/news-details/2020/gilead-announces-new-data-on-biktarvy-for-the-treatment-of-hiv-in-black-americans 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/gilead-announces-presentation-of-more-than-40-abstracts-from-extensive-liver-disease-programs-at-the-digital-international-liver-congress-2020 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/gilead-announces-racial-equity-community-impact-fund-to-support-black-communities-across-united-states 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/gilead-announces-results-from-phase-3-trial-of-investigational-antiviral-remdesivir-in-patients-with-severe-covid-19 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/gilead-announces-results-from-phase-3-trial-of-remdesivir-in-patients-with-moderate-covid-19 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/gilead-appoints-michael-quigley-to-lead-research-biology-group-and-names-linda-higgins-as-head-of-companys-external-innovation-center 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2020/gilead-completes-acquisition-of-forty-seven-inc 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/gilead-kite-and-onko-innate-announce-research-collaboration-to-discover-cancer-immunotherapies-focused-on-natural-killer-nk-cells 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2020/gilead-presents-96-week-discover-trial-data-demonstrating-favorable-renal-and-bone-safety-profile-of-descovy-for-hiv-prep-in-at-risk-populations 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/gilead-presents-additional-data-on-investigational-antiviral-remdesivir-for-the-treatment-of-covid-19 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/gilead-presents-biktarvy-findings-from-switch-studies--analysis-of-real-world-bicstar-study-at-hiv-glasgow-2020 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/gilead-presents-new-data-from-antiviral-development-programs-at-idweek-2020 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/gilead-provides-additional-information-regarding-2020-annual-meeting-of-stockholders-due-to-covid-19-precautions 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2020/gilead-receives-complete-response-letter-for-filgotinib-for-the-treatment-of-moderately-to-severely-active-rheumatoid-arthritis 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/gilead-sciences-and-arcus-biosciences-complete-closing-of-their-10-year-partnership-to-co-develop-and-co-commercialize-next-generation-cancer-immunotherapies 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2020/gilead-sciences-and-arcus-biosciences-establish-10-year-partnership-to-co-develop-and-co-commercialize-next-generation-cancer-immunotherapies 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/gilead-sciences-and-jounce-therapeutics-announce-exclusive-license-agreement-for-novel-immunotherapy-program 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/gilead-sciences-and-satcher-health-leadership-institute-at-morehouse-school-of-medicine-partner-to-study-racial-health-inequities-associated-with-covid-19 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/gilead-sciences-and-second-genome-announce-strategic-collaboration-in-biomarker-and-inflammatory-bowel-disease-drug-discovery 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/gilead-sciences-and-tango-therapeutics-to-expand-strategic-oncology-collaboration 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/gilead-sciences-announces-8-percent-increase-in-first-quarter-2020-dividend 2024-07-23 daily 0.5 https://www.gilead.com/news/news-details/2020/gilead-sciences-announces-expiration-of-hart-scott-rodino-waiting-period-for-immunomedics-tender-offer 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2020/gilead-sciences-announces-first-quarter-2020-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/gilead-sciences-announces-fourth-quarter-2020-dividend 2024-07-23 daily 0.5 https://www.gilead.com/news/news-details/2020/gilead-sciences-announces-fourth-quarter-and-full-year-2019-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/gilead-sciences-announces-second-quarter-2020-dividend 2024-07-23 daily 0.5 https://www.gilead.com/news/news-details/2020/gilead-sciences-announces-second-quarter-and-first-half-2020-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/gilead-sciences-announces-third-quarter-2020-dividend 2024-07-23 daily 0.5 https://www.gilead.com/news/news-details/2020/gilead-sciences-announces-third-quarter-2020-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/gilead-sciences-completes-acquisition-of-immunomedics-inc 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/gilead-sciences-demonstrates-commitment-to-scientific-innovation-in-hiv-with-new-prevention-treatment-and-cure-research-data-presented-at-aids-2020-virtual 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/gilead-sciences-initiates-two-phase-3-studies-of-investigational-antiviral-remdesivir-for-the-treatment-of-covid-19 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/gilead-sciences-licenses-portfolio-of-hiv-antibodies-from-the-rockefeller-university 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/gilead-sciences-presents-data-from-hiv-research-and-development-programs-at-hiv-glasgow-2020 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/gilead-sciences-presents-data-supporting-a-potential-six-month-dosing-interval-for-investigational-hiv-1-capsid-inhibitor-lenacapavir-gs-6207 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/gilead-sciences-presents-survey-findings-on-prep-access-and-utilization-in-the-us-during-covid-19-shelter-in-place-orders 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/gilead-sciences-prices-725-billion-of-senior-unsecured-notes 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2020/gilead-sciences-secures-exclusive-option-to-acquire-pionyr-immunotherapeutics 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2020/gilead-sciences-secures-exclusive-option-to-acquire-tizona-therapeutics-for-300-million 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/gilead-sciences-signs-joint-procurement-agreement-with-the-european-commission-for-veklury-remdesivir 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/gilead-sciences-statement-on-positive-data-emerging-from-national-institute-of-allergy-and-infectious-diseases-study-of-investigational-antiviral-remdesivir-for-covid-19 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/gilead-sciences-to-acquire-immunomedics 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/gilead-sciences-to-acquire-myr-gmbh 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/gilead-sciences-to-present-at-the-39th-annual-jp-morgan-healthcare-conference-on-monday-january-11-2021 2024-07-23 daily 0.5 https://www.gilead.com/news/news-details/2020/gilead-sciences-to-present-at-the-3rd-annual-evercore-isi-healthconx-conference-on-wednesday-december-2-2020 2024-07-23 daily 0.5 https://www.gilead.com/news/news-details/2020/gilead-sciences-to-present-at-the-cowen-and-company-40th-annual-health-care-conference-on-monday-march-2-2020 2024-07-23 daily 0.5 https://www.gilead.com/news/news-details/2020/gilead-sciences-to-release-first-quarter-2020-financial-results-on-thursday-april-30-2020 2024-07-23 daily 0.5 https://www.gilead.com/news/news-details/2020/gilead-sciences-to-release-fourth-quarter-and-full-year-2019-financial-results-on-tuesday-february-4-2020 2024-07-23 daily 0.5 https://www.gilead.com/news/news-details/2020/gilead-sciences-to-release-second-quarter-2020-financial-results-on-thursday-july-30-2020 2024-07-23 daily 0.5 https://www.gilead.com/news/news-details/2020/gilead-sciences-to-release-third-quarter-2020-financial-results-on-wednesday-october-28-2020 2024-07-23 daily 0.5 https://www.gilead.com/news/news-details/2020/gilead-sciences-update-on-supply-and-distribution-of-veklury-remdesivir-in-the-united-states 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/gileads-investigational-antiviral-remdesivir-receives-us-food-and-drug-administration-emergency-use-authorization-for-the-treatment-of-covid-19 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/gileads-investigational-antiviral-veklury-remdesivir-receives-us-food-and-drug-administration-emergency-use-authorization-for-the-treatment-of-patients-with-moderate-covid-19 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/gileads-magrolimab-an-investigational-anti-cd47-monoclonal-antibody-receives-fda-breakthrough-therapy-designation-for-treatment-of-myelodysplastic-syndrome 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2020/gilead-submits-new-drug-application-to-us-food-and-drug-administration-for-veklury-remdesivir-for-the-treatment-of-covid-19 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/gilead-to-acquire-forty-seven-for-49-billion 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/investigational-magrolimab-in-combination-with-azacitidine-demonstrates-durable-activity-in-previously-untreated-myelodysplastic-syndrome-and-acute-myeloid-leukemia 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2020/javier-rodriguez-joins-gilead-sciences-board-of-directors 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/jeffrey-a-bluestone-joins-gilead-sciences-board-of-directors 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/jyseleca-filgotinib-approved-in-japan-for-rheumatoid-arthritis 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/kite-and-hifibio-therapeutics-partner-to-discover-novel-targets-and-antibodies-against-acute-myeloid-leukemia 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/kite-licenses-antibodies-and-establishes-collaboration-with-teneobio-in-multiple-myeloma 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/kite-receives-european-medicines-agency-approval-for-car-t-cell-therapy-manufacturing-facility-in-europe 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/kites-tecartus-kte-x19-granted-conditional-marketing-authorization-for-the-treatment-of-relapsed-or-refractory-mantle-cell-lymphoma-in-europe 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2020/kite-submits-supplemental-biologics-license-application-to-us-food-and-drug-administration-for-yescarta-in-relapsed-or-refractory-indolent-non-hodgkin-lymphomas 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/magrolimab-demonstrates-clinical-responses-in-ongoing-phase-1b-trial-of-previously-untreated-acute-myeloid-leukemia-patients 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/mark-genovese-joins-gilead-to-lead-clinical-development-of-companys-inflammation-programs 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/new-analyses-of-phase-2-equator-clinical-program-support-durable-efficacy-of-filgotinib-in-psoriatic-arthritis 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/new-clinical-study-data-for-gileads-investigational-hiv-1-capsid-inhibitor-gs-6207-presented-at-croi-2020 2024-07-23 daily 0.5 https://www.gilead.com/news/news-details/2020/new-data-for-tecartustm-demonstrate-durable-responses-at-one-year-follow-up-in-relapsed-or-refractory-mantle-cell-lymphoma 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/new-data-on-gileads-biktarvy-presented-at-croi-2020-including-data-in-black-americans-and-older-adults 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/new-findings-on-gileads-biktarvy-presented-at-aids-2020-virtual-include-positive-switch-data-in-older-adults 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/new-four-year-data-show-long-term-survival-in-patients-with-large-b-cell-lymphoma-treated-with-yescarta-in-zuma-1-trial 2024-08-20 daily 0.5 https://www.gilead.com/news/news-details/2020/phase-2b3-trial-shows-efficacy-of-filgotinib-for-the-induction-and-maintenance-of-remission-in-moderately-and-severely-active-ulcerative-colitis 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/sandra-horning-md-joins-gilead-sciences-board-of-directors 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/treatment-with-gileads-vesatolimod-is-evaluated-for-safety-and-virologic-and-immunologic-response-versus-placebo-in-phase-1b-hiv-functional-cure-study 2024-07-23 daily 0.5 https://www.gilead.com/news/news-details/2020/us-fda-approves-kites-tecartus-the-first-and-only-car-t-treatment-for-relapsed-or-refractory-mantle-cell-lymphoma 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/us-fda-grants-priority-review-for-kites-kte-x19-biologics-license-application-bla-in-relapsed-or-refractory-mantle-cell-lymphoma 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/us-food-and-drug-administration-approves-epclusa-sofosbuvir-velpatasvir-for-children-ages-6-and-older-or-weighing-at-least-17-kg-with-chronic-hepatitis-c-infection 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/us-food-and-drug-administration-approves-gileads-antiviral-veklury-remdesivir-for-treatment-of-covid-19 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/yescarta-axicabtagene-ciloleucel-demonstrates-high-rates-of-response-in-relapsed-or-refractory-indolent-non-hodgkin-lymphoma 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2020/yescarta-is-first-car-t-cell-therapy-to-demonstrate-high-response-rates-and-durable-clinical-benefit-in-a-pivotal-indolent-non-hodgkin-lymphoma-study 2024-08-20 daily 0.5 https://www.gilead.com/news/news-details/2020/yescarta-shows-positive-results-as-a-first-line-treatment-for-patients-with-high-risk-large-b-cell-lymphoma 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/biktarvy-demonstrates-high-efficacy-and-durable-viral-suppression-in-treatment-nave-adults-in-four-year-data-presented-at-croi 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/biontech-completes-acquisition-of-kites-neoantigen-tcr-cell-therapy-rd-platform-and-manufacturing-facility-in-gaithersburg-maryland 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/biontech-to-acquire-kites-neoantigen-tcr-cell-therapy-rd-platform-and-manufacturing-facility-in-gaithersburg-md 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/clinical-and-patient-reported-outcomes-in-people-living-with-hiv-on-biktarvy-in-observational-bicstar-study-demonstrate-consistent-efficacy-profile-in-real-world-setting 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/daiichi-sankyo-authorizes-the-first-yescarta-axicabtagene-ciloleucel-car-t-cell-therapy-treatment-site-in-japan 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/european-commission-expands-indication-for-veklury-remdesivir-for-the-treatment-of-adults-not-on-supplemental-oxygen-and-considered-high-risk-for-covid-19-disease-progression 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/european-medicines-agency-validates-gileads-marketing-authorization-application-for-lenacapavir-an-investigational-long-acting-capsid-inhibitor-for-the-treatment-of-hiv-1-in-people-with-limi 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/european-medicines-agency-validates-marketing-authorization-application-for-sacituzumab-govitecan-hziy-for-the-treatment-of-metastatic-triple-negative-breast-cancer 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/everest-medicines-and-gilead-sciences-jointly-announce-phase-2b-study-of-sacituzumab-govitecan-conducted-in-china-of-patients-with-metastatic-triple-negative-breast-cancer-meets-primary-over 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/fda-approves-trodelvy-the-first-treatment-for-metastatic-triple-negative-breast-cancer-shown-to-improve-progression-free-survival-and-overall-survival 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/four-year-biktarvy-data-presented-at-ias-2021-demonstrate-high-efficacy-and-durable-viral-suppression-in-treatment-nave-adults 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/francesco-m-marincola-joins-kite-as-worldwide-head-of-cell-therapy-research 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/galapagos-and-gilead-discontinue-isabela-phase-3-trials-in-ipf 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/gilead-and-arcus-biosciences-complete-closing-of-option-exercise-for-three-clinical-stage-programs-and-new-research-collaboration 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/gilead-and-kite-oncology-demonstrate-broad-leadership-in-cell-therapy-and-expanding-blood-cancer-pipeline 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/gilead-and-merck-announce-agreement-to-jointly-develop-and-commercialize-long-acting-investigational-treatment-combinations-of-lenacapavir-and-islatravir-in-hiv 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/gilead-and-merck-initiate-phase-2-study-evaluating-an-oral-weekly-combination-regimen-of-investigational-lenacapavir-and-investigational-islatravir-for-hiv-1-treatment-in-virologically-suppr 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/gilead-and-novo-nordisk-expand-nash-clinical-collaboration 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/gilead-and-the-human-rights-campaign-will-work-together-to-combat-hiv-epidemic-and-promote-transgender-justice 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/gilead-and-vir-biotechnology-establish-clinical-collaboration-to-explore-combination-strategies-for-functional-cure-for-chronic-hepatitis-b-virus 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/gilead-announces-clinical-hold-on-studies-evaluating-injectable-lenacapavir-for-hiv-treatment-and-prevention-due-to-vial-quality-concerns 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/gilead-announces-clinical-trial-collaboration-with-merck-to-evaluate-trodelvy-sacituzumab-govitecan-hziy-in-combination-with-keytruda-pembrolizumab-in-patients-with-first-line-metastatic-tri 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/gilead-announces-new-england-journal-of-medicine-publication-of-data-demonstrating-veklury-remdesivir-significantly-reduced-risk-of-hospitalization-in-high-risk-patients-with-covid-19 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/gilead-exercises-options-to-three-arcus-biosciences-clinical-stage-programs-and-adds-research-collaboration 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/gilead-kite-oncology-to-present-transformative-science-from-growing-portfolio-at-asco-2021 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/gilead-marks-fifth-approval-for-trodelvy-in-metastatic-triple-negative-breast-cancer-under-project-orbis-initiative-with-health-canada-authorization 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/gilead-presents-long-term-switch-data-reinforcing-biktarvy-as-a-treatment-option-for-a-broad-range-of-people-living-with-hiv 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/gileads-bold-ambition-of-transforming-triple-negative-breast-cancer-treatment-to-be-highlighted-with-new-data-at-sabcs 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/gilead-sciences-and-gritstone-announce-collaboration-utilizing-gritstones-vaccine-platform-technology-for-hiv-cure 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/gilead-sciences-and-wake-forest-university-school-of-divinity-partner-to-address-hiv-epidemic-through-faith-based-programming-and-community-outreach 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/gilead-sciences-announces-44-percent-increase-in-first-quarter-2021-dividend 2024-07-23 daily 0.5 https://www.gilead.com/news/news-details/2021/gilead-sciences-announces-first-quarter-2021-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/gilead-sciences-announces-fourth-quarter-and-full-year-2020-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/gilead-sciences-announces-second-quarter-2021-dividend 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/gilead-sciences-announces-second-quarter-2021-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/gilead-sciences-announces-steps-to-expand-availability-of-remdesivir-in-india 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/gilead-sciences-announces-third-quarter-2021-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/gilead-sciences-announces-updated-2020-guidance 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/gilead-sciences-announces-veklury-donations-to-help-address-the-ongoing-covid-19-crisis-in-indonesia-and-armenia 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/gilead-sciences-appoints-flavius-martin-md-as-executive-vice-president-research 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/gilead-sciences-comments-on-the-passing-of-john-c-martin-phd 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/gilead-sciences-completes-acquisition-of-myr-gmbh 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/gilead-sciences-endows-its-foundation-with-more-than-200-million-to-support-health-justice-community-giving-and-employee-match-program 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/gilead-sciences-to-present-at-upcoming-investor-conference 2025-11-17 daily 0.5 https://www.gilead.com/news/news-details/2021/gilead-sciences-to-present-at-upcoming-investor-conference-5bf52c37a 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/gilead-sciences-to-present-at-upcoming-investor-conference-fd4f200e2 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/gilead-sciences-to-present-at-upcoming-investor-conferences 2025-11-17 daily 0.5 https://www.gilead.com/news/news-details/2021/gilead-sciences-to-present-at-upcoming-investor-conferences-4bdf93446 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/gilead-sciences-to-present-at-upcoming-investor-conferences-662f97dad 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/gilead-sciences-to-release-first-quarter-2021-financial-results-on-thursday-april-29-2021 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/gilead-sciences-to-release-fourth-quarter-and-full-year-2020-financial-results-on-thursday-february-4-2021 2024-07-23 daily 0.5 https://www.gilead.com/news/news-details/2021/gilead-sciences-to-release-second-quarter-2021-financial-results-on-thursday-july-29-2021 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/gilead-sciences-to-release-third-quarter-2021-financial-results-on-thursday-october-28-2021 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/gileads-investigational-lenacapavir-demonstrates-sustained-long-acting-efficacy-through-week-26-in-data-presented-at-croi 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/gilead-submits-biologics-license-application-to-us-food-and-drug-administration-for-bulevirtide-an-investigational-treatment-for-people-living-with-chronic-hepatitis-delta 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/gilead-submits-new-drug-application-to-us-food-and-drug-administration-for-lenacapavir-an-investigational-long-acting-capsid-inhibitor-for-the-treatment-of-hiv-1-in-people-with-limited-thera 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/gileads-veklury-remdesivir-associated-with-a-reduction-in-mortality-rate-in-hospitalized-patients-with-covid-19-across-three-analyses-of-large-retrospective-real-world-data-sets 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/gilead-to-present-data-from-liver-disease-development-programs-at-the-liver-meeting 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/gilead-to-present-latest-antiviral-research-data-addressing-urgent-global-needs-in-infectious-disease-at-idweek-2021 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/gilead-to-present-more-than-70-abstracts-from-diverse-liver-disease-programs-at-the-international-liver-congress-2021 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/gilead-to-present-new-data-at-croi-2021-demonstrating-the-companys-commitment-to-addressing-urgent-global-health-needs 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/gilead-to-present-new-data-at-esmo-congress-2021-reinforcing-the-practice-changing-potential-of-trodelvy 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/gilead-to-present-new-data-at-ias-2021-demonstrating-the-companys-commitment-to-advancing-innovation-in-hiv-research 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/kite-and-appia-bio-announce-collaboration-to-research-and-develop-allogeneic-cell-therapies-for-cancer 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/kite-and-oxford-biotherapeutics-establish-cell-therapy-research-collaboration-in-blood-cancers-and-solid-tumors 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2021/kite-and-shoreline-biosciences-enter-into-strategic-partnership-to-develop-novel-allogeneic-cell-therapies 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/kite-announces-new-zuma-1-cohort-analysis-evaluating-prophylactic-corticosteroid-use-with-yescarta-in-patients-with-relapsed-or-refractory-large-b-cell-lymphoma 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/kite-announces-yescarta-car-t-cell-therapy-improved-event-free-survival-by-60-over-chemotherapy-plus-stem-cell-transplant-in-second-line-relapsed-or-refractory-large-b-cell-lymphoma 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/kite-appoints-frank-neumann-as-worldwide-head-of-clinical-development 2024-08-16 daily 0.5 https://www.gilead.com/news/news-details/2021/kite-joint-venture---fosun-kite---gains-the-first-car-t-cell-therapy-approval-in-china 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/kites-tecartus-demonstrates-high-response-rate-in-adults-with-relapsed-or-refractory-b-cell-acute-lymphoblastic-leukemia-earning-priority-review-designation 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/kite-submits-supplemental-biologics-license-application-to-us-food-and-drug-administration-for-earlier-use-of-yescarta-in-large-b-cell-lymphoma 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/kite-submits-supplemental-biologics-license-application-to-us-food-and-drug-administration-for-tecartus-in-adult-patients-with-relapsed-or-refractory-acute-lymphoblastic-leukemia 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/longer-term-data-for-kites-yescarta-in-relapsed-or-refractory-follicular-lymphoma-demonstrate-substantial-survival-improvement-over-current-therapies-in-comparative-analysis 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/new-data-demonstrate-trodelvy-survival-benefit-in-metastatic-triple-negative-breast-cancer-patients-regardless-of-initial-hrher2-status 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/new-phase-3-data-support-the-sustained-long-acting-efficacy-of-lenacapavir-gileads-investigational-hiv-1-capsid-inhibitor 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/sacituzumab-govitecan-receives-positive-chmp-opinion-as-2l-treatment-for-adult-patients-with-metastatic-triple-negative-breast-cancer 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/treatment-with-hepcludex-bulevirtide-was-shown-to-achieve-significant-response-in-chronic-hepatitis-delta-virus-after-24-weeks 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/trodelvy-demonstrates-clinical-benefit-for-black-patients-consistent-with-full-metastatic-triple-negative-breast-cancer-population-in-ascent-study 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/trodelvy-demonstrates-superior-outcomes-to-standard-of-care-in-second-line-treatment-of-metastatic-triple-negative-breast-cancer-in-phase-3-ascent-study 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/trodelvy-sacituzumab-govitecan-granted-european-commission-marketing-authorization-for-treatment-of-metastatic-triple-negative-breast-cancer-in-second-line 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/trodelvy-significantly-improved-quality-of-life-over-standard-of-care-in-2l-metastatic-triple-negative-breast-cancer-in-phase-3-ascent-study 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/us-fda-approves-kites-tecartus-as-the-first-and-only-car-t-for-adults-with-relapsed-or-refractory-b-cell-acute-lymphoblastic-leukemia 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/us-fda-approves-yescarta-for-relapsed-or-refractory-follicular-lymphoma-after-two-or-more-lines-of-systemic-therapy 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/us-fda-grants-accelerated-approval-to-trodelvy-for-the-treatment-of-metastatic-urothelial-cancer 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/us-food-and-drug-administration-approves-expanded-indication-of-gileads-biktarvy-for-treatment-of-hiv-1-in-pediatric-populations 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/us-food-and-drug-administration-approves-new-formulation-of-epclusa-expanding-pediatric-indication-to-treat-children-ages-3-and-older-with-chronic-hepatitis-c 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/veklury-remdesivir-significantly-reduced-risk-of-hospitalization-in-high-risk-patients-with-covid-19 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/yescarta-car-t-cell-therapy-quadruples-median-event-free-survival-duration-over-standard-of-care-in-second-line-relapsed-or-refractory-large-b-cell-lymphoma 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/yescarta-demonstrates-durable-two-year-clinical-benefit-in-adults-with-relapsed-or-refractory-indolent-non-hodgkin-lymphoma-including-follicular-lymphoma 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/yescarta-is-first-car-t-cell-therapy-to-report-five-year-survival-data-from-pivotal-study-showing-durable-long-term-survival-in-patients-with-refractory-large-b-cell-lymphoma 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2021/yescarta-zuma-12-study-demonstrates-78-complete-response-rate-as-part-of-first-line-treatment-in-newly-diagnosed-high-risk-large-b-cell-lymphoma 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/anti-tigit-domvanalimab-containing-study-arms-improve-progression-free-survival-compared-to-anti-pd1-alone-in-phase-2-non-small-cell-lung-cancer-study 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/biktarvy-demonstrates-high-efficacy-and-durable-viral-suppression-at-five-years-in-treatment-nave-adults 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/biktarvy-demonstrates-high-efficacy-for-a-broad-range-of-people-initiating-treatment-for-hiv-including-those-with-hbv-coinfection 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/body-of-evidence-grows-from-zuma-7-study-supporting-initial-treatment-with-kites-yescarta-car-t-cell-therapy-for-patients-with-relapsed-or-refractory-large-b-cell-lymphoma 2024-08-28 daily 0.5 https://www.gilead.com/news/news-details/2022/chmp-adopts-positive-opinion-recommending-veklury-remdesivir-receive-full-marketing-authorization-for-the-treatment-of-patients-with-covid-19 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/chmp-adopts-positive-opinion-to-extend-indication-of-veklury-remdesivir-for-the-treatment-of-pediatric-patients-with-covid-19 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/european-commission-grants-expanded-marketing-authorization-for-gileads-biktarvy-for-the-treatment-of-hiv-in-pediatric-populations 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/fda-approves-veklury-remdesivir-for-the-treatment-of-non-hospitalized-patients-at-high-risk-for-covid-19-disease-progression 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/fda-lifts-clinical-hold-on-investigational-lenacapavir-for-the-treatment-and-prevention-of-hiv 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/fda-lifts-partial-clinical-hold-on-mds-and-aml-magrolimab-studies 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/final-data-from-phase-3-ascent-study-demonstrates-trodelvy-extends-overall-survival-over-chemotherapy-in-second-line-metastatic-tnbc 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/gilead-and-arcus-biosciences-announce-positive-update-on-joint-tigit-program-from-interim-analysis-of-arc-7-study-in-non-small-cell-lung-cancer 2024-08-30 daily 0.5 https://www.gilead.com/news/news-details/2022/gilead-and-dragonfly-announce-strategic-research-collaboration-to-develop-natural-killer-cell-engagers-in-oncology-and-inflammation 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/gilead-and-kite-oncology-demonstrate-transformative-impact-of-cell-therapy-and-promise-of-blood-cancer-portfolio-at-ash-2022 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/gilead-and-kite-oncology-to-highlight-advances-supporting-new-innovations-in-cancer-care-at-the-asco-annual-meeting 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/gilead-and-macrogenics-announce-oncology-collaboration-to-develop-bispecific-antibodies 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/gilead-announces-clinical-trial-collaborations-with-merck-to-evaluate-trodelvy-in-combination-with-keytruda-in-first-line-metastatic-non-small-cell-lung-cancer 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/gilead-announces-first-global-regulatory-approval-of-sunlenca-lenacapavir-the-only-twice-yearly-hiv-treatment-option 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/gilead-announces-partial-clinical-hold-for-studies-evaluating-magrolimab-in-combination-with-azacitidine 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/gilead-demonstrates-strength-of-oncology-portfolio-across-diverse-tumor-types-at-esmo-congress-2022 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/gilead-endorses-the-kigali-declaration-on-preventing-controlling-and-eliminating-neglected-tropical-diseases 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/gilead-foundation-awards-20-million-to-organizations-working-to-advance-health-through-education-equity 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/gilead-joins-first-of-its-kind-public-private-initiative-to-improve-management-of-viral-hepatitis-in-vietnam-and-the-philippines 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/gilead-presents-real-world-and-long-term-data-from-hiv-research-programs-at-hiv-glasgow-2022 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/gilead-presents-real-world-evidence-reinforcing-the-use-of-biktarvy-for-the-treatment-of-people-living-with-hiv-with-a-range-of-comorbidities 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/gilead-reaches-number-one-spot-as-top-overall-philanthropic-funder-of-hiv-related-programs-according-to-funders-concerned-about-aids-report 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/gilead-receives-complete-response-letter-from-us-fda-for-investigational-lenacapavir-due-to-vial-compatability-issues 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/gilead-resubmits-new-drug-application-to-us-food-and-drug-administration-for-lenacapavir-an-investigational-long-acting-hiv-1-capsid-inhibitor 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/gilead-sciences-again-named-to-dow-jones-sustainability-world-index 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/gilead-sciences-and-a-coalition-of-lgbtq-and-human-rights-focused-organizations-mobilize-to-address-monkeypox-public-health-emergency 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/gilead-sciences-announces-24-million-in-grants-to-help-end-the-hiv-epidemic-for-everyone-everywhere 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/gilead-sciences-announces-28-percent-increase-in-first-quarter-2022-dividend 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/gilead-sciences-announces-collaboration-with-morehouse-school-of-medicine-and-xavier-university-of-louisiana-college-of-pharmacy-to-address-inequities-in-hiv-care 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/gilead-sciences-announces-first-quarter-2022-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/gilead-sciences-announces-fourth-quarter-and-full-year-2021-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/gilead-sciences-announces-second-quarter-2022-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/gilead-sciences-announces-third-quarter-2022-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/gilead-sciences-appoints-deborah-telman-as-executive-vice-president-corporate-affairs-and-general-counsel 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/gilead-sciences-appoints-stacey-ma-phd-as-executive-vice-president-pharmaceutical-development-and-manufacturing 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/gilead-sciences-completes-acquisition-of-mirobio 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/gilead-sciences-contributes-additional-85-million-to-its-foundation-to-advance-health-equity 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/gilead-sciences-signs-new-joint-procurement-agreement-with-the-european-commission-for-veklury-remdesivir 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/gilead-sciences-to-acquire-mirobio 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/gilead-sciences-to-present-at-upcoming-investor-conference 2025-11-17 daily 0.5 https://www.gilead.com/news/news-details/2022/gilead-sciences-to-present-at-upcoming-investor-conferences 2026-02-23 daily 0.5 https://www.gilead.com/news/news-details/2022/gilead-sciences-to-present-at-upcoming-investor-conferences-29de28d18 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/gilead-sciences-to-present-at-upcoming-investor-conferences-7274175be 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/gilead-sciences-to-present-at-upcoming-investor-conferences-bd9bd0ae9 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/gilead-sciences-to-release-first-quarter-2022-financial-results-on-thursday-april-28-2022 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/gilead-sciences-to-release-fourth-quarter--full-year-2021-financial-results-on-tuesday-february-1-2022 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/gilead-sciences-to-release-second-quarter-2022-financial-results-on-tuesday-august-2-2022 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/gilead-sciences-to-release-third-quarter-2022-financial-results-on-thursday-october-27-2022 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/gilead-to-acquire-all-remaining-rights-to-potential-first-in-class-immunotherapy-gs-1811-from-jounce-therapeutics 2024-11-29 daily 0.5 https://www.gilead.com/news/news-details/2022/gilead-to-acquire-remaining-worldwide-rights-of-trodelvy 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/gilead-to-present-data-across-viral-hepatitis-and-liver-fibrosis-at-the-liver-meeting-2022-reinforcing-gilead-as-a-leader-in-addressing-treatment-needs-for-people-living-with-liver-disease 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/gilead-to-present-latest-antiviral-research-and-development-data-at-croi-2022-addressing-urgent-global-needs 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/gilead-to-present-latest-data-from-across-liver-disease-development-programs-at-the-international-liver-congress-2022 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/investigational-lenacapavir-receives-positive-chmp-opinion-for-people-with-multi-drug-resistant-hiv 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/kite-and-arcellx-announce-strategic-collaboration-to-co-develop-and-co-commercialize-late-stage-clinical-cart-ddbcma-in-multiple-myeloma 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/kite-and-daiichi-sankyo-announce-changes-to-yescarta-car-t-cell-therapy-licensing-agreement-in-japan 2024-08-28 daily 0.5 https://www.gilead.com/news/news-details/2022/kite-and-refuge-biotechnologies-announce-exclusive-license-agreement-for-investigational-gene-expression-platform-for-blood-cancers 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/kite-receives-us-fda-approval-of-new-state-of-the-art-car-t-cell-therapy-manufacturing-facility-in-maryland 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/kite-receives-us-fda-approval-of-viral-vector-manufacturing-facility-in-southern-california-to-produce-commercial-product 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/kites-car-t-cell-therapy-tecartus-granted-european-marketing-authorization-for-the-treatment-of-relapsed-or-refractory-acute-lymphoblastic-leukemia-rr-all 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/kites-car-t-cell-therapy-tecartus-receives-positive-chmp-opinion-in-relapsed-or-refractory-acute-lymphoblastic-leukemia-rr-all 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/kites-car-t-cell-therapy-yescarta-first-in-europe-to-receive-positive-chmp-opinion-for-use-in-second-line-diffuse-large-b-cell-lymphoma-and-high-grade-b-cell-lymphoma 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/kites-car-t-cell-therapy-yescarta-granted-european-marketing-authorization-for-the-treatment-of-relapsed-or-refractory-follicular-lymphoma 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/kites-yescarta-first-car-t-cell-therapy-to-receive-european-marketing-authorization-for-use-in-second-line-diffuse-large-b-cell-lymphoma-and-high-grade-b-cell-lymphoma 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/kite-to-acquire-tmunity-therapeutics-to-pursue-next-generation-car-t-cell-therapy-advancements-in-cancer 2024-08-28 daily 0.5 https://www.gilead.com/news/news-details/2022/new-analyses-of-kites-tecartus-car-t-cell-therapy-provide-additional-evidence-supporting-overall-survival-and-durability-of-response 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/new-clinical-data-support-the-sustained-efficacy-of-long-acting-lenacapavir-gileads-investigational-hiv-1-capsid-inhibitor 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/new-data-for-trodelvy-demonstrate-clinical-efficacy-across-trop-2-expression-levels-in-hrher2--metastatic-breast-cancer 2024-08-29 daily 0.5 https://www.gilead.com/news/news-details/2022/new-tropics-02-data-in-hrher2--metastatic-breast-cancer-patients-demonstrates-progression-free-survival-benefit-of-trodelvy-regardless-of-their-her2-status 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/phase-23-interim-data-evaluating-the-safety-tolerability-and-clinical-outcomes-of-veklury-remdesivir-in-pediatric-patients-with-covid-19-presented-at-croi-2022 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/phase-3-tropics-02-study-met-the-primary-endpoint-of-progression-free-survival-in-late-line-hrher2--metastatic-breast-cancer 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/scientific-innovation-and-collaboration-highlighted-at-aids-2022-as-gilead-extends-leadership-efforts-toward-ending-the-global-hiv-epidemic 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/several-new-studies-presented-at-eccmic-2022-confirm-veklury-remdesivir-activity-in-treating-covid-19 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/sub-analyses-of-landmark-zuma-7-trial-reinforce-yescarta-car-t-cell-therapy-superiority-over-standard-of-care-soc-as-initial-treatment-for-patients-with-relapsed-or-refractory-large-b-cell-l 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/sunlenca-lenacapavir-receives-fda-approval-as-a-first-in-class-twice-yearly-treatment-option-for-people-living-with-multi-drug-resistant-hiv 2024-08-28 daily 0.5 https://www.gilead.com/news/news-details/2022/tecartus-car-t-cell-therapy-demonstrates-strong-overall-survival-rates-and-continued-durable-responses-in-long-term-follow-up-of-two-pivotal-studies-including-longest-ever-follow-up-of-a-car 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/three-year-follow-up-analysis-of-kites-yescarta-car-t-cell-therapy-zuma-5-trial---52-of-patients-with-indolent-lymphomas-continued-to-have-ongoing-responses-at-a-median-follow-up-of-405-months 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/time-to-car-t-cell-therapy-may-impact-outcomes-for-patients-with-relapsedrefractory-large-b-cell-lymphoma-in-new-cibmtr-analysis 2024-08-28 daily 0.5 https://www.gilead.com/news/news-details/2022/treatment-with-hepcludex-bulevirtide-meets-primary-endpoint-and-achieves-significant-response-in-chronic-hepatitis-delta-virus-at-48-weeks 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/trodelvy-improved-progression-free-survival-by-34-in-heavily-pre-treated-hrher2--metastatic-breast-cancer-patients 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/trodelvy-significantly-improved-overall-survival-in-pre-treated-hrher2--metastatic-breast-cancer-patients-in-tropics-02-study 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/trodelvy-significantly-improves-overall-survival-in-pre-treated-hrher2--metastatic-breast-cancer-patients-in-the-tropics-02-study 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/us-fda-accepts-for-priority-review-the-supplemental-biologics-license-application-for-gileads-trodelvy-for-pre-treated-hrher2--metastatic-breast-cancer 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/us-fda-approves-new-label-update-for-car-t-cell-therapy-yescarta-showing-prophylactic-steroid-use-improves-management-of-cytokine-release-syndrome 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/us-food-and-drug-administration-approves-vemlidy-tenofovir-alafenamide-for-treatment-of-chronic-hepatitis-b-virus-infection-in-pediatric-patients 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/veklury-remdesivir-is-first-and-only-approved-treatment-for-pediatric-patients-under-12-years-of-age-with-covid-19 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/veklury-remdesivir-retains-antiviral-activity-against-omicron-delta-and-other-emergent-sars-cov-2-variants-in-multiple-in-vitro-studies 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/who-expands-recommendation-for-veklury-remdesivir-to-patients-with-severe-disease-in-latest-update-to-covid-19-guideline 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/yescarta-car-t-cell-therapy-demonstrates-consistent-survival-outcomes-and-safety-in-real-world-setting-regardless-of-race-and-ethnicity 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2022/yescarta-now-approved-in-japan-for-initial-treatment-of-relapsedrefractory-large-b-cell-lymphoma 2024-08-28 daily 0.5 https://www.gilead.com/news/news-details/2022/yescarta-receives-us-fda-approval-as-first-car-t-cell-therapy-for-initial-treatment-of-relapsed-or-refractory-large-b-cell-lymphoma-lbcl 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2023/analyses-of-kites-yescartacar-t-cell-therapy-support-curative-potential-in-patients-with-non-hodgkin-lymphomas 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2023/chmp-adopts-positive-opinion-recommending-hepcludex-bulevirtide-for-full-marketing-authorization-for-the-treatment-of-hepatitis-delta-virus-hdv 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2023/chmp-adopts-positive-opinion-to-extend-the-use-of-veklury-remdesivir-to-treat-covid-19-in-people-with-hepatic-impairment 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2023/chmp-adopts-positive-opinion-to-extend-the-use-of-veklury-remdesivir-to-treat-covid-19-in-people-with-severe-renal-impairment-including-those-on-dialysis 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2023/european-commission-approves-gileads-trodelvy-for-pre-treated-hrher2--metastatic-breast-cancer 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2023/european-medicines-agency-validates-marketing-authorization-application-for-trodelvy-sacituzumab-govitecan-hziy-for-pre-treated-hrher2--metastatic-breast-cancer 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2023/fda-approves-veklury-remdesivir-for-covid-19-treatment-in-patients-with-severe-renal-impairment-including-those-on-dialysis 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2023/fda-approves-veklury-remdesivir-to-treat-covid-19-in-people-with-mild-to-severe-hepatic-impairment-with-no-dose-adjustment 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2023/gilead-and-arcus-announce-anti-tigit-domvanalimab-continues-to-demonstrate-consistent-improvement-in-progression-free-survival-in-non-small-cell-lung-cancer-study 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2023/gilead-and-arcus-announce-new-data-showing-encouraging-clinical-activity-of-anti-tigit-domvanalimab-containing-regimen-as-first-line-treatment-for-upper-gi-cancers 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2023/gilead-and-assembly-biosciences-establish-partnership-to-develop-next-generation-therapeutics-for-serious-viral-diseases 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2023/gilead-and-compugen-announce-exclusive-license-agreement-for-novel-pre-clinical-immunotherapy-program 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2023/gilead-and-evoq-therapeutics-announce-collaboration-to-advance-immunotherapies 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2023/gilead-and-kite-oncology-demonstrate-growing-hematology-pipeline-and-strength-of-leading-cell-therapy-portfolio-at-eha 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2023/gilead-and-kite-oncology-present-data-demonstrating-car-t-cell-therapy-survival-benefit-and-showcasing-latest-advances-in-blood-cancer-portfolio-at-ash-2023 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2023/gilead-and-kite-oncology-present-important-new-data-across-multiple-difficult-to-treat-cancers-at-esmo-congress-2023 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2023/gilead-and-kite-oncology-to-showcase-advances-across-the-pipeline-aiming-to-address-unmet-needs-in-cancer-care-at-asco-2023 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2023/gilead-and-tentarix-to-discover-and-develop-novel-therapies-to-address-unmet-medical-needs-across-cancer-and-inflammation 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2023/gilead-announces-8-million-in-grant-funding-for-viral-hepatitis-relink-program-in-the-us 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2023/gilead-announces-partial-clinical-hold-for-magrolimab-studies-in-aml 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2023/gilead-appoints-cindy-perettie-executive-vice-president-of-kite 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2023/gilead-awards-76-million-in-grants-to-advance-health-equity-in-breast-cancer 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2023/gilead-board-director-kevin-e-lofton-named-to-list-of-influential-leaders 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2023/gilead-demonstrates-the-impact-of-global-collaboration-in-advancing-hiv-research-and-health-equity-at-eacs-2023 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2023/gilead-demonstrates-transformative-potential-impact-of-antiviral-innovation-at-croi-2023 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2023/gilead-exercises-option-to-license-nurixs-irak4-targeted-protein-degrader-development-candidate-nx-0479 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2023/gilead-named-number-one-overall-philanthropic-funder-of-hiv-related-programs-for-second-year-in-a-row-by-funders-concerned-about-aids 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2023/gilead-named-to-dow-jones-sustainability-world-index-for-third-consecutive-year 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2023/gilead-partners-with-chai-and-penta-to-improve-treatment-and-adherence-rates-among-children-with-hiv-in-low-and-middle-income-countries 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2023/gilead-presents-new-data-from-hiv-cure-research-program-and-collaborations-exploring-novel-investigational-combinations-and-strategies 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2023/gilead-presents-positive-proof-of-concept-data-for-investigational-combination-regimen-of-lenacapavir-with-broadly-neutralizing-antibodies-as-a-potential-twice-yearly-approach-for-the-treatm 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2023/gilead-prices-2-billion-of-senior-unsecured-notes 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2023/gilead-receives-chmp-positive-opinion-for-trodelvy-in-pre-treated-hrher2--metastatic-breast-cancer 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2023/gilead-sciences-and-arcus-biosciences-expand-partnership-to-include-research-programs-in-inflammation 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2023/gilead-sciences-and-meharry-medical-college-highlight-five-year-impact-of-gilead-compass-initiative-on-hiv-in-the-southern-united-states 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2023/gilead-sciences-announces-27-percent-increase-in-first-quarter-2023-dividend 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2023/gilead-sciences-announces-3-million-in-grant-funding-to-eight-organizations-addressing-hiv-disparities-in-rural-us-communities 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2023/gilead-sciences-announces-first-quarter-2023-financial-results 2024-11-01 daily 0.5 https://www.gilead.com/news/news-details/2023/gilead-sciences-announces-fourth-quarter-and-full-year-2022-financial-results 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2023/gilead-sciences-announces-its-largest-commitment-to-health-equity-for-australian-and-canadian-indigenous-communities 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2023/gilead-sciences-announces-new-clinical-trial-in-europe-to-assess-lenacapavir-for-hiv-prevention-as-part-of-landmark-purpose-program 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2023/gilead-sciences-announces-second-quarter-2023-financial-results 2024-12-04 always https://www.gilead.com/news/news-details/2023/gilead-sciences-announces-third-quarter-2023-financial-results 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2023/gilead-sciences-to-present-at-upcoming-investor-conference 2025-11-17 daily 0.5 https://www.gilead.com/news/news-details/2023/gilead-sciences-to-present-at-upcoming-investor-conference-d84031620 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2023/gilead-sciences-to-present-at-upcoming-investor-conferences 2025-11-17 daily 0.5 https://www.gilead.com/news/news-details/2023/gilead-sciences-to-present-at-upcoming-investor-conferences-06f5fda0a 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2023/gilead-sciences-to-present-at-upcoming-investor-conferences-4dd4d79b5 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2023/gilead-sciences-to-present-at-upcoming-investor-conferences-84a74bbcc 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2023/gilead-sciences-to-release-first-quarter-2023-financial-results-on-thursday-april-27-2023 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2023/gilead-sciences-to-release-fourth-quarter--full-year-2022-financial-results-on-thursday-february-2-2023 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2023/gilead-sciences-to-release-second-quarter-2023-financial-results-on-thursday-august-3-2023 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2023/gilead-sciences-to-release-third-quarter-2023-financial-results-on-tuesday-november-7-2023 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2023/gilead-showcases-latest-hiv-pipeline-progress-and-the-impact-of-global-collaboration-on-health-equity-efforts-at-ias-2023 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2023/gileads-leadership-in-metastatic-breast-cancer-showcased-with-new-trodelvy-data-at-san-antonio-breast-cancer-symposium-2023 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2023/gileads-phase-2-evoke-02-study-of-trodelvy-sacituzumab-govitecan-hziy-in-combination-with-keytruda-pembrolizumab-demonstrates-promising-clinical-activity-in-first-line-metastatic-non-small-c 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2023/gilead-strengthens-early-pipeline-in-oncology-and-inflammation-through-the-acquisition-of-xinthera 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2023/gilead-to-discontinue-phase-3-enhance-study-of-magrolimab-plus-azacitidine-in-higher-risk-mds 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2023/gilead-to-present-late-breaking-data-and-real-world-evidence-highlighting-key-hepatitis-indications-at-the-liver-meeting-2023 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2023/gilead-to-present-latest-innovative-virology-data-on-current-and-potentially-transformative-therapies-across-hiv-and-covid-19-at-idweek-2023 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2023/gilead-to-present-latest-liver-disease-research-at-the-european-association-for-the-study-of-the-liver-easl-congress-2023 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2023/hepcludex-bulevirtide-demonstrates-sustained-efficacy-and-safety-profile-in-people-with-chronic-hepatitis-delta-virus-at-96-weeks 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2023/kite-and-arcellx-announce-expansion-in-strategic-partnership 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2023/kite-and-arcellx-close-agreement-to-co-develop-and-co-commercialize-late-stage-clinical-cart-ddbcma-in-multiple-myeloma 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2023/kite-and-epic-bio-announce-collaboration-to-develop-new-therapies-for-cancer 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2023/kite-announces-completion-of-marketing-authorization-transfer-for-yescarta-car-t-cell-therapy-in-japan 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2023/kite-completes-acquisition-of-tmunity 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2023/kites-car-t-cell-therapy-yescarta-demonstrates-high-response-rate-and-durable-remission-in-alycante-study-as-initial-treatment-for-transplant-ineligible-patients-with-relapsedrefractory-larg 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2023/kites-tecartus-car-t-celltherapy-demonstrates-78-complete-response-rate-and-90-overall-response-rate-in-largest-real-world-evidence-analysis-for-relapsedrefractory-mantle-cell-lymphoma 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2023/kites-tecartus-car-t-cell-therapy-demonstrates-overall-survival-benefit-in-three-year-follow-up-of-pivotal-zuma-3-trial-in-relapsedrefractory-b-cell-acute-lymphoblastic-leukemia 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2023/kites-yescarta-car-t-cell-therapy-demonstrates-a-statistically-significant-improvement-in-overall-survival-for-initial-treatment-of-relapsedrefractory-large-b-cell-lymphoma 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2023/kites-yescarta-car-t-cell-therapy-demonstrates-significantly-longer-overall-survival-versus-standard-of-care-as-initial-treatment-of-relapsedrefractory-large-b-cell-lymphoma 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2023/long-term-data-for-kites-yescarta-car-t-cell-therapy-presented-at-ash-2023-demonstrate-high-rate-of-durable-response-in-patients-with-high-risk-large-b-cell-lymphoma 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2023/new-analyses-presented-at-ash-2023-support-the-potential-long-term-response-and-safety-of-kites-tecartus-in-patients-with-aggressive-blood-cancers 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2023/new-biktarvy-data-presented-at-ias-2023-further-demonstrate-safety-and-efficacy-profile-in-a-broad-range-of-people-and-communities-affected-by-the-global-hiv-epidemic 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2023/new-data-presented-at-eacs-2023-further-demonstrate-strong-clinical-profile-of-twice-yearly-sunlenca-for-adults-with-multi-drug-resistant-hiv 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2023/real-world-evidence-reinforces-biktarvy-as-a-long-term-treatment-option-with-a-high-barrier-to-resistance-for-people-with-hiv-and-a-range-of-comorbidities 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2023/trodelvy-continues-to-show-durable-overall-survival-advantage-in-pre-treated-hrher2--metastatic-breast-cancer 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2023/trodelvy-demonstrates-positive-efficacy-treating-both-platinum-ineligible-and-rapidly-progressing-post-platinum-metastatic-urothelial-cancer 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2023/twice-yearly-lenacapavir-demonstrates-sustained-impact-on-health-related-quality-of-life-in-people-with-hiv 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2023/us-fda-approves-label-update-for-kites-yescarta-car-t-cell-therapy-to-include-overall-survival-data 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2023/us-fda-approves-trodelvy-in-pre-treated-hrher2--metastatic-breast-cancer 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2023/veklury-remdesivir-efficacy-and-safety-profile-further-demonstrated-in-vulnerable-patient-populations 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2023/veklury-remdesivir-reduced-risk-of-mortality-in-hospitalized-covid-19-patients-across-all-variant-time-periods-in-a-real-world-study-of-more-than-500000-hospitalized-patients 2024-08-19 daily 0.5 https://www.gilead.com/news/news-details/2024/biktarvy-demonstrates-high-rates-of-viral-suppression-in-people-with-hiv-and-comorbidities 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2024/gilead-and-terray-therapeutics-announce-multi-target-research-collaboration-to-discover-and-develop-novel-small-molecule-therapies 2025-01-07 daily 0.5 https://www.gilead.com/news/news-details/2024/gilead-and-tubulis-enter-into-exclusive-option-and-license-agreement-to-develop-adc-candidate-for-select-solid-tumor-target 2025-01-07 daily 0.5 https://www.gilead.com/news/news-details/2024/gilead-announces-new-england-journal-of-medicine-publication-of-purpose-2-results 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2024/gilead-sciences-appoints-dietmar-berger-md-phd-as-chief-medical-officer 2025-01-07 daily 0.5 https://www.gilead.com/news/news-details/2024/gilead-sciences-to-present-at-upcoming-investor-conference 2025-11-17 daily 0.5 https://www.gilead.com/news/news-details/2024/gileads-livdelzi-seladelpar-demonstrated-a-sustained-efficacy-and-long-term-safety-profile-in-management-of-primary-biliary-cholangitis 2025-01-07 daily 0.5 https://www.gilead.com/news/news-details/2024/gileads-seladelpar-receives-positive-chmp-opinion-for-primary-biliary-cholangitis 2025-01-07 daily 0.5 https://www.gilead.com/news/news-details/2024/kite-presents-new-data-underscoring-curative-potential-of-yescarta-in-relapsedrefractory-large-b-cell-lymphoma-at-ash 2025-01-07 daily 0.5 https://www.gilead.com/news/news-details/2024/kites-yescarta-only-car-t-cell-therapy-to-show-durable-response-and-long-term-survival-after-five-years-in-patients-with-relapsedrefractory-non-hodgkin-lymphomas-at-ash-2024 2025-01-07 daily 0.5 https://www.gilead.com/news/news-details/2024/longest-follow-up-data-reported-for-kites-tecartus-car-t-cell-therapy-at-ash-2024-reinforce-durable-efficacy-and-survival-benefits 2025-01-07 daily 0.5 https://www.gilead.com/news/news-details/2024/us-fda-grants-breakthrough-therapy-designation-to-trodelvy-sacituzumab-govitecan-hziy-for-second-line-treatment-of-extensive-stage-small-cell-lung-cancer 2025-01-07 daily 0.5 https://www.gilead.com/news/news-details/2024/chief-medical-officer-merdad-parsey-to-leave-gilead-early-2025 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2024/encouraging-new-data-presented-on-kites-yescarta-for-relapsedrefractory-central-nervous-system-lymphoma 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2024/evoke-01-study-results-in-metastatic-nsclc-to-be-presented-at-an-oral-session-at-asco-2024 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2024/fda-approves-biktarvy-label-update-with-data-for-pregnant-adults-with-hiv 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2024/fda-expands-indication-for-gileads-vemlidy-tenofovir-alafenamide-to-treat-chronic-hbv-infection-in-pediatric-patients-as-young-as-six 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2024/full-efficacy-and-safety-results-for-gilead-investigational-twice-yearly-lenacapavir-for-hiv-prevention-presented-at-aids-2024 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2024/gilead-signs-royalty-free-voluntary-licensing-agreements-with-six-generic-manufacturers-to-increase-access-to-lenacapavir-for-hiv-prevention-in-high-incidence-resource-limited-countries 2025-01-07 daily 0.5 https://www.gilead.com/news/news-details/2024/gilead-and-arcus-announce-amended-collaboration-and-equity-investment 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2024/gilead-and-arcus-announce-anti-tigit-domvanalimab-plus-zimberelimab-and-chemotherapy-exceeded-one-year-of-median-progression-free-survival-as-a-first-line-treatment-for-upper-gi-cancers 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2024/gilead-and-arcus-announce-etrumadenant-plus-zimberelimab-regimen-significantly-reduced-the-risk-of-death-in-third-line-metastatic-colorectal-cancer 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2024/gilead-and-genesis-therapeutics-announce-strategic-collaboration-to-discover-and-develop-novel-therapies 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2024/gilead-and-kite-oncology-to-highlight-broad-and-diverse-oncology-portfolio-at-asco-2024 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2024/gilead-and-merck-announce-phase-2-data-showing-an-investigational-oral-once-weekly-combination-regimen-of-islatravir-and-lenacapavir-maintained-viral-suppression-at-week-24 2024-12-12 daily 0.5 https://www.gilead.com/news/news-details/2024/gilead-and-merck-announce-phase-2-data-showing-a-treatment-switch-to-an-investigational-oral-once-weekly-combination-regimen-of-islatravir-and-lenacapavir-maintained-viral-suppression-in-adu 2025-01-07 daily 0.5 https://www.gilead.com/news/news-details/2024/gilead-and-merus-announce-collaboration-to-discover-novel-antibody-based-trispecific-t-cell-engagers 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2024/gilead-and-the-elton-john-aids-foundation-announce-additional-five-years-of-radian-partnership-to-help-address-the-growing-hiv-crisis-in-eastern-europe-and-central-asia 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2024/gilead-and-xilio-announce-exclusive-license-agreement-for-tumor-activated-il-12-program 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2024/gilead-announces-funding-initiative-to-support-hiv-prevention-anti-stigma-and-health-equity-efforts-for-black-cisgender-and-transgender-women-and-girls-in-the-us 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2024/gilead-announces-new-england-journal-of-medicine-publication-of-data-that-demonstrate-bulevirtide-with-pegifn-achieved-post-treatment-undetectable-hdv-rna 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2024/gilead-named-one-of-americas-most-just-companies-by-just-capital-and-cnbc 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2024/gilead-presents-additional-efficacy-safety-and-demographic-data-from-purpose-2-trial-at-5th-hiv-research-for-prevention-conference 2025-01-07 daily 0.5 https://www.gilead.com/news/news-details/2024/gilead-prices-35-billion-of-senior-unsecured-notes 2025-01-07 daily 0.5 https://www.gilead.com/news/news-details/2024/gilead-presents-full-purpose-2-data-results-for-twice-yearly-lenacapavir-for-hiv-prevention-at-hiv-glasgow 2025-01-07 daily 0.5 https://www.gilead.com/news/news-details/2024/gilead-presents-research-data-across-its-broad-and-innovative-hiv-treatment-portfolio-and-pipeline 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2024/gilead-provides-update-on-phase-3-evoke-01-study 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2024/gilead-provides-update-on-phase-3-tropics-04-study 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2024/gilead-sciences-announces-27-percent-increase-in-first-quarter-2024-dividend 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2024/gilead-sciences-announces-completion-of-acquisition-of-cymabay 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2024/gilead-sciences-announces-expiration-of-hart-scott-rodino-waiting-period-for-cymabay-tender-offer 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2024/gilead-sciences-announces-first-quarter-2024-financial-results 2024-11-15 daily 0.5 https://www.gilead.com/news/news-details/2024/gilead-sciences-announces-fourth-quarter-and-full-year-2023-financial-results 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2024/gilead-sciences-announces-second-quarter-2024-financial-results 2024-12-04 always https://www.gilead.com/news/news-details/2024/gilead-sciences-announces-third-quarter-2024-financial-results 2025-01-07 always https://www.gilead.com/news/news-details/2024/gilead-sciences-expands-liver-portfolio-with-acquisition-of-cymabay-therapeutics 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2024/gilead-sciences-to-present-at-upcoming-investor-conferences 2025-11-17 daily 0.5 https://www.gilead.com/news/news-details/2024/gilead-sciences-to-present-at-upcoming-investor-conferences-e2bdecfa1 2025-01-07 daily 0.5 https://www.gilead.com/news/news-details/2024/gilead-sciences-to-present-at-upcoming-investor-conferences-eead0d159 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2024/gilead-sciences-to-present-at-upcoming-investor-engagements 2025-01-07 daily 0.5 https://www.gilead.com/news/news-details/2024/gilead-sciences-to-release-first-quarter-2024-financial-results-on-thursday-april-25-2024 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2024/gilead-sciences-to-release-fourth-quarter--full-year-2023-financial-results-on-tuesday-february-6-2024 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2024/gilead-sciences-to-release-second-quarter-2024-financial-results-on-thursday-august-8-2024 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2024/gilead-sciences-to-release-third-quarter-2024-financial-results-on-wednesday-november-6-2024 2025-01-07 daily 0.5 https://www.gilead.com/news/news-details/2024/gileads-innovative-hiv-treatment-research-pipeline-aims-to-address-unmet-needs-and-advance-public-health 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2024/gileads-livdelzi-seladelpar-granted-accelerated-approval-for-primary-biliary-cholangitis-by-us-fda 2025-01-07 daily 0.5 https://www.gilead.com/news/news-details/2024/gileads-seladelpar-demonstrated-a-sustained-and-consistent-long-term-efficacy-and-safety-profile-in-primary-biliary-cholangitis 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2024/gileads-twice-yearly-lenacapavir-demonstrated-100-efficacy-and-superiority-to-daily-truvada-for-hiv-prevention 2024-12-12 daily 0.5 https://www.gilead.com/news/news-details/2024/gileads-twice-yearly-lenacapavir-for-hiv-prevention-reduced-hiv-infections-by-96-and-demonstrated-superiority-to-daily-truvada-in-second-pivotal-phase-3-trial 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2024/gilead-to-highlight-landmark-progress-in-research-across-hiv-prevention-treatment-and-cure-programs-at-aids-2024 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2024/gilead-to-present-late-breaking-data-and-real-world-evidence-highlighting-innovative-antiviral-portfolio-and-research-pipeline-at-croi-2024 2024-12-12 daily 0.5 https://www.gilead.com/news/news-details/2024/gilead-to-present-late-breaking-data-highlighting-antiviral-portfolio-innovative-research-pipeline-and-hiv-leadership-at-idweek-2024 2025-01-07 daily 0.5 https://www.gilead.com/news/news-details/2024/gilead-to-present-latest-research-across-key-liver-disease-indication-at-the-american-association-for-the-study-of-liver-disease-aasld-meeting-2024 2025-01-07 daily 0.5 https://www.gilead.com/news/news-details/2024/gilead-to-present-latest-research-across-key-liver-disease-indications-at-the-european-association-for-the-study-of-the-liver-congress-2024 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2024/gilead-to-present-new-trodelvy-data-at-the-iaslc-2024-world-conference-on-lung-cancer 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2024/investigational-seladelpar-demonstrates-significant-improvements-in-liver-disease-progression-and-reduced-itching-in-primary-biliary-cholangitis 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2024/kite-and-arcellx-continue-momentum-with-advances-in-anito-cel-multiple-myeloma-program 2024-12-16 daily 0.5 https://www.gilead.com/news/news-details/2024/kite-data-at-eha-2024-demonstrate-positive-patient-outcomes-and-advances-in-delivery-of-car-t-cell-therapy 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2024/kite-receives-us-fda-approval-of-manufacturing-process-change-resulting-in-reduced-median-turnaround-time-for-yescarta-car-t-cell-therapy 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2024/kites-tecartus-demonstrates-sustained-overall-survival-in-adult-patients-with-relapsedrefractory-b-cell-acute-lymphoblastic-leukemia 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2024/kite-to-highlight-industry-leading-car-t-cell-therapy-portfolio-at-ash-2024-including-positive-survival-outcomes-in-both-clinical-trials-and-the-real-world 2025-03-11 daily 0.5 https://www.gilead.com/news/news-details/2024/late-breaking-clinical-data-and-real-world-evidence-presented-at-hiv-glasgow-as-gilead-extends-leadership-efforts-toward-ending-the-epidemic 2025-01-07 daily 0.5 https://www.gilead.com/news/news-details/2024/media-update-gilead-sciences-advances-enrollment-in-collaborative-studies-to-assess-twice-yearly-hiv-prevention-option-for-both-cisgender-women-in-the-us-and-people-who-inject-drugs-in-the-us 2025-11-17 daily 0.5 https://www.gilead.com/news/news-details/2024/new-kite-clinical-research-and-real-world-evidence-for-yescarta-demonstrate-benefit-from-earlier-lines-of-treatment 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2024/new-real-world-data-further-support-the-use-of-veklury-remdesivir-for-people-hospitalized-with-covid-19 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2024/scientific-leadership-spotlighted-as-gilead-presents-research-data-across-its-broad-and-innovative-hiv-treatment-portfolio-and-pipeline 2025-01-07 daily 0.5 https://www.gilead.com/news/news-details/2024/ted-love-md-joins-gilead-sciences-board-of-directors 2024-12-04 daily 0.5 https://www.gilead.com/news/news-details/2024/us-fda-approves-expanded-indication-for-gileads-biktarvy-to-treat-people-with-hiv-with-suppressed-viral-loads-pre-existing-resistance 2024-12-19 daily 0.5 https://www.gilead.com/news/news-details/2025/ascent-03-trodelvy-demonstrates-highly-statistically-significant--clinically-meaningful-improvement-in-progression-free-survival-in-patients-with-first-line-metastatic-triple-negative-breast 2025-11-04 daily 0.5 https://www.gilead.com/news/news-details/2025/european-commission-authorizes-twice-yearly-yeytuo-lenacapavir-for-hiv-prevention 2025-11-04 daily 0.5 https://www.gilead.com/news/news-details/2025/european-medicines-agency-validates-gileads-marketing-authorization-application-and-eu-medicines-for-all-application-for-twice-yearly-lenacapavir-for-hiv-prevention 2025-11-04 daily 0.5 https://www.gilead.com/news/news-details/2025/final-data-from-the-phase-3-myr301-study-demonstrated-longer-treatment-with-bulevirtide-was-associated-with-sustaining-undetectability-after-stopping-treatment 2025-05-14 daily 0.5 https://www.gilead.com/news/news-details/2025/first-clinical-data-for-gileads-investigational-once-yearly-lenacapavir-for-hiv-prevention-presented-at-croi-2025-and-published-in-the-lancet 2025-11-04 daily 0.5 https://www.gilead.com/news/news-details/2025/gilead-and-kite-announce-presentation-of-transformative-data-in-1l-metastatic-triple-negative-breast-cancer-updated-results-in-multiple-myeloma-and-early-data-from-novel-investigational-car- 2025-11-04 daily 0.5 https://www.gilead.com/news/news-details/2025/gilead-and-kite-reinforce-bold-commitment-to-transform-cancer-care-with-new-data-at-esmo-2025 2025-10-15 daily 0.5 https://www.gilead.com/news/news-details/2025/gilead-and-kite-showcase-continued-progress-in-transforming-blood-cancer-care-with-new-cell-therapy-data-at-ash-2025 2025-11-03 daily 0.5 https://www.gilead.com/news/news-details/2025/gilead-and-leo-pharma-enter-into-strategic-partnership-to-accelerate-development-of-oral-stat6-program-with-potential-in-multiple-inflammatory-diseases 2025-05-14 daily 0.5 https://www.gilead.com/news/news-details/2025/gilead-and-u-s--government-enter-agreement-to-lower-costs-of-medicines-for-americans 2025-12-19 daily 0.5 https://www.gilead.com/news/news-details/2025/gilead-announces-partnership-with-pepfar-to-deliver-twice-yearly-lenacapavir-for-hiv-prevention-for-up-to-two-million-people-in-primarily-low--and-lower-middle-income-countries 2025-11-04 daily 0.5 https://www.gilead.com/news/news-details/2025/gilead-finalizes-agreement-with-the-global-fund-to-accelerate-access-to-twice-yearly-lenacapavir-for-hiv-prevention-for-up-to-two-million-people-in-primarily-low--and-lower-middle-income-countries 2025-11-04 daily 0.5 https://www.gilead.com/news/news-details/2025/gilead-foundation-awards-over-3-million-to-support-people-living-with-metastatic-breast-cancer 2025-12-09 daily 0.5 https://www.gilead.com/news/news-details/2025/gilead-foundation-commits-over-3-million-to-address-food-insecurity 2025-11-24 daily 0.5 https://www.gilead.com/news/news-details/2025/gilead-foundation-grants-6-5-million-in-commitment-to-stem-education 2025-11-04 daily 0.5 https://www.gilead.com/news/news-details/2025/gilead-joins-partners-for-delivery-of-first-shipments-of-breakthrough-twice-yearly-lenacapavir-for-hiv-prevention-to-sub-saharan-africa 2025-11-18 daily 0.5 https://www.gilead.com/news/news-details/2025/gilead-presents-new-data-on-twice-yearly-lenacapavir-yeztugo-for-hiv-prevention-at-ias-2025 2025-11-04 daily 0.5 https://www.gilead.com/news/news-details/2025/gilead-presents-new-hiv-research-data-at-eacs-2025--driving-scientific-innovation-in-treatment-and-prevention 2025-11-04 daily 0.5 https://www.gilead.com/news/news-details/2025/gilead-presents-new-hiv-treatment-and-cure-research-data-at-croi-2025-including-an-investigational-long-acting-twice-yearly-therapy-option 2025-11-04 daily 0.5 https://www.gilead.com/news/news-details/2025/gilead-provides-update-on-phase-3-ascent-07-study 2025-11-07 daily 0.5 https://www.gilead.com/news/news-details/2025/gilead-receives-positive-chmp-opinions-under-accelerated-review-from-european-medicines-agency-for-twice-yearly-lenacapavir-for-hiv-prevention 2025-07-25 daily 0.5 https://www.gilead.com/news/news-details/2025/gilead-sciences-and-kymera-therapeutics-enter-into-exclusive-option-and-license-agreement-to-develop-novel-oral-molecular-glue-cdk2-degraders 2025-07-09 daily 0.5 https://www.gilead.com/news/news-details/2025/gilead-sciences-announces-26-percent-increase-in-first-quarter-2025-dividend 2025-05-14 daily 0.5 https://www.gilead.com/news/news-details/2025/gilead-sciences-announces-first-quarter-2025-financial-results 2025-05-14 daily 0.5 https://www.gilead.com/news/news-details/2025/gilead-sciences-announces-fourth-quarter-and-full-year-2024-financial-results 2025-05-14 daily 0.5 https://www.gilead.com/news/news-details/2025/gilead-sciences-announces-second-quarter-2025-financial-results 2025-08-07 daily 0.5 https://www.gilead.com/news/news-details/2025/gilead-sciences-announces-third-quarter-2025-financial-results 2025-10-30 daily 0.5 https://www.gilead.com/news/news-details/2025/gilead-sciences-appoints-keeley-wettan-as-executive-vice-president-general-counsel-legal--compliance 2025-12-18 daily 0.5 https://www.gilead.com/news/news-details/2025/gilead-sciences-breaks-ground-on-new-manufacturing-hub-a-cornerstone-of-its-u-s--growth-and-innovation-strategy 2025-11-04 daily 0.5 https://www.gilead.com/news/news-details/2025/gilead-sciences-exercises-option-to-license-assembly-biosciences-helicase-primase-inhibitor-programs-for-recurrent-genital-herpes 2025-12-22 daily 0.5 https://www.gilead.com/news/news-details/2025/gilead-sciences-launches-choose-u-campaign-spotlighting-the-inspiring-experiences-of-people-living-with-hiv 2025-11-04 daily 0.5 https://www.gilead.com/news/news-details/2025/gilead-sciences-to-present-at-upcoming-investor-conferences 2025-11-17 daily 0.5 https://www.gilead.com/news/news-details/2025/gilead-sciences-to-present-at-upcoming-investor-conferences-169ec42ab 2025-11-06 daily 0.5 https://www.gilead.com/news/news-details/2025/gilead-sciences-to-present-at-upcoming-investor-conferences-2b4614bef 2025-11-04 daily 0.5 https://www.gilead.com/news/news-details/2025/gilead-sciences-to-present-at-upcoming-investor-conferences-a7217e8f5 2025-11-04 daily 0.5 https://www.gilead.com/news/news-details/2025/gilead-sciences-to-release-first-quarter-2025-financial-results-on-thursday-april-24-2025 2025-11-04 daily 0.5 https://www.gilead.com/news/news-details/2025/gilead-sciences-to-release-fourth-quarter--full-year-2024-financial-results-on-tuesday-february-11-2025 2025-11-04 daily 0.5 https://www.gilead.com/news/news-details/2025/gilead-sciences-to-release-second-quarter-2025-financial-results-on-thursday-august-7-2025 2025-11-04 daily 0.5 https://www.gilead.com/news/news-details/2025/gilead-sciences-to-release-third-quarter-2025-financial-results-on-thursday-october-30-2025 2025-11-04 daily 0.5 https://www.gilead.com/news/news-details/2025/gilead-sciences-wins-prestigious-2025-prix-galien-usa-award-for-best-pharmaceutical-product-with-yeztugo-lenacapavir 2025-10-31 daily 0.5 https://www.gilead.com/news/news-details/2025/gileads-investigational-single-tablet-regimen-of-bictegravir-and-lenacapavir-for-hiv-1-treatment-meets-primary-endpoint-in-phase-3-artistry-1-trial 2025-11-13 daily 0.5 https://www.gilead.com/news/news-details/2025/gileads-investigational-single-tablet-regimen-of-bictegravir-and-lenacapavir-for-hiv-treatment-meets-primary-endpoint-in-phase-3-artistry-2-trial 2025-12-15 daily 0.5 https://www.gilead.com/news/news-details/2025/gileads-livdelzi-demonstrates-sustained-efficacy-in-primary-biliary-cholangitis-pbc-offering-alkaline-phosphatase-alp-reduction-itch-relief-and-potential-to-slow-disease-progression 2025-11-07 daily 0.5 https://www.gilead.com/news/news-details/2025/gileads-livdelzi-seladelpar-demonstrated-consistent-efficacy-and-safety-regardless-of-prior-treatment-history-in-new-data-presented-at-easl-2025 2025-11-04 daily 0.5 https://www.gilead.com/news/news-details/2025/gileads-seladelpar-granted-conditional-european-marketing-authorization-for-the-treatment-of-primary-biliary-cholangitis 2025-11-04 daily 0.5 https://www.gilead.com/news/news-details/2025/gilead-to-present-latest-advancements-across-primary-biliary-cholangitis-and-viral-hepatitis 2025-05-14 daily 0.5 https://www.gilead.com/news/news-details/2025/gilead-to-showcase-interim-long-term-efficacy-data-for-livdelzi-seladelpar-in-primary-biliary-cholangitis-pbc-and-investigational-bulevirtide-in-chronic-hepatitis-delta 2025-11-04 daily 0.5 https://www.gilead.com/news/news-details/2025/gilead-to-spotlight-new-virology-data-across-hiv-viral-hepatitis-and-respiratory-diseases-at-idweek-2025 2025-11-04 daily 0.5 https://www.gilead.com/news/news-details/2025/kite-announces-new-data-for-pivotal-immagine-1-study-at-ash-2025-highlighting-anito-cels-opportunity-in-relapsed-or-refractory-multiple-myeloma 2025-12-06 daily 0.5 https://www.gilead.com/news/news-details/2025/kite-presents-new-real-world-data-supporting-use-of-potentially-curative-yescarta-in-outpatient-care-setting-for-patients-with-relapsedrefractory-large-b-cell-lymphoma-at-asco-2025 2025-11-04 daily 0.5 https://www.gilead.com/news/news-details/2025/kites-next-generation-bicistronic-car-t-cell-therapies-show-encouraging-phase-1-results-in-relapsedrefractory-b-cell-lymphoma-in-new-data-at-ash-2025 2025-12-06 daily 0.5 https://www.gilead.com/news/news-details/2025/kite-to-acquire-interius-biotherapeutics-to-advance-in-vivo-platform 2025-08-21 daily 0.5 https://www.gilead.com/news/news-details/2025/trodelvy-plus-keytruda-demonstrates-a-statistically-significant-and-clinically-meaningful-improvement-in-progression-free-survival-in-patients-with-previously-untreated-pd-l1-metastatic-trip 2025-11-04 daily 0.5 https://www.gilead.com/news/news-details/2025/trodelvy-plus-keytruda-reduces-risk-of-disease-progression-or-death-by-35-versus-keytruda-and-chemotherapy-in-first-line-pd-l1-metastatic-triple-negative-breast-cancer 2025-11-04 daily 0.5 https://www.gilead.com/news/news-details/2025/trodelvy-reduces-risk-of-disease-progression-or-death-by-38-versus-chemotherapy-as-first-line-therapy-in-patients-with-metastatic-triple-negative-breast-cancer-in-ascent-03-study 2025-11-04 daily 0.5 https://www.gilead.com/news/news-details/2025/us-fda-accepts-gileads-new-drug-applications-for-twice-yearly-lenacapavir-for-hiv-prevention-under-priority-review 2025-11-04 daily 0.5 https://www.gilead.com/news/news-details/2025/yescarta-delivers-consistent-safety-efficacy-and-quality-of-life-benefits-across-broad-range-of-relapsedrefractory-large-b-cell-lymphoma-patients-in-new-analysis-at-ash-2025 2025-12-07 daily 0.5 https://www.gilead.com/news/news-details/2025/yeztugo-lenacapavir-is-now-the-first-and-only-fda-approved-hiv-prevention-option-offering-6-months-of-protection 2026-02-04 daily 0.5 https://www.gilead.com/news/news-details/2026/fda-approves-label-update-for-kites-yescarta-for-relapsedrefractory-primary-central-nervous-system-lymphoma 2026-02-23 daily 0.5 https://www.gilead.com/news/news-details/2026/gilead-extends-tender-offer-to-acquire-arcellx 2026-04-01 daily 0.5 https://www.gilead.com/news/news-details/2026/gilead-foundation-awards-12-million-to-empower-community-health-workers-and-expand-hiv-prevention-initiatives-across-14-states-and-the-district-of-columbia 2026-03-24 daily 0.5 https://www.gilead.com/news/news-details/2026/gilead-sciences-to-acquire-ouro-medicines-to-advance-first-in-class-t-cell-engager-program-for-autoimmune-diseases 2026-03-23 daily 0.5 https://www.gilead.com/news/news-details/2026/gileads-single-tablet-regimen-of-bictegravir-and-lenacapavir-maintained-virological-suppression-in-people-with-hiv-who-switched-antiretroviral-therapy 2026-02-25 daily 0.5 https://www.gilead.com/news/news-details/2026/gilead-sciences-announces-3-8-percent-increase-in-first-quarter-2026-dividend 2026-02-23 daily 0.5 https://www.gilead.com/news/news-details/2026/gilead-sciences-announces-fourth-quarter-and-full-year-2025-financial-results 2026-02-23 daily 0.5 https://www.gilead.com/news/news-details/2026/gilead-sciences-to-present-at-upcoming-investor-conferences 2026-02-23 daily 0.5 https://www.gilead.com/news/news-details/2026/gilead-sciences-to-acquire-arcellx-to-maximize-long-term-potential-of-anito-cel 2026-03-24 daily 0.5 https://www.gilead.com/news/news-details/2026/gilead-sciences-to-release-fourth-quarter--full-year-2025-financial-results-on-tuesday-february-10-2026 2026-02-23 daily 0.5 https://www.gilead.com/news/news-details/2026/new-england-journal-of-medicine-publishes-phase-3-ascent-04keynote-d19-results-supporting-trodelvy-plus-keytruda-as-a-potential-new-standard-of-care-in-first-line-pd-l1-metastatic-triple-neg 2026-02-23 daily 0.5 https://www.gilead.com/responsibility/giving-at-gilead/corporate-giving/overview 2024-08-19 daily 0.5 https://www.gilead.com/responsibility/giving-at-gilead/corporate-giving/strategic-initiatives 2024-09-05 daily 0.5 https://www.gilead.com/responsibility/giving-at-gilead/corporate-giving/how-to-apply-for-funding 2024-09-05 daily 0.5 https://www.gilead.com/responsibility/giving-at-gilead/gilead-foundation/overview 2024-08-19 daily 0.5 https://www.gilead.com/responsibility/giving-at-gilead/gilead-foundation/creating-possible-fund 2024-08-31 daily 0.5 https://www.gilead.com/responsibility/giving-at-gilead/gilead-foundation/building-community-donations 2025-01-16 daily 0.5 https://www.gilead.com/responsibility/global-health-and-access/access-in-low--and-middle-income-countries/overview 2025-01-08 daily 0.5 https://www.gilead.com/responsibility/global-health-and-access/access-in-low--and-middle-income-countries/access-strategy-for-long-acting-prep 2025-10-27 daily 0.5 https://www.gilead.com/responsibility/global-health-and-access/access-in-low--and-middle-income-countries/invasive-fungal-infection 2025-01-08 daily 0.5 https://www.gilead.com/responsibility/global-health-and-access/access-in-low--and-middle-income-countries/access-partnerships 2025-03-10 daily 0.5 https://www.gilead.com/responsibility/inclusion-and-diversity/employee-resource-groups/overview 2024-09-04 daily 0.5 https://www.gilead.com/responsibility/inclusion-and-diversity/employee-resource-groups/adapt 2025-10-13 daily 0.5 https://www.gilead.com/responsibility/inclusion-and-diversity/employee-resource-groups/gain 2024-08-31 daily 0.5 https://www.gilead.com/responsibility/inclusion-and-diversity/employee-resource-groups/gileados 2025-10-13 daily 0.5 https://www.gilead.com/responsibility/inclusion-and-diversity/employee-resource-groups/globe 2024-08-31 daily 0.5 https://www.gilead.com/responsibility/inclusion-and-diversity/employee-resource-groups/gvet 2024-08-31 daily 0.5 https://www.gilead.com/responsibility/inclusion-and-diversity/employee-resource-groups/pride-alliance 2024-08-31 daily 0.5 https://www.gilead.com/responsibility/inclusion-and-diversity/employee-resource-groups/women-at-gilead 2024-08-31 daily 0.5 https://www.gilead.com/company/company-statements/2015/gilead-publishes-its-2014-corporate-contributions-report 2024-08-22 daily 0.5 https://www.gilead.com/company/company-statements/2015/gilead-supports-prep-education-to-increase-hiv-prevention-and-awareness 2024-08-22 daily 0.5 https://www.gilead.com/company/company-statements/2016/gilead-hiv-medicines-now-reaching-10-million-people-in-developing-countries 2024-08-22 daily 0.5 https://www.gilead.com/company/company-statements/2016/gilead-publishes-2015-corporate-social-responsibility-report 2024-08-22 daily 0.5 https://www.gilead.com/company/company-statements/2016/gilead-recognized-as-top-corporate-philanthropist-in-funders-concerned-about-aids-report 2024-08-22 daily 0.5 https://www.gilead.com/company/company-statements/2016/statement-on-discover-study-of-ftaf-for-prep 2024-08-22 daily 0.5 https://www.gilead.com/company/company-statements/2017/gilead-implements-emergency-disaster-response-procedures-to-ensure-medicine-access 2024-08-22 daily 0.5 https://www.gilead.com/company/company-statements/2017/gilead-publishes-year-in-review-2016 2024-08-22 daily 0.5 https://www.gilead.com/company/company-statements/2017/gilead-sciences-announces-100-percent-score-on-2018-human-rights-campaign-corporate-equality-index 2024-07-29 daily 0.5 https://www.gilead.com/company/company-statements/2018/a-perspective-from-our-ceo-gilead-subsidiary-to-launch-authorized-generics-to-treat-hcv 2024-08-22 daily 0.5 https://www.gilead.com/company/company-statements/2018/gilead-publishes-2017-year-in-review 2024-07-29 daily 0.5 https://www.gilead.com/company/company-statements/2018/gilead-sciences-announces-steep-discounts-for-ambisome-to-treat-cryptococcal-meningitis-in-low--and-middle-income-countries 2024-08-22 daily 0.5 https://www.gilead.com/company/company-statements/2018/gilead-sciences-statement-on-grants-to-spouses-of-caricom-leaders-action-network-sclan-to-expand-access-to-youth-hiv-prevention-and-care-in-the-caribbean 2024-08-22 daily 0.5 https://www.gilead.com/company/company-statements/2019/gilead-sciences-announces-500000-grant-to-pan-american-development-foundation-to-provide-emergency-health-services-for-venezuelan-migrants-and-host-communities-in-colombia 2024-08-22 daily 0.5 https://www.gilead.com/company/company-statements/2019/gilead-sciences-commits-to-reducing-our-global-greenhouse-gas-emissions-by-25-percent-by-2025- 2024-08-22 daily 0.5 https://www.gilead.com/company/company-statements/2019/gilead-sciences-statement-on-commitment-to-providing-price-information 2024-08-22 daily 0.5 https://www.gilead.com/company/company-statements/2019/gilead-sciences-statement-on-inaccurate-reporting-on-truvada 2024-09-20 daily 0.5 https://www.gilead.com/company/company-statements/2019/gilead-sciences-statement-on-us-preventive-services-task-force-a-recommendation-for-prep-as-an-hiv-prevention-strategy 2024-08-22 daily 0.5 https://www.gilead.com/company/company-statements/2019/gilead-statement-on-commitment-to-advancing-descovy-for-prep-study-in-cisgender-women--adolescent-females 2024-09-20 daily 0.5 https://www.gilead.com/company/company-statements/2019/gilead-statement-on-us-government-complaint-regarding-hiv-prep-and-pep-patents 2024-08-22 daily 0.5 https://www.gilead.com/company/company-statements/2019/petitions-to-us-patent-and-trademark-office-on-hiv-prep-patents 2024-08-22 daily 0.5 https://www.gilead.com/company/company-statements/2020/gilead-announces-new-arm-of-hiv-womens-prevention-study-to-evaluate-the-investigational--long-acting-hiv-1-capsid-inhibitor-lenacapavir-in-addition-to-descovy-for-prep 2025-07-29 daily 0.5 https://www.gilead.com/company/company-statements/2020/gilead-remains-committed-to-maintaining-advancing-access-program-for-hiv-prevention-and-treatment-medicines 2024-09-20 daily 0.5 https://www.gilead.com/company/company-statements/2020/gilead-sciences-statement-on-access-to-remdesivir-outside-of-clinical-trials 2024-08-22 daily 0.5 https://www.gilead.com/company/company-statements/2020/gilead-sciences-statement-on-data-from-remdesivir-study-in-patients-with-severe-covid-19-in-china 2024-08-22 daily 0.5 https://www.gilead.com/company/company-statements/2020/gilead-sciences-statement-on-ensuring-continued -supply-of-hiv--medicine-amid-coronavirus-outbreak 2024-08-22 daily 0.5 https://www.gilead.com/company/company-statements/2020/gilead-sciences-statement-on-expanding-global-supply-of-investigational-antiviral-remdesivir 2025-07-29 daily 0.5 https://www.gilead.com/company/company-statements/2020/gilead-sciences-statement-on-nejm-publication-of-remdesivir-data-from-niaid--study 2025-07-29 daily 0.5 https://www.gilead.com/company/company-statements/2020/gilead-sciences-statement-on-phase-23-clinical-trial-of-remdesivir-in-pediatric-patients-hospitalized-with-covid-19 2024-08-22 daily 0.5 https://www.gilead.com/company/company-statements/2020/gilead-sciences-statement-on-remdesivir-clinical-data 2025-07-29 daily 0.5 https://www.gilead.com/company/company-statements/2020/gilead-sciences-statement-on-request-to-rescind-remdesivir-orphan-drug-designation 2024-08-22 daily 0.5 https://www.gilead.com/company/company-statements/2020/gilead-sciences-statement-on-state-attorneys-general-letter-on-remdesivir 2025-07-29 daily 0.5 https://www.gilead.com/company/company-statements/2020/gilead-sciences-statement-on-the-company-ongoing-response-to-the-2019-novel-coronavirus-2019-ncov 2024-09-20 daily 0.5 https://www.gilead.com/company/company-statements/2020/gilead-sciences-statement-on-the-initiation-of-clinical-testing-of-an-inhaled-solution-of-remdesivir-for-potential-outpatient-treatment-of-covid-19 2025-07-29 daily 0.5 https://www.gilead.com/company/company-statements/2020/gilead-sciences-statement-on-the-solidarity-trial 2024-08-22 daily 0.5 https://www.gilead.com/company/company-statements/2020/gilead-sciences-statement-on-the-world-health-organizations-updated-veklury-remdesivir-covid-19-treatment-guidelines 2024-10-08 daily 0.5 https://www.gilead.com/company/company-statements/2020/gilead-sciences-update-on-veklury-remdesivir-manufacturing-network 2025-07-29 daily 0.5 https://www.gilead.com/company/company-statements/2020/gilead-statement-on-complaint-against-federal-government-in-the-court-of-federal-claims 2024-08-22 daily 0.5 https://www.gilead.com/company/company-statements/2020/gilead-statement-on-us-patent-and-trademark-office-decision-to-deny-request-for-inter-partes-review-of-hiv-prep-patents 2024-08-22 daily 0.5 https://www.gilead.com/company/company-statements/2020/statement-from-brett-pletcher-on-gilead-sciences-settlement-over-charitable-donations 2024-08-22 daily 0.5 https://www.gilead.com/company/company-statements/2021/gilead-and-merck-announce-temporary-pause-in-enrollment-for-phase-2-study-evaluating-an-oral-weekly-combination-regimen-of-investigational-islatravir-and-investigational-lenacapavir 2024-08-22 daily 0.5 https://www.gilead.com/company/company-statements/2021/gilead-announces-additional-updates-to-the-advancing-access-patient-assistancemedication-assistance-program 2025-07-29 daily 0.5 https://www.gilead.com/company/company-statements/2021/gilead-announces-decision-not-to-pursue-marketing-authorization-for-descovy-for-pre-exposure-prophylaxis-in-the-european-union 2024-09-20 daily 0.5 https://www.gilead.com/company/company-statements/2021/gilead-announces-plans-for-new-location-in-north-carolina-research-triangle-region-dedicated-to-business-services 2024-09-20 daily 0.5 https://www.gilead.com/company/company-statements/2021/gilead-announces-updates--to-the-advancing--access-patient-assistancemedication-assistance-program 2024-09-20 daily 0.5 https://www.gilead.com/company/company-statements/2021/gilead-issues-a-voluntary-nationwide-recall-of-two-lots-of-veklury-remdesivir--due-to-presence-of-glass-particulates 2026-01-30 daily 0.5 https://www.gilead.com/company/company-statements/2021/gilead-sciences-response-to-open-letter-regarding-access-to-ambisome-liposomal-amphotericin-b 2024-10-08 daily 0.5 https://www.gilead.com/company/company-statements/2021/gilead-sciences-statement-on-phase-3-veklury-remdesivir-intravenous-study-in-high-risk-non-hospitalized-patients-with-covid-19 2024-09-20 daily 0.5 https://www.gilead.com/company/company-statements/2021/gilead-sciences-statement-on-positive-phase-3-ambition-study-findings-for-the-treatment-of-hiv-associated-cryptococcal-meningitis 2024-08-22 daily 0.5 https://www.gilead.com/company/company-statements/2021/gilead-sciences-statement-on-requiring-vaccination-against-covid-19-for-employees 2024-08-22 daily 0.5 https://www.gilead.com/company/company-statements/2021/gilead-sciences-statement-on-the-passing-of-the-honorable-george-p-shultz-phd 2024-08-22 daily 0.5 https://www.gilead.com/company/company-statements/2021/gilead-statement-on-new-england-journal-of-medicine-publication-of-positive-phase-3-ascent-study-of-trodelvy-in-metastatic-triple-negative-breast-cancer 2024-08-22 daily 0.5 https://www.gilead.com/company/company-statements/2021/gilead-statement-on-new-nccn-clinical-practice-guidelines-in-oncology-recommendation-for-sacituzumab-govitecan-hziy-in-second-line-and-later-metastatic-triple-negative-breast-cancer 2024-08-22 daily 0.5 https://www.gilead.com/company/company-statements/2021/gilead-statement-on-veklury-remdesivir-and-the-sars-cov-2-omicron-variant 2024-10-08 daily 0.5 https://www.gilead.com/company/company-statements/2021/gilead-warns-of-counterfeit-hiv-medication-being-distributed-in-the-united-states 2026-01-30 daily 0.5 https://www.gilead.com/company/company-statements/2021/veklury-remdesivir-receives-positive-chmp-opinion-for-the-treatment-of-adults-not-on-supplemental-oxygen-and-considered-high-risk-for-covid-19-disease-progression 2024-09-20 daily 0.5 https://www.gilead.com/company/company-statements/2022/all-magrolimab-studies-re-opening-for-patient-enrollment-in-the-us 2024-08-22 daily 0.5 https://www.gilead.com/company/company-statements/2022/gilead-announces-actions-to-remove-counterfeit-hiv-medications-from-us-supply-chain 2025-07-29 daily 0.5 https://www.gilead.com/company/company-statements/2022/gilead-announces-global-resolution-of-bictegravir-patent-dispute-with-viiv-healthcare 2024-08-22 daily 0.5 https://www.gilead.com/company/company-statements/2022/gilead-continues-efforts-to-halt-the-distribution-of-counterfeit-hiv-medications-and-protect-patient-safety 2024-08-22 daily 0.5 https://www.gilead.com/company/company-statements/2022/gilead-enables-easier-veklury-remdesivir-access-through-retail-and-specialty-pharmacies-for-long-term-care-and-skilled-nursing-facilities 2024-11-11 daily 0.5 https://www.gilead.com/company/company-statements/2022/gilead-expands-availability-of-veklury-remdesivir-to-non-hospital-outpatient-facilities 2025-07-29 daily 0.5 https://www.gilead.com/company/company-statements/2022/gilead-implements-contract-pharmacy-integrity-initiative-for-branded-hepatitis-c-products 2024-08-22 daily 0.5 https://www.gilead.com/company/company-statements/2022/gilead-receives-complete-response-letter-from-us-fda-for-bulevirtide-for-the-treatment-of-adults-with-hepatitis-delta-virus 2024-11-11 daily 0.5 https://www.gilead.com/company/company-statements/2022/gilead-sciences-statement-on-fda-acceptance-of-new-drug-application-for-investigational-lenacapavir 2024-08-22 daily 0.5 https://www.gilead.com/company/company-statements/2022/gilead-statement-on-us-supreme-court-overturning-roe-v-wade 2024-08-22 daily 0.5 https://www.gilead.com/company/company-statements/2022/gilead-statement-on-who-recommendation-of-veklury-remdesivir-and-acceleration-of-prequalification-submission 2025-07-29 daily 0.5 https://www.gilead.com/company/company-statements/2022/gilead-statement-on-zydelig-us-indication-for-follicular-lymphoma-and-small-lymphocytic-leukemia 2024-09-20 daily 0.5 https://www.gilead.com/company/company-statements/2022/gilead-to-expand-footprint-in-oceanside 2024-08-22 daily 0.5 https://www.gilead.com/company/company-statements/2022/sacituzumab-govitecan-hziy-elevated-to-category-1-preferred-recommendation-in-second-line-metastatic-triple-negative-breast-cancer-and-added-as-a-category-2a-preferred-recommendation-for-hr-her2 2024-08-22 daily 0.5 https://www.gilead.com/company/company-statements/2022/veklury-remdesivir-demonstrates-continued-in-vitro-antiviral-activity-against-omicron-subvariants-including-ba4-and-ba5 2024-09-20 daily 0.5 https://www.gilead.com/company/company-statements/2023/christi-shaw-to-depart-gilead-and-kite-leadership-end-of-q1 2024-08-22 daily 0.5 https://www.gilead.com/company/company-statements/2023/gilead-prevails-in-hiv-antitrust-trial 2024-08-22 daily 0.5 https://www.gilead.com/company/company-statements/2023/gilead-remains-steadfast-in-support-for-hepatitis-c-elimination-efforts 2024-08-22 daily 0.5 https://www.gilead.com/company/company-statements/2023/gilead-sciences-commends-convictions-in-counterfeiting-scheme-pledges-continued-commitment-to-protect-patients 2024-08-22 daily 0.5 https://www.gilead.com/company/company-statements/2023/gilead-sciences-statement-on-phase-3-obeldesivir-clinical-trials-in-covid-19-birch-study-to-stop-enrollment-while-oaktree-study-nears-full-enrollment 2024-08-22 daily 0.5 https://www.gilead.com/company/company-statements/2023/gilead-sciences-statement-on-sustaining-access-to-ambisome-in-low--and-middle-income-countries 2024-09-20 daily 0.5 https://www.gilead.com/company/company-statements/2023/gilead-statement-on-favorable-verdict-in-hiv-prep-patents-litigation 2024-08-22 daily 0.5 https://www.gilead.com/company/company-statements/2023/gilead-statement-on-new-york-times-story-on-tdf-and-taf-development-for-hiv 2024-09-20 daily 0.5 https://www.gilead.com/company/company-statements/2023/gilead-statement-on-the-discontinuation-of-magrolimab-study-in-aml-with-tp53-mutations 2024-08-22 daily 0.5 https://www.gilead.com/company/company-statements/2024/access-planning-in-high-incidence-resource-limited-countries--for-lenacapavir-for-hiv-prevention 2025-07-29 daily 0.5 https://www.gilead.com/company/company-statements/2024/gilead-donates-remdesivir-for-emergency-use-in-response-to-marburg-virus-disease-in-rwanda 2024-10-04 daily 0.5 https://www.gilead.com/company/company-statements/2024/gilead-provides-update-on-us-indication-for-trodelvy-in-metastatic-urothelial-cancer 2025-07-29 daily 0.5 https://www.gilead.com/company/company-statements/2024/gilead-submits-new-drug-application-to-us-food-and-drug-administration-for-twice-yearly-lenacapavir-for-hiv-prevention 2024-12-19 daily 0.5 https://www.gilead.com/company/company-statements/2024/gilead-statement-on-agreement-in-principle-to-resolve-federal-tdf-litigation 2024-09-22 daily 0.5 https://www.gilead.com/company/company-statements/2024/gilead-statement-on-discontinuation-of-phase-3-enhance-3-study-in-aml 2024-09-22 daily 0.5 https://www.gilead.com/company/company-statements/2024/gilead-statement-on-magrolimab-studies-in-solid-tumors 2025-07-29 daily 0.5 https://www.gilead.com/company/company-statements/2024/gilead-statement-on-ugandas-anti-homosexuality-act 2024-10-25 daily 0.5 https://www.gilead.com/company/company-statements/2024/gilead-issues-voluntary-nationwide-recall-of-one-lot-of-veklury-remdesivir-for-injection-100-mg-vial-due-to-the-presence-of-a-glass-particle 2024-09-27 daily 0.5 https://www.gilead.com/company/company-statements/2024/updated-statement-on-access-planning-in-high-incidence-resource-limited-countries-for-lenacapavir-for-hiv-prevention 2024-09-22 daily 0.5 https://www.gilead.com/company/company-statements/2024/updated-statement-on-global-access-planning-for-lenacapavir-for-hiv-prevention 2025-07-29 daily 0.5 https://www.gilead.com/company/company-statements/2025/gilead-donates-remdesivir-for-ebola-clinical-trial-in-the-democratic-republic-of-the-congo 2025-10-08 daily 0.5 https://www.gilead.com/company/company-statements/2025/gilead-donates-remdesivir-to-aid-ethiopia-marburg-virus-response 2025-12-03 daily 0.5 https://www.gilead.com/company/company-statements/2025/gilead-provides-update-on-clinical-studies-evaluating-gs-1720-and-or-gs-4182-for-the-treatment-of-hiv-1-infection 2025-06-10 daily 0.5 https://www.gilead.com/company/company-statements/2025/gilead-provides-update-on-phase-3-star-221-study 2025-12-12 daily 0.5 https://www.gilead.com/company/company-statements/2025/gilead-sciences-update-on-access-strategy-for-lenacapavir-for-hiv-prevention-in-high-incidence-resource-limited-countries 2025-09-24 daily 0.5 https://www.gilead.com/company/company-statements/2025/gilead-statement-on-access-planning-for-lenacapavir-for-hiv-prevention-in-low--and-middle-income-countries 2025-06-18 daily 0.5 https://www.gilead.com/company/company-statements/2025/gilead-statement-on-commitment-to-us-biopharma-investments-innovation-and-affordability 2025-10-02 daily 0.5 https://www.gilead.com/company/company-statements/2025/gilead-statement-on-new-cdc-guidelines-on-twice-yearly-yeztugo-lenacapavir-for-hiv-prevention 2025-09-18 daily 0.5 https://www.gilead.com/company/company-statements/2025/gilead-statement-on-new-who-implementation-and-testing-guidelines-for-twice-yearly-lenacapavir-for-hiv-prevention 2025-07-28 daily 0.5 https://www.gilead.com/company/company-statements/2025/gilead-statement-on-settlement-agreement-with-us-department-of-justice-resolving-legacy-compliance-matter 2025-04-29 daily 0.5 https://www.gilead.com/company/company-statements/2025/gilead-statement-on-successful-resolution-with-us-department-of-justice-and-the-department-of-health-and-human-services-on-patents 2025-01-15 daily 0.5 https://www.gilead.com/company/company-statements/2025/gilead-submits-marketing-authorization-applications-to-european-medicines-agency-for-twice-yearly-lenacapavir-for-hiv-prevention 2025-02-03 daily 0.5 https://www.gilead.com/company/company-statements/2025/gilead-submits-request-to-anvisa-for-the-registration-of-twice-yearly-lenacapavir-for-hiv-prevention-under-the-priority-review-pathway 2025-04-03 daily 0.5 https://www.gilead.com/company/company-statements/2025/gilead-us-investment-to-create-43-billion-value-to-us-economy 2025-05-07 daily 0.5 https://www.gilead.com/company/company-statements/2025/time-names-gilead-sciences-as-a-2025-most-influential-company 2025-06-26 daily 0.5 https://www.gilead.com/company/company-statements/2025/us-fda-approves-new-biktarvy-indication-for-people-with-hiv-who-are-treatment-experienced-and-restarting-antiretroviral-treatment 2025-07-30 daily 0.5 https://www.gilead.com/company/company-statements/2026/trodelvy-added-as-preferred-regimen-within-first-line-metastatic-triple-negative-breast-cancer-in-nccn-clinical-practice-guidelines-in-oncology-nccn-guidelines 2026-03-16 daily 0.5 https://www.gilead.com/company/company-statements/2026/us-fda-grants-full-approval-of-kite-tecartus-for-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma 2026-04-02 daily 0.5 https://www.gilead.com/careers/opportunities/early-career-opportunities/overview 2024-09-05 daily 0.5 https://www.gilead.com/careers/opportunities/early-career-opportunities/gilead-internship-program 2024-09-05 daily 0.5 https://www.gilead.com/careers/opportunities/early-career-opportunities/postdoctoral-fellowships 2025-11-20 daily 0.5 https://www.gilead.com/global-operations/europe/portugal/historical-support 2024-08-29 daily 0.5 https://www.gilead.com/global-operations/europe/portugal/portugal-translation 2024-07-22 daily 0.5 https://www.gilead.com/global-operations/europe/netherlands/dutch-translation 2024-07-22 daily 0.5 https://www.gilead.com/global-operations/europe/poland/polish-translation 2024-07-22 daily 0.5 https://www.gilead.com/global-operations/europe/russia/historical-support 2024-08-29 daily 0.5 https://www.gilead.com/global-operations/europe/russia/russian-translation 2024-07-22 daily 0.5 https://www.gilead.com/global-operations/middle-east/saudi-arabia/arabic-translation 2024-07-23 daily 0.5 https://www.gilead.com/global-operations/north-america/mexico/spanish-translation 2024-07-23 daily 0.5 https://www.gilead.com/global-operations/south-america/argentina/spanish-translation 2024-07-23 daily 0.5 https://www.gilead.com/global-operations/south-america/brazil/portuguese-translation 2024-07-23 daily 0.5 https://www.gilead.com/global-operations/south-america/colombia/spanish-translation 2024-07-23 daily 0.5 https://www.gilead.com/science/research/research-funding-programs/external-sponsored-research/overview 2024-09-05 daily 0.5 https://www.gilead.com/science/research/research-funding-programs/external-sponsored-research/virology-rfp-opportunities 2026-03-19 daily 0.5 https://www.gilead.com/science/research/research-funding-programs/external-sponsored-research/oncology-rfp-opportunities 2025-03-19 daily 0.5 https://www.gilead.com/science/research/research-funding-programs/external-sponsored-research/inflammation-rfp-opportunities 2025-03-19 daily 0.5 https://www.gilead.com/responsibility/giving-at-gilead/corporate-giving/strategic-initiatives/overview 2024-09-05 daily 0.5 https://www.gilead.com/responsibility/giving-at-gilead/corporate-giving/strategic-initiatives/all4liver 2024-09-12 daily 0.5 https://www.gilead.com/responsibility/giving-at-gilead/corporate-giving/strategic-initiatives/asia-pacific-rainbow-grant 2024-09-12 daily 0.5 https://www.gilead.com/responsibility/giving-at-gilead/corporate-giving/strategic-initiatives/compass-initiative 2024-10-04 daily 0.5 https://www.gilead.com/responsibility/giving-at-gilead/corporate-giving/strategic-initiatives/hepconnect 2024-09-05 daily 0.5 https://www.gilead.com/responsibility/giving-at-gilead/corporate-giving/strategic-initiatives/hiv-age-positively 2024-09-05 daily 0.5 https://www.gilead.com/responsibility/giving-at-gilead/corporate-giving/strategic-initiatives/radian 2024-09-12 daily 0.5 https://www.gilead.com/responsibility/giving-at-gilead/corporate-giving/strategic-initiatives/setting-the-pace 2024-09-05 daily 0.5 https://www.gilead.com/responsibility/giving-at-gilead/corporate-giving/strategic-initiatives/gilead-oncology-grant 2025-05-29 daily 0.5 https://www.gilead.com/responsibility/giving-at-gilead/corporate-giving/strategic-initiatives/toward-health-equity-for-black-people-impacted-by-tnbc 2024-09-05 daily 0.5 https://www.gilead.com/responsibility/giving-at-gilead/corporate-giving/strategic-initiatives/transcend 2025-04-22 daily 0.5 https://www.gilead.com/responsibility/giving-at-gilead/corporate-giving/strategic-initiatives/zeroing-in-ending-the-hiv-epidemic 2024-09-05 daily 0.5 https://www.gilead.com/responsibility/giving-at-gilead/corporate-giving/how-to-apply-for-funding/overview 2024-08-19 daily 0.5 https://www.gilead.com/responsibility/giving-at-gilead/corporate-giving/how-to-apply-for-funding/giving-in-africa 2024-09-10 daily 0.5 https://www.gilead.com/responsibility/giving-at-gilead/corporate-giving/how-to-apply-for-funding/giving-in-asia 2024-09-04 daily 0.5 https://www.gilead.com/responsibility/giving-at-gilead/corporate-giving/how-to-apply-for-funding/giving-in-australia 2024-09-04 daily 0.5 https://www.gilead.com/responsibility/giving-at-gilead/corporate-giving/how-to-apply-for-funding/giving-in-europe-and-the-middle-east 2024-09-05 daily 0.5 https://www.gilead.com/responsibility/giving-at-gilead/corporate-giving/how-to-apply-for-funding/giving-in-latin-america-and-the-caribbean 2024-09-05 daily 0.5 https://www.gilead.com/responsibility/giving-at-gilead/corporate-giving/how-to-apply-for-funding/giving-in-north-america 2025-04-01 daily 0.5 https://www.gilead.com/responsibility/giving-at-gilead/corporate-giving/how-to-apply-for-funding/terms-and-conditions 2025-03-25 daily 0.5 https://www.gilead.com/responsibility/giving-at-gilead/corporate-giving/how-to-apply-for-funding/faqs 2025-03-25 daily 0.5 https://www.gilead.com/global-operations/europe/portugal/historical-support/portuguese-translation 2024-07-22 daily 0.5 https://www.gilead.com/responsibility/giving-at-gilead/corporate-giving/strategic-initiatives/compass-initiative/gilead-compass-initiative 2024-02-05 daily 0.5 https://www.gilead.com/responsibility/giving-at-gilead/corporate-giving/strategic-initiatives/hiv-age-positively/hiv-age-positively-grantees 2024-08-29 daily 0.5 https://www.gilead.com/responsibility/giving-at-gilead/corporate-giving/strategic-initiatives/radian/radian-hiv 2024-07-12 daily 0.5 https://www.gilead.com/responsibility/giving-at-gilead/corporate-giving/how-to-apply-for-funding/giving-in-africa/terms-and-conditions 0001-01-01 daily 0.5 https://www.gilead.com/responsibility/giving-at-gilead/corporate-giving/how-to-apply-for-funding/giving-in-africa/faqs-outside-north-america 2024-07-15 daily 0.5 https://www.gilead.com/responsibility/giving-at-gilead/corporate-giving/how-to-apply-for-funding/giving-in-asia/terms-and-conditions 0001-01-01 daily 0.5 https://www.gilead.com/responsibility/giving-at-gilead/corporate-giving/how-to-apply-for-funding/giving-in-asia/faqs-outside-north-america 2024-07-15 daily 0.5 https://www.gilead.com/responsibility/giving-at-gilead/corporate-giving/how-to-apply-for-funding/giving-in-australia/terms-and-conditions 0001-01-01 daily 0.5 https://www.gilead.com/responsibility/giving-at-gilead/corporate-giving/how-to-apply-for-funding/giving-in-australia/faqs-outside-north-america 2024-07-15 daily 0.5 https://www.gilead.com/responsibility/giving-at-gilead/corporate-giving/how-to-apply-for-funding/giving-in-europe-and-the-middle-east/terms-and-conditions 2024-09-06 daily 0.5 https://www.gilead.com/responsibility/giving-at-gilead/corporate-giving/how-to-apply-for-funding/giving-in-europe-and-the-middle-east/faqs-outside-north-america 2024-07-15 daily 0.5 https://www.gilead.com/responsibility/giving-at-gilead/corporate-giving/how-to-apply-for-funding/giving-in-latin-america-and-the-caribbean/overview 2024-07-11 daily 0.5 https://www.gilead.com/responsibility/giving-at-gilead/corporate-giving/how-to-apply-for-funding/giving-in-latin-america-and-the-caribbean/terms-and-conditions 2024-07-12 daily 0.5 https://www.gilead.com/responsibility/giving-at-gilead/corporate-giving/how-to-apply-for-funding/giving-in-latin-america-and-the-caribbean/faqs-outside-north-america 2024-07-15 daily 0.5 https://www.gilead.com/responsibility/giving-at-gilead/corporate-giving/strategic-initiatives/radian/radian-hiv/all4liver 2024-07-04 daily 0.5